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 Exercise interventions in cancer patients have been demonstrated to reduce 
cancer-treatment related side effects.  Despite this, the underlying mechanisms associated 
with the protective aspects of exercise are generally uncharacterized, but treatment-
associated oxidative stress is thought to play a role.   The purpose of this study was to 
determine the effect of an exercise intervention on fatigue, cardiorespiratory fitness 
(CRF), muscular strength, and blood markers of DNA and protein oxidation compared to 
a non-exercising, cancer control group.  METHODOLOGY:  An initial fasting blood 
draw and assessments of muscular strength and CRF were administered to fifteen cancer 
patients within six weeks of completing radiation or chemotherapy treatment.   Eight 
cancer patients participated in a 10-week exercise intervention (EX) while seven 
continued standard care (CON).  Following the intervention, subjects completed another 
fasted blood draw and a reassessment of fatigue, strength and CRF.  Changes in plasma 
protein carbonyls, 8-OHdG, and antioxidant status were compared between the exercise 
and control groups.  Baseline markers of oxidative stress were compared between healthy 





parameters and oxidative stress in cancer patients was conducted.  RESULTS:   Baseline 
total antioxidant capacity was significantly lower, and plasma protein carbonyls 
significantly higher in cancer patients compared to NC (p < 0.05).   Mean total fatigue 
scores decreased significantly from 5.0 ± 2.2 to 2.6 ± 1.5 (p < 0.05) in EX, whereas 
changes in CON (4.7 ± 2.5 to 3.2 ± 2.4) were not significant.  All fatigue subscales 
significantly decreased in EX, while only cognitive fatigue increased significantly in 
CON (p < 0.05).  Antioxidant capacity increased and protein carbonyls decreased in EX 
(p < 0.01) but not CON.  Improvements in composite arm (41%) and leg strength (34%), 
isometric handgrip strength (11%), and VO2peak (16%) all significantly improved in the 
EX group (p < 0.05), while none of these parameters significantly changed in CON.  No 
significant changes over time were found in 8-OHdG, but a group by time interaction 
effect was detected (p < 0.05).  Baseline antioxidant capacity significantly correlated (p < 
0.05) with total, affective, sensory, and cognitive fatigue.  Increases in antioxidant 
capacity were correlated (p < 0.05) with reductions in affective, sensory, and cognitive 
fatigue.  Although 8-OHdG was not correlated with any fatigue parameter at baseline, 
changes in total and affective fatigue exhibited significant correlations with changes in 8-
OHdG over time.  CONCLUSIONS:   A whole-body exercise intervention is an 
effective method of increasing muscular strength, CRF and antioxidant capacity, while 
reducing markers of protein oxidation.  An exercise intervention was an effective method 
of reducing fatigue in cancer patients following cessation of treatment, whereas standard 
care resulted in non-significant reductions in fatigue.  Oxidative stress may be implicated 
in cancer-related fatigue, while improved antioxidant capacity following an exercise 
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 Cancer is a group of diseases characterized by uncontrolled growth and regulation 
of cells.  The etiology of cancer is associated with both environmental (chemicals, 
radiation, smoking, diet, and infectious organisms) and inherent factors (inherited genetic 
mutations, hormones, and immune conditions).  The development of cancer depends on 
an interaction between these factors, and requires the circumvention of various cellular 
checkpoints.  When a cell receives a “hit,” a carcinogen alters a cell’s DNA, affecting its 
function and growth.    Normally, the cellular reproductive processes are halted or 
terminated at the checkpoints to prevent cancer development or progression, but in the 
presence of a promoter, the genetically altered cell may proliferate and metastasize, 
resulting in cancer. 
 Although nearly 600,000 people are expected to die of cancer in the US this year, 
overall cancer mortality has drastically decreased in the previous several decades, due to 
improved detection and treatment methods (American Cancer Society, 2014).  The 
National Cancer Institute estimates that 13.7 million Americans with a history of cancer 
were alive in 2012 and about 1,665,540 new cancer cases are expected to be diagnosed in 





214.95 per 100,000 rate in 1990, illustrating improved efficacy of cancer treatment 
methods (Howlader, 2012).  Although this is an encouraging trend, the adverse side 
effects of surgery, radiation, chemotherapy, and other treatment modalities are associated 
with severe physiological side effects that may last for years.  Typical side effects include 
muscle weakness, reduced cardiorespiratory fitness, peripheral neuropathy, 
immunosuppression, and general fatigue, resulting in an overall decrease in quality of 
life.  While these conditions are multicausal and multifactorial, oxidative stress is thought 
to play a pivotal role in many pathological processes associated with cancer and its 
treatments (Fang, Seki, & Maeda, 2009; Robbins & Zhao, 2004; Zhao & Robbins, 2009). 
 Oxidative stress is a state in which reactive oxygen species (ROS) are produced at 
a rate that exceeds cellular adaptive and repair capacities, namely enzymatic and non-
enzymatic antioxidants.   Also known as free radicals, ROS can cause damage to tissues 
by stealing electrons from nearby molecules, creating new free radicals and propagating a 
chain reaction.  This process causes damage to lipid membranes within any cell, in a 
process called lipid peroxidation.  ROS can also damage other cellular components, 
including proteins and nucleic acids, resulting in skeletal and cardiac muscle dysfunction, 
and potentially DNA modification, respectively.  The development and progression of 
many cancers are associated with oxidative stress-induced DNA modification, but cancer 
cells themselves can produce increased levels of ROS, perpetuating dysfunction and 
cancer growth (Valko, Rhodes, Moncol, Izakovic, & Mazur, 2006; Yeh et al., 2006), 
Interestingly, many modes of cancer treatment depend on extremely high doses of ROS 
as a mechanism of cancer killing, including radiation, many chemotherapy regimens, and 





oxidative stress typically affects healthy tissue in addition to malignant tissue, resulting in 
both acute and chronic side effects.   
 The most commonly produced ROS are superoxide and hydroxyl radicals.  Most 
free radical production in healthy individuals occurs in the mitochondria, due to a 
“leakage” of electrons from 1-2% of the oxygen in the electron transport chain (Boveris 
& Chance, 1973).  This can form a superoxide radical (O2
•-
), as the unstable intermediate 
semiquinone anion can directly transfer electrons to molecular oxygen instead of 
reducing to ubiquinone (Turrens, 1997).   Although once considered merely a byproduct 
of oxidative phosphorylation, several alternate sources of ROS production have since 
been identified.    Among these, the inducible enzymatic production of various ROS 
indicates that they play important roles in cellular function.  NAD(P)H oxidase catalyzes 
the production of superoxide in phagocytes, which use free radicals to destroy pathogens, 
in what is known as a respiratory burst.  Another enzyme, xanthine reductase, is 
expressed in two forms: xanthine reductase, which creates the antioxidant uric acid, and 
xanthine oxidase, a pro-oxidant enzyme (Vorbach, Harrison, & Capecchi, 2003).   These 
enzymes are tightly regulated to ensure an appropriate cellular level of ROS, and to 
maintain redox balance, illustrating the importance of ROS creation in healthy 
individuals.    
 While oxidative stress can be damaging to every cell and system within the body, 
ROS are necessary for proper cellular functioning.  Nitric oxide (NO) is a free radical, 
but has long been recognized as an important mediator of vasodilation.  In recent years, 
other ROS, including superoxide (Buetler, Krauskopf, & Ruegg, 2004), have been 





shown to play signaling roles in muscular contraction, adaptive responses to stress, 
including heat shock proteins and cytokines, and activation of the MAP-K pathway and  
p53 tumor suppressor protein (Emerling et al., 2005; Jackson, 2009a; Liu, Chen, & St 
Clair, 2008; Valko et al., 2007; Zhang & Gutterman, 2007).   Additionally, ROS are 
thought to be involved in the chronic adaptive response to exercise (Powers, Duarte, 
Kavazis, & Talbert, 2009).  
Because ROS production is a normal physiological process, an antioxidant 
defense system is in place to counteract normally produced free radicals.  Antioxidants 
are molecules that inhibit free radical reactions, typically acting as a reducing agent by 
donating an electron and ceasing the oxidative chain reaction.  Enzymatic antioxidants 
include superoxide dismutases, catalases, and glutathione peroxidases, and common 
endogenous non-enzymatic antioxidants include glutathione, albumin, ferritin, uric acid, 
bilirubin and pyruvate.  Common dietary non-enzymatic antioxidants include vitamin C 
and vitamin E.  Any disruption in antioxidant capacity of healthy cells can alter redox 
balance and health status.  Cancer cells typically have reduced antioxidant enzyme 
activity, but in certain types of cancers and metastatic growth, antioxidant enzyme 
activity is augmented, conveying multidrug resistance to these cells (Oberley, 2002). 
 Due to the extremely transient nature of ROS, it is difficult to perform chemical 
analyses of ROS themselves.  Rather, downstream products of oxidative stress in blood 
and tissues may be analyzed via biochemical analysis.  Malondialdehyde (MDA), a stable 
end product of lipid peroxidation, is likely the most common marker of oxidative stress.  
Other markers of lipid peroxidation include 4-hydroxynonenal (4-HNE) and F2 





2’deoxyguanosine (8-OHdG), a fairly ubiquitous byproduct of oxidative DNA damage, is 
the primary biomarker for DNA oxidation. Carbonyl derivatives of proline, lysine, 
arginine and threonine are the most common oxidation product of protein.  Additionally, 
the ratio of reduced glutathione to oxidized glutathione (GSH:GSSG) is a commonly used 
determinant of oxidative stress (Serru et al., 2001). 
 In addition to generalized damage to body tissues, and the association between 
chronic oxidative stress and cancer, numerous chronic pathophysiological conditions may 
be linked to oxidative stress, including diabetes, hypertension, vascular disease, cachexia, 
neural dysfunction, chronic heart failure, and ischemia-reperfusion injury.  Cancer 
chemotherapy and radiation therapy are known to elicit many of these pathologies as side 
effects, most notably cardiac dysfunction.  Oxidative stress has been hypothesized to 
initiate or aggravate these medical conditions (Y. Chen, Jungsuwadee, Vore, Butterfield, 
& St Clair, 2007; Robbins & Zhao, 2004; J. Wang & Yi, 2008).   
 Some of the most effective cancer treatments also are the most damaging to 
normal tissue.  Doxorubicin, for instance, is a highly effective antineoplastic agent used 
for various cancers, yet causes a dose-dependent cardiotoxicity associated with oxidative 
stress (Chaiswing et al., 2004; Kanter, Hamlin, Unverferth, Davis, & Merola, 1985).  
While the primary antineoplastic mechanisms of DOX are inhibition of topoisomerase II 
and intercalation in DNA (Chen, Jungsuwadee, Butterfield, & St Clair, 2007), resulting in 
inhibition of DNA replication and RNA transcription, the induction of ROS may 
contribute to antitumor activity (Taatjes, Fenick, Gaudiano, & Koch, 1998).  Doxorubicin 
cardiotoxicity causes morphological damage within the myocardium, often apparent 





congestive heart failure (Ng, Better, & Green, 2006).  Several authors have identified 
oxidative stress as a primary mechanism of DOX cardiotoxicity (Y. Chen et al., 2007; 
Simunek et al., 2009).  Other common chemotherapy drugs, including tamoxifen, 
etoposide, 5-fluorouracil, alkylating agents and platinum coordinating complexes are 
known to induce significant oxidative stress.  Radiation, by nature, is characterized by 
ROS production and exerts its physiological effects, both beneficial and harmful, via this 
mechanism.  Even surgery is capable of producing enough ROS as a side effect to 
facilitate increased growth of metastatic tumors (Hyoudou, Nishikawa, Kobayashi, 
Umeyama, et al., 2006).    
The challenge for oncologists and the entire cancer care team is to maximize 
effectiveness of treatment while minimizing side effects.  Reduction of oxidative stress in 
healthy tissues is a method which may reduce or eliminate many of the cancer treatment-
associated side effects.  Antioxidant therapy, while an attractive strategy, is currently not 
advocated by the American Cancer Society (D'Andrea, 2005) due to the potential for 
reduced treatment efficacy and relatively poor reduction of side effects with dietary 
antioxidant supplementation (Lawenda et al., 2008; Myers et al., 1983; Unverferth et al., 
1983).  Additionally, endogenous antioxidant enzymes are coordinately regulated, so that 
glutathione peroxidases and catalases are upregulated in concert with SOD to match the 
current level of ROS production (McCord, 2008).  Exogenous administration of any one 
of these alone could result in aberrant redox regulation.   
An increasingly popular rehabilitation method in cancer patients is prescriptive, 
whole-body exercise.  Exercise has been shown to minimize many side effects of cancer 





chemotherapy (Chicco, Schneider, & Hayward, 2006) and can reduce the damaging side 
effect of hormonal therapy (Hydock, Lien, Schneider, & Hayward, 2007).  Furthermore, 
exercise following treatment may reduce the chance for cancer recurrence (Courneya, 
2003).  Exercise following surgery has been shown to be beneficial in increasing the 
natural killer (NK) cell cytotoxic activity (NKCA), (Na, Kim, Kim, Ha, & Sup Yoon, 
2000) suggesting that exercise may play a role in cancer treatment, rather than simply 
rehabilitation. 
Resistance and aerobic exercise during and following treatment have been found 
to be beneficial as a means to reduce self reported fatigue (Mock et al., 2001; Schneider, 
Hsieh, Sprod, Carter, & Hayward, 2007c; Schwartz, 2007), which is the most prevalent 
symptom in cancer survivors.   Prescriptive exercise programs have successfully 
improved muscular strength (Courneya et al., 2007) and muscular endurance (Schneider, 
Hsieh, Sprod, Carter, & Hayward, 2007a) in cancer survivors.  A similar effect on 
cardiorespiratory endurance has been noted in cancer survivors (Schneider et al., 2007c).   
Improvements in functional capacity in cancer patients are associated with increased self-
reported quality of life (L. W. Jones et al., 2008; Schneider et al., 2007a; Thorsen et al., 
2005).   
While acute, high intensity exercise bouts generate ROS, it is well documented 
that exercise training increases antioxidant enzyme capacity in animals and healthy 
individuals (Finaud, Lac, & Filaire, 2006; Ji, 2002).  The concept of hormesis describes 
the positive adaptation to a mild stressor, whereas a larger dosage of the same stressor 
would be damaging or fatal.  The response to ROS is exemplary of hormesis; lower doses 





antioxidant enzymes are upregulated.  High doses, like those caused by radiation and 
chemotherapy, can cause severe side effects.   Although a single bout of exercise can 
transiently activate mitochondrial (manganese) superoxide dismutase (MnSOD) gene 
transcription, substantial MnSOD upregulation may require more chronic stimulation, 
such as a prescriptive exercise intervention (Hollander et al., 1999).   The effectiveness of 
exercise may be due, in part, to the reduction of oxidative stress in normal cells, and 
therefore protection of healthy tissues without a protective effect within cancer cells.  It 
appears that the antioxidant enzyme upregulation in response to exercise is 
compartmentalized, as unilateral resistance training stimulated an enzymatic response 
only in the trained leg (Parise, Phillips, Kaczor, & Tarnopolsky, 2005). This suggests that 
healthy, exercising tissue can be protected, without increased antioxidant defense within 
cancer cells. 
While oxidative stress is recognized as a contributing factor in cancer and 
treatment-related decrements in health, there is little research addressing the effect of 
exercise on both functional parameters and markers of oxidative stress or antioxidant 
enzymes.  A notable study from 1985 investigating the effect of exercise on 
cardiotoxicity and antioxidant enzymes in rats remains one of the most sophisticated 
studies supporting exercise as a strategy to reduce treatment-induce oxidative stress and 
subsequent side effects (Kanter et al., 1985).  Swim training significantly reduced 
cardiotoxicity of doxorubicin and increased blood values for three antioxidant enzymes 
(glutathione peroxidase, superoxide dismutase, catalase), indicating a protective effect of 
exercise via improved antioxidant defense.  To date, no similar study has been conducted 





effect of a prescriptive exercise intervention on oxidative stress markers in cancer 
survivors following treatment known to induce severe oxidative stress. 
Statement of Purpose 
 The primary purpose of this study is to determine the effects of a 10-week 
prescribed aerobic and resistance exercise intervention on plasma markers of oxidative 
stress and antioxidant enzyme capacity in cancer survivors versus a non-exercising, 
cancer control group. Markers of oxidative stress to be measured are 8-OHdG, and 
reactive carbonyl derivatives.  Trolox-equivalent antioxidant capacity (TEAC) will be 
measured as a universal marker of antioxidant capacity in the blood.   Additionally, 
selected physiological variables, including peak VO2, muscular strength, and fatigue will 
be compared between groups.  The relationship between oxidative stress and baseline 
physiological variables will be determined.  Similarly, the relationship between the 
change in oxidative stress and changes in physiological variables will be determined.  
Baseline oxidative stress and antioxidant enzyme capacity in cancer patients will be 














H1  There will be a significant decrease in blood markers of oxidative stress in 
 exercising subjects compared to standard care following the 10-week 
 intervention. 
 
H2  There will be a significant improvement in total antioxidant capacity in 
 exercising subjects compared to standard care following the 10-week 
 intervention. 
 
H3  There will be a significant improvement in cardiopulmonary function in 
 exercising subjects compared to standard care following the 10-week 
 intervention. 
 
H4  There will be a significant improvement in muscular strength in exercising 
 subjects compared to standard care following the 10-week intervention. 
 
H5  There will be a significant improvement in self-reported fatigue in 
 exercising subjects compared to standard care following the 10-week 
 intervention. 
 
H6  There will be significantly greater baseline levels of oxidative stress 
 markers in cancer survivors than in healthy, age and gender-matched 
 controls. 
 
H7  At baseline, oxidative stress will exhibit a negative correlation with 
 cardiopulmonary function and muscular strength, and a positive 
 correlation with fatigue.  In contrast, antioxidant capacity will exhibit a 
 positive correlation with cardiopulmonary function and strength, and a 
 negative correlation with fatigue 
 
H8  Changes in oxidative stress will exhibit a negative correlation with 
 changes in cardiopulmonary function and muscular strength, and a 
 positive correlation with fatigue.  Changes in antioxidant capacity will 
 exhibit a positive correlation with changes in cardiopulmonary function 
 and strength, and a negative correlation with fatigue.    
 
Significance of the Study 
 All cancer treatments inevitably have side effects, and beyond altering quality of 
life, they often limit the aggressiveness of treatment.   Radiation, chemotherapy, and even 
surgery result in production of (ROS) and ultimately oxidative stress.  Cancer cells 





from fatigue, cachexia, decrements in cardiorespiratory fitness, and neurological 
disorders, all which may be associated with increased oxidative stress.  Additionally, 
increased oxidative stress from radiation treatment is associated with the development of 
second cancers (Bostrom & Soloway, 2007).  Unfortunately, there has been little success 
in antioxidant supplementation as a means to reduce treatment-associated side effects 
without affecting treatment efficacy (Lawenda et al., 2008).  Prescriptive exercise, on the 
other hand, has been shown to increase muscular endurance and strength and 
cardiorespiratory fitness, while reducing fatigue.  Additionally, in animal models, 
exercise has been shown to reduce treatment-associated side effects, increase antioxidant 
enzyme activity, and decrease markers of oxidative stress (Ascensao et al., 2005a; 
Wonders & Reigle, 2009).  While exercise training has been shown to increase 
antioxidant capacity in healthy individuals and some pathological conditions, such as 
Parkinson’s disease (Bloomer et al., 2008; Finaud et al., 2006) and diabetes (Ristow et 
al., 2009), to date, no study has examined the effect of a prescriptive exercise intervention 
on markers of oxidative stress and antioxidant capacity in cancer survivors.  Additionally, 
there is little data on the degree of chronic oxidative stress in cancer survivors post 
treatment. 
Assumptions 
 This study is based upon the assumption that all subjects accurately report their 
previous exercise, smoking, and antioxidant supplementation habits.  It is assumed that 
blood draws were taken while the subjects were fasted, and had not engaged in strenuous 
activity for the previous 72 hours.  Subjects in the standard care group are assumed to 






 All subjects were recruited in Greeley, Colorado and surrounding towns, and 
therefore the results may not be generalizable to the entire US population.  Due to the 
self-selected nature of participation in this study, it is possible that psychological factors 
beyond the scope of this study independently affected fatigue values at baseline or fatigue 
changes over time.  Diets were not controlled and food logs were not utilized to evaluate 
subjects’ consumption of antioxidant-containing foods, therefore it is possible that whole 
foods containing variable antioxidant compositions affected plasma antioxidant capacity 
or oxidative stress at either baseline or follow-up.  Because there were a variety of cancer 
types and treatments among the subjects in this study, it is possible that undetected 
prolonged physiological effects of treatment and cancer type may play a role in patient 
response to time out of treatment in the control group, or response to exercise in the 
intervention group.  Finally, although exercise interventions were similar, 
individualization of exercise regimens for each cancer patient based upon specific needs 
may have affected the biochemical and fatigue responses to exercise and could 
potentially limit the generalizability of this study. 
Definition of Terms 
Antioxidant.   A molecule that inhibits free radical reactions, typically by acting as a 
reducing agent by donating an electron and ceasing the oxidative chain reaction.  
Enzymatic antioxidants include superoxide dismutases, catalases, and glutathione. 
peroxidases.  Non-enzymatic antioxidants include glutathione, ascorbic acid (vitamin C), 
α-tocopherol (vitamin E), flavonoids, and carotenoids  (Baskin & Salem, 1997). 
 
Cachexia.  A syndrome of progressive weight loss, anorexia, and persistent erosion of 
host body cell mass, often in response to a malignant growth (Laviano, Meguid, Preziosa, 
& Rossi Fanelli, 2007). 
 
Cancer.  Cancer is a group of diseases characterized by abnormal, uncontrolled growth 






Cancer Related Fatigue.  An overwhelming, whole-body tiredness, unrelated to activity 
or exertion, that makes a person feel drained and produces a strong desire to lie down and 
sleep (Schneider, Dennehy, & Carter, 2003).   
 
Carcinogen.  A chemical, biological, or physical agent capable of permanently, directly, 
and irreversibly changing the molecular structure of a cell.  With prolonged or continuous 
exposure, this predisposes the cell to transformation, and ultimately cancer development 
(Langhorne, Fulton, & Otto, 2007).  
 
Chemotherapy.  Treatment with at least one drug (Langhorne et al., 2007) employed as 
the primary means of anti-cancer therapy, to limit the spread of localized tumors, 
particularly in late stage cancers, or as adjuvant therapy to shrink tumors prior to 
radiation or surgery and destroy microscopic metastases following tumor removal (Chu 
& DeVita 2005). 
 
Lipid Peroxidation.  Oxidative degradation of lipids whereby free radicals "steal" 
electrons from the lipids in cell membranes, resulting in cellular damage (Baskin & 
Salem, 1997).  
 
Hormesis.   A beneficial physiological response or adaptation to a mildly damaging 
stimulus (Ji, Maria-Carmen, & Jose, 2006). 
 
Oxidative Phosphorylation.  The coupling of the phosphorylation of ATP to oxidation, in 
the electron transport chain of the mitochondrial membrane (Brooks, Fahey, & Baldwin, 
2005).   
 
Oxidative stress.  A state in which the production of ROS exceeds the capacity of the 
enzymatic and non-enzymatic antioxidant system, resulting in a disturbance in redox 
balance and cellular damage (Valko et al., 2007). 
 
Radiation Therapy.  The use of high energy irradiation to destroy malignant cancer cells.  
There are two general types of radiation: brachytherapy (internal) and teletherapy 
(external).  Cancer cells are destroyed both by the radiation directly and the free radicals 
it produces (Hellman, 2005). 
 
Reactive Oxygen and Nitrogen Species (ROS).  Extremely unstable molecules containing 
an unpaired valence electron, also known as free radicals, which can cause damage to 
tissues by stealing electrons from nearby molecules (Halliwell & Gutteridge, 2007).  ROS 
also act as important signaling molecules (Valko et al., 2007). 
 
Superoxide.  The most commonly produced free radical.  It is an oxygen with an 
additional electron  (Halliwell & Gutteridge, 2007).  Most free radical production in 
healthy individuals occurs in the mitochondria, due to a “leakage” of electrons from 1-2% 















CHAPTER II  
REVIEW OF LITERATURE 
Introduction 
 The primary purpose of this study was to determine the effects of a 10-week 
prescribed aerobic and resistance exercise intervention on plasma markers of oxidative 
stress and antioxidant enzyme capacity in cancer survivors versus a non-exercising, 
cancer control group. Markers of oxidative stress measured were 8-OHdG and reactive 
carbonyl derivatives.  Trolox-equivalent antioxidant capacity was measured as a 
universal marker of antioxidant capacity in the blood.   Additionally, selected 
physiological variables, including VO2 peak, muscular strength, and fatigue were 
compared between groups.  The relationship between oxidative stress and baseline 
physiological variables was determined.  Similarly, the relationship between the change 
in oxidative stress and changes in physiological variables was determined.  Baseline 
oxidative stress and antioxidant enzyme capacity in cancer patients was compared to a 
group of healthy individuals.  The following literature review will include carcinogenesis, 
cancer treatments and their side effects, the effect that exercise has on cancer patients 






Overview of Cancer 
Cancer Incidence 
 Cancer is characterized by abnormal cell growth, resulting from a failure in the 
normal growth and repair processes in the cell.  As of January 2012, 13.7 million cancer 
survivors were living in America, and more than 1.6 million new cases of cancer are 
expected to have been diagnosed in 2013, making cancer the second leading cause of 
death in the United States, next to cardiovascular disease (American Cancer Society, 
2014).  Fortunately, advancements in cancer detection and treatment methods have 
markedly improved the survival rate for most cancer types.  A consequence of reduced 
mortality is an increase in the number of people living with the damaging side effects of 
cancer treatments, including surgery, radiation, and chemotherapy. 
Normal Cell Growth and Division 
The normal cell cycle involves two distinct phases, called interphase and mitosis 
(M phase) (Voet, Voet, & Pratt, 2008).  During interphase, no cell division occurs, but 
normal growth and metabolism take place, whereas cell division occurs during mitosis.  
Interphase, which comprises the majority of the cell cycle, is divided into three events: 
synthesis (S phase), and two gap phases (G1 and G2).   Additionally, during the G0 phase, 
or postmitotic stage, the cell is quiescent, meaning that the cell is not actively dividing or 
preparing to divide.  Depending on the type of cell and the current needs of the organism, 
the length of the G0 phase varies, and may be permanent in cells that do not divide, 
including mature cardiac muscle and nerve cells. 
Cells proceed through the cell cycle in response to numerous external stimuli, 





by a series of checkpoints that will arrest the cell cycle if certain conditions are not met 
(Voet et al., 2008).  One checkpoint halts progression into mitosis until all cellular DNA 
has been replicated.  Other checkpoints in G1 and S arrests the cell cycle in response to 
damaged DNA to allow time for DNA repair.  If the appropriate cellular conditions are 
not met after a period of time at a checkpoint, the cell will undergo apoptosis.  These 
checkpoints are crucial to the preservation of an organism’s DNA and thus the prevention 
of mutations, including those resulting in cancer development.   
The cell can transition from the G0 phase to the G1 phase in response to external 
signals, such as apoptosis of an identical cell.  During the G1 phase, cells undergo rapid 
protein synthesis in preparation for ribonucleic acid (RNA) and deoxyribonucleic acid 
(DNA) synthesis (Burke, 1996).   Once initiated, the G1 phase lasts approximately 12 to 
14 hours before proceeding to the S phase (Langhorne et al., 2007).  During the S phase, 
which typically lasts 7-20 hours, RNA and DNA are formed, as well as histones, the 
basic protein of chromatin.    Two strands of the newly formed DNA, the body’s genetic 
code, wrap themselves around the histones, forming a double helix structure.  The strands 
form bonds to one another between their nucleotide bases in specific pairs; the purines, 
adenine (A) and guanine (G), bind respectively to the pyrimidines, thymine (T) and 
cytosine (C).   
The G2 phase follows the S phase, and lasts 1-12 hours (Burke, 1996).  The cell 
further prepares itself for mitosis by continued RNA synthesis, and development of 
organelles and the mitotic spindle apparatus, where chromosomes are condensed.  
Additionally, proofreading and repair is performed by enzymes, DNA ligase and the 





that are inappropriately matched with the original DNA strand (Guyton & Hall, 2000).   
Mitosis (M phase) is the period of actual cell division, and is further divided into 4 
phases: prophase, metaphase, anaphase, and telophase.  During mitosis, the cell is divided 
into 2 daughter cells containing the same number and type of chromosomes as the 

















Figure 1.  The cell cycle.  Adapted from Biochemistry, By D. Voet, J.G. Voet, and C.W. 
Pratt, 2006. p. 1054.  Copyright 2006 by John Wiley and Sons, Inc. 
 
 
Cells within the late G1 and early S phases are more susceptible to carcinogenesis 
(Ullrich, 2005).  When a cell becomes cancerous, the cell cycle is completed more 
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cell cycle engaged in cell proliferation(Voet et al., 2008).  Rapidly proliferating cells are 
more sensitive to radiation and chemotherapy, as many therapies are most effective 
during the M phase, making cancer cells more susceptible to these treatments (Ullrich, 
2005).       
Carcinogenesis 
Cancer cells are characterized by certain characteristics, including loss of 
proliferative control and capacity to differentiate, altered biochemical properties, 
chromosomal instability, and capacity to metastasize.  Loss of proliferative control is the 
primary characteristic shared by all cancer cells.   Normally, cell division is initiated by 
numerous factors, including cyclins and growth factors, and inhibited by others, such as 
lack of cellular space (contact inhibition) (Burke, 1996; Langhorne et al., 2007; 
Schneider et al., 2003).   In a malignant cell, cell division continues even when the 
cellular environment does not favor proliferation, resulting in uncontrolled growth.  Loss 
of capacity to differentiate indicates that cells do not attain the specific structural and 
functional characteristics of the tissue from which they are derived, as determined by 
their genetic coding (Langhorne et al., 2007).  The degree of differentiation (well-
differentiated, poorly-differentiated, or undifferentiated) is an important clinical 
indication of cancer progression.  Altered biochemical properties allow for continued loss 
of proliferative control and differentiation, in addition to increased rates of anaerobic 
glycolysis, loss of cellular adhesiveness, and production of tumor-associated antigens and 
metabolic by-products, including hormone-like substances.  Some of these metabolic 
alterations allow for some degree of biological and therapeutic targeting of cancer cells.   





continued cellular mutation, resulting in variable subpopulations of neoplasms within a 
given tumor, some of which may be particularly resistant to cancer therapy (Langhorne et 
al., 2007). 
While the exact cause of most cancers is still undetermined (Pfeifer, 2007), there 
are several known processes and events which may need to act in concert in order to 
initiate carcinogenesis.  The hypothesis that more than one insult, or “hit,” to a cell’s 
genes cause cancer is called the “multiple hit theory” (Schneider et al., 2003).   Because 
the human body has numerous, redundant protective mechanisms against genetic 
alteration, more than one hit is necessary to overwhelm this elaborate defense system.   
Protective mechanisms include tumor suppressor genes (also known as antioncogenes), 
which, in the presence of DNA alteration, can inhibit growth, prevent adhesion of 
metastatic cells, repair DNA, or induce apoptosis, depending on the gene and biological 
circumstances (Langhorne et al., 2007).  Possible insults to a cell include radiation 
(including solar), endogenous substances, (e.g., tobacco smoke, certain plastics, 
laboratory chemicals), lifestyle (e.g., obesity, alcohol consumption, stress level, lack of 
exercise, poor diet), and viruses (e.g., Human papilloma virus, Epstein-Barr, hepatitis B)  
(Schneider et al., 2003; Ullrich, 2005).   Any material known to stimulate the 
development of cancer is known as a carcinogen.  Carcinogens can cause genetic 
mutations in several ways, including DNA replication errors, elimination, insertion, or 
substitution of one of the components of the DNA strand. 
Carcinogenesis is often described as occurring in two distinct events: initiation 
and promotion.   Initiation is the mutational change that occurs when a carcinogen 





cancer occurs.  Otherwise, the cell may become permanently damaged, ultimately 
resulting in cellular death, or may develop into cancer in the presence of a cocarcinogen.  
Promotion describes the interaction of the cocarcinogens, or promoting agents, with the 
altered gene, resulting in damage to the proliferating mechanism of the cell (Langhorne et 
al., 2007).  The introduction of an activator, followed by the introduction of a promoter, 
is necessary for the development of a tumor.   A promoter does not mutate DNA or cause 
cancer itself, but rather interacts with the initiator to allow carcinogenesis to proceed.  
See figure 2.  A final stage, progression, is sometimes described as the process of 





Figure 2.  Initiation and Promotion.   Adapted from Oncology Nursing 5
th
 Edition, by M. 












Introduction of Initiator 






 Although every type of cell in the body is capable of becoming cancerous, there 
are five broad classes of cancer.  Carcinomas are solid tumors originating in epithelial 
cells, particularly in secretory tissues such as breast, prostate and pancreas (Schneider et 
al., 2003).  Between 85% and 90% of all human cancers are carcinomas, making it by far 
the most common cancer.  Melanomas are cancers originating in melanocytes, pigment-
producing cells.  These occur primarily in skin cells, but may occur elsewhere, including 
mucosal tissue and within the eye.  Sarcomas are cancers that develop in bone, muscle, 
cartilage, fat or connective tissue and are fairly rare, accounting for less than 2% of all 
cancers.  Leukemia is a cancer of blood-synthesizing organs, primarily the bone marrow, 
which results in abnormal leukocyte production.  This type of cancer is diffuse, rather 
than a solid tumor, and therefore requires different treatment strategies than other types of 
cancer.  Lymphomas are cancers of lymphoid tissue, and are broadly classified as 
Hodgkin’s or Non-Hodgkin’s, according to cell type, degree of differentiation, growth 
patterns, and type of reaction elicited by tumor cells (Langhorne et al., 2007).  Although 
lymphoma originates in the lymphatic system and is classified as hematological 
malignancy, it presents as a solid tumor.    
Cancer Stages and Grades 
 Most solid tumors are classified in severity using the TNM staging system.  This 
system classifies tumors according to tumor size, the degree of spread to regional lymph 
nodes, and the presence or absence of distant metastases.  Generally, stage I tumors are 
limited to the site of origin, stage II cancers have spread to local tissues, and stage III 





deeper structures (Schneider et al., 2003).  A cancer is considered to be stage IV when 
distinct metastases are present, regardless of other criteria.  Refer to Table 1 on page 23.  
Cancer grading is another method of evaluating the severity of a cancer.  The 
microscopic appearance of the cancer cells, as opposed to the tumor as a whole, is 
considered, and differentiation is the primary indicator of cancer grade.  
Metastasis is the spread of cancer beyond the site of origin through veins, arteries 
and the lymphatic system.  The ability to metastasize, the process in which cancer spreads 
from the tissue of origin to distant sites, is a trait unique to cancer and is another indicator 
of disease severity (Stetler-Stevenson & Kleiner, 2005).  For metastasis to occur, cancer 
cells detach from a primary tumor due to increased motility, enter the circulatory system, 
and aggregate with blood borne elements (including other metastases), protecting them 
from destruction (Langhorne et al., 2007).  The cells must then leave the circulation and 
penetrate the distant tissue (extravasation).  Angiogenesis in the distant tissue provides 
blood to the metastatic lesion, supporting growth and malignancy.  Less than 1% of 
metastases survive this process, and the longer they are in the circulatory system, the 
more likely they will be destroyed.  Metastases can invade any type of tissue, regardless 
of the origin of cancer, but are common in local lymph nodes, lungs, bones, liver, and 
brain (National Cancer Institute, 2013).  Metastatic spread of cancer is typically 
indicative of a more aggressive cancer, even compared to direct spread of cancer, which 
penetrate and destroy adjoining tissues.  Often, metastases are microscopic and 
undetectable until further progression (Stetler-Stevenson & Kleiner, 2005).  Because of 





a treatment regimen, even if the primary cancer has apparently been cleanly removed in 
entirety with surgery (DeVita, 2005).   
Table 1   
 
General Staging of the TNM System  
Tumor stage Tumor size Lymph node status Metastasis 
I < 2cm None None 
II 2-5 cm No, or on same side None 
III > 5 cm Yes, on same side None 
IV Does not matter Does not matter Yes 




 In addition to removal of cancerous tissue as a cancer treatment, surgery can be 
used to prevent or detect cancer.   Certain precancerous conditions, such as moles and 
other skin anomalies, have a high risk of developing into malignant tissue.  Removal of 
this tissue can therefore prevent the onset of cancer.   Similarly, in individuals with a 
significant genetic risk of developing a certain type of cancer, as indicated by family 
history or genetic markers, may warrant prophylactic surgery to reduce the risk of cancer 
(DeVita, 2005).   There are several surgical methods that may be employed to obtain 
tissue for the purpose of histological examination.  Depending on the type of biopsy, 
varying degrees of tissue removal are required for analysis to determine if the tissue is 
cancerous, and to diagnose the stage of the cancer.  Surgery, including open biopsies of 
the lungs or liver, may also be used to diagnose opportunistic infections following 





 Surgery may be used alone as cancer treatment, or in combination with adjuvant 
therapies, such as chemotherapy and radiation.  The decision to include adjuvant therapy 
is largely determined by the extent of the primary lesion.  When the tumor is confined to 
the site of origin, surgery alone is typically the preferred method (Rosenberg, 2005).  The 
side effects of surgery alone are less damaging, and removal of the tumor can often 
permanently cure the patient of cancer.  Because approximately 70% of patients 
presenting solid tumors already have micrometastases beyond the primary site, adjuvant 
therapy is often incorporated (DeVita, 2005).   Beyond removal of the primary tumor 
mass, surgery may be used to remove metastatic tissue or tissue that is a risk of becoming 
metastatic (such as local lymph nodes), for reconstructive purposes, or for palliative 
purposes, such as removal of a tumor mass to improve comfort.   The initial health of the 
patient is another determinant in cancer treatment (DeVita, 2005; Schneider et al., 2003).  
Very frail or elderly individuals may decide to only have surgery to remove the primary 
tumor burden to reduce the toxic side effects of radiation and chemotherapy, even if the 
cancer has already metastasized.   
Radiation 
 Although long-term exposure to high energy irradiation can be carcinogenic, 
radiation therapy uses high energy irradiation to destroy malignant cancer cells.  The 
objective of radiotherapy is to sterilize cancer cells so that they are incapable of unlimited 
proliferation (Hellman, 2005).  There are two general types of radiation: brachytherapy 
(internal) and teletherapy (external).  With both types, the target area is small, and 
therefore radiation is typically not used to treat metastatic cancers (Schneider et al., 





Placement of the implant is important in brachytherapy, because the dose of radiation is 
related to the inverse square of the distance from the radiation source (Hellman, 2005).  
Therefore, any cancerous tissue outside of a given radius may not be adequately affected 
by the radiation dose.  In teletherapy, beams of radiation from outside the body are aimed 
at the target tissue.  Dosage is determined both by intensity of the beam and exposure 
time. 
Radiation-associated damage to biological systems spans a time scale of ~25 





 seconds), the radiation is actually absorbed (direct effect of radiation).  In the 
chemical stage, (10
-12
 to 1 second), highly reactive excited states and reactive oxygen 
species are formed.  In the biological stage (seconds to decades), the biochemical and 
cellular consequences of radiation are seen throughout the entire body.  It was previously 
thought that the antitumor effects of radiation are due entirely to the direct effect of 
radiation on cell membranes and DNA, but it is now recognized that the production of 
free radicals is important as well (Bensasson et al., 1993).   ROS react with tumor cell 
DNA, causing single or double strand breaks.  The presence of cellular oxygen is 
important for the formation of ROS.  Because tumors may be more poorly perfused than 
normal tissue, it is possible that radiation may damage healthy cells more than cancer 
cells.  To improve ROS production within the tumor, hyperbaria in conjunction with 
radiotherapy has successfully improved clinical effectiveness (Kirk, Wingate, & Watson, 
1976), but because this method is cumbersome, it is rarely used anymore.  The formation 
of other cytotoxic agents following radiation may also facilitate the antitumor effect of 





(Ralph et al., 2002),  interleukins-1 and -6 (Hallahan, Haimovitz-Friedman, Kufe, Fuks, 
& Weichselbaum, 1993), and cell adhesion molecules (Hallahan, Kuchibhotla, & Wyble, 
1996). 
There are several possible effects of radiation on both normal and cancer cells: 
cellular death (either apoptosis or necrosis), accelerated senescence, terminal 
differentiation, or no or minor alterations in their divisional process (DeVita, 2005).  
Cells are most likely to be destroyed while proliferating, particularly in the M and G2 
phases, therefore making cancer cells more vulnerable to radiation than normal cells.  
Even so, normal cells are considerably damaged by radiation therapy.  Local side effects 
of radiation therapy include pain, blistering, reduce range of motion, cell membrane 
damage, necrosis, fibrosis, fistula formation, and ulcerations (Allavena, Conroy, Aletti, 
Bey, & Lederlin, 1992; DeVita, 2005; Schneider et al., 2003).  Whole body side effects 
include nausea, pain, fatigue, diarrhea, lung fibrosis, anemia, and cardiomyopathy.  Local 
effects are typically associated with the radiation dose itself as well as cytotoxic agents 
and ROS, while whole body effects are associated mostly with cytotoxic agents and ROS 
production.   
Chemotherapy 
 The use of chemotherapy is common, as more than half of cancer survivors have 
undergone treatment with at least one drug (Langhorne et al., 2007). Chemotherapy can 
be employed as the primary means of anti-cancer therapy (neoadjuvant therapy) to limit 
the spread of localized tumors, particularly in late stage cancers, or as adjuvant therapy to 
shrink tumors prior to radiation or surgery and destroy microscopic metastases following 





combating hematological and metastatic cancers.  There are numerous types of 
chemotherapy, with varying anti-cancer mechanisms, but typically the drugs damage or 
disable cells with abnormal growth cycles.  The primary classes of chemotherapy drugs 
are alkylating agents, antimetabolites, antitumor antibiotics, and alkaloids.  Almost 
universally, there is collateral damage to healthy cells, but less significantly than the 
damage to cancer cells.  As in radiation therapy, chemotherapy can itself induce future 
cancer development, known as second cancers.  (Van Leeuwen & Travis, 2005)  
 Typically, a chemotherapy regimen consists of drug administration every 2-4 
weeks for 3-6 months.  Administration methods can be oral (pill, liquid, capsule),  
intravenous (single venipuncture, catheter, port), intraperitoneal, or via spinal taps 
(Schneider et al., 2003).  One challenge to the success of chemotherapy is the ability of 
malignant cells to adapt to a given drug, thereby becoming “drug resistant.”  To combat 
drug resistance, as well as to increase the overall antitumor effectiveness and minimizing 
the toxicity of the regimen, two or more different drugs are often administrated 
concomitantly (Kramer, Zakher, & Kim, 1988).  Typical side effects of chemotherapy are 
whole-body and include fatigue, cachexia, anorexia, and nausea, as well as cardiac, 
endothelial, pulmonary, gastrointestinal, hepatic, and neuroendocrine dysfunction 
(Schneider et al., 2003).  Local side effects usually are related to port implantation and 
acute pain and cellular damage at the site of administration (Langhorne et al., 2007).  
Treatment-related side effects not only affect quality of life and physical capacity, but can 
be dose-limiting, decreasing overall effectiveness and reducing a cancer patient’s survival 
time.  Oxidative stress-induced side effects, particularly associated with anthracyline 





Hormonal Therapy and Targeted Therapy 
 Hormonal therapy is most commonly used in cancers affecting primary or 
secondary sexual organs, including breast, prostate, and endometrial carcinomas.  These 
cancers can be dependent upon binding of sex hormones to their receptors (if present) in 
cancer cells to continue growth.  Hormonal therapy retains cancer cells in quiescence (G1 
or G0), preventing continued growth (Sing-Hung, 2007).  A common treatment used in 
breast cancer survivors is the anti-estrogen Tamoxifen, which may be used as an adjuvant 
treatment for as many as five years.  Tamoxifen is used to treat metastases and to prevent 
recurrence (Schneider et al., 2003), as well as to prevent the onset of breast cancer in 
post-menopausal women with genetic risk or precancerous conditions.  Aromatase 
inhibitors such as Arimidex® similarly decrease circulating levels of estrogen, but act 
upon the enzyme aromatase in the adrenal glands, reducing the endogenous production of 
hormones (Langhorne et al., 2007).  Anti-androgens are used to target prostate cancer 
using a similar mechanism as anti-estrogens.  Luteinizing hormone releasing hormone 
(LHRH) agonists such as goserelin acetate bind to LHRH receptors in the pituitary gland 
and inhibit luteinizing hormone production, in turn reducing the endogenous production 
of testosterone in males and estrogen in women.  In advanced cases of breast or prostate 
cancer, or in very old cancer patients, hormone therapy is used alone as a palliative 
treatment by slowing or temporarily halting the growth of cancer without actually 
eliminating the tumor mass.  Despite typically resulting in fewer and less severe side 
effects than radiation and chemotherapy, hormonal therapy is not without consequence, 
as Tamoxifen may result in post-menopausal symptoms and thromboembolic events 





al., 1999; Nazarewicz et al., 2007), and, like radiation and chemotherapy, the induction of 
ROS by Tamoxifen likely plays a role in its antitumor effects.   
 Much like hormonal therapy, targeted therapy exploits specific characteristics of 
cancer cells, in this case mutant kinases, which can be used to identify and attack a tumor 
(Sawyers, 2004).   A well-known drug using this strategy is Herceptin (Trastuzumab), a 
monoclonal antibody that targets ErbB-2 (HER-2), a tyrosine kinase receptor that is 
involved in the development of breast cancer.  These therapies have a relatively high 
response rate when appropriately used, but as of yet, only a fraction of human cancers 
contain known kinase-domain mutations.  Another proposed form of targeted therapy 
alters the redox balance within a cancer cell, either increasing oxidative stress by 
inhibition of antioxidant (AOX) enzymes or induction of ROS production, or decreasing 
oxidative stress, by activation of AOX enzymes or inhibition of ROS production (J. 
Wang & Yi, 2008).  These strategies will be discussed in a later section.   
Immunotherapy 
 An alternate method of cancer treatment involves the use of cancer vaccines to 
stimulate the immune system to destroy cancer cells.  Because the molecular composition 
of many tumor-associated antigens have been identified, it is possible to specifically 
target cancer cells.  The effect is similar to an autoimmune disease, in which the immune 
system recognizes particular protein fragments and attacks these “self-antigens” (Dudley 
et al., 2002).  The primary advantage of this method is the significant reduction in side 
effects, if used alone.  Additionally, because the immune system is designed to protect 
the entire body, as various leukocytes circulate in the circulatory and lymphatic systems, 





from the primary lesion.  Unfortunately, the objective response rate to immunotherapy 
has, to date, been very low (2.6%) (Rosenberg, Yang, & Restifo, 2004).  
Reactive Oxygen Species and Oxidative Stress 
 Reactive oxygen (and nitrogen) species (ROS / RNS) are extremely unstable 
molecules containing an unpaired valence electron (Halliwell & Gutteridge, 2007).  Also 
known as free radicals, ROS can cause damage to tissues by stealing electrons from 
nearby molecules, creating a new radical and propagating a chain reaction.  Such a chain 
reaction in lipid membranes can damage any cell, in a process called lipid peroxidation, 
but damage also occurs to other cellular components, including proteins, causing skeletal 
and cardiac muscle dysfunction, and nucleic acids, potentially resulting in DNA 
modification.   
 ROS are formed in all organisms, including healthy humans.  Although oxygen is 
required for aerobic metabolism, and therefore human life, it can be toxic when it 
becomes a radical.  The most commonly produced ROS are superoxide (O2
•-
) and 
hydroxyl radicals (OH·) (Halliwell & Gutteridge, 2007).   The dot (·) indicates that a 
molecule is a radical, with an unpaired electron.  Additionally, non-radical oxygen 
derivatives such as hydrogen peroxide (H2O2), singlet oxygen (
1
O2), lipid hydroperoxides 
(LOOH), and various other hydroperoxides (ROOH), although not truly radicals, are 
included in the ROS classification (Berlett & Stadtman, 1997).   Most free radical 
production in healthy individuals occurs in the mitochondria, due to a “leakage” of 
electrons from 1-2% of the oxygen in oxidative phosphorylation (Boveris & Chance, 
1973),  which can form O2
•-
.  Because this original value was determined using isolated 





an overestimation (Vollaard, Shearman, & Cooper, 2005).   Superoxide production in this 
manner occurs in complex I, but primarily occurs in complex III of the electron transport 
chain, as the unstable intermediate semiquinone anion can directly transfer electrons to 
molecular oxygen instead of reducing to ubiquinone (coenzyme Q) (Agostinelli & Seiler, 
2006; Turrens, 1997).  Because this process is non-enzymatic, a higher flux of oxygen 
through the mitochondria typically results in greater O2
•-
 production. 
ROS production is an important element of biological defense against pathogens 
and toxins.  Free radical production occurs in leukocytes, which create superoxide to 
destroy pathogens, in what is known as a respiratory burst.  NAD(P)H oxidase catalyzes 






 ).  A downstream reaction of the 
respiratory burst catalyzed by myeloperoxidase creates hypochlorous acid, a highly 
reactive oxidant, from H2O2 and a chloride ion (Babior, 2000).   The cytochrome P450 
system in the endoplasmic reticulum, which plays diverse roles metabolizing steroids, 
fat-soluble vitamins, fatty acids, eicosanoids, drugs, and carcinogens, is another source of 
ROS in healthy individuals via a NADPH mechanism (Symons & King, 2003).  
Oxidative stress produced by the P450 system have been found to mediate the chemical 
toxicity of certain drugs, including alcohol and acetaminophen (Gonzalez, 2005) 
Cyclooxygenase (COX) (Armstead, 2001) and xanthine oxygenase (XO) are 
further pro-oxidant enzymes known to produce superoxide in both healthy and diseased 
individuals.  XO, like NAD(P)H, is expressed phagocytic cells, but also plays a role 
innate immune function as it is expressed on the epithelial surface  (Vorbach et al., 2003).  
Xanthine oxidoreductase has two forms: xanthine reductase, which creates the 





constitutively expressed, but is rapidly converted to xanthine oxidase (Vorbach et al., 
2003).  Similarly, COX-2 is not constitutively expressed, but is highly inducible (Chan, 
2001).  These tightly regulated pro-oxidant enzymes illustrate the importance of ROS 
creation in healthy individuals.    
Superoxide can dismutate spontaneously or enzymatically, producing hydrogen 




 →  
Fe
2+
 + O2) (Halliwell & Gutteridge, 2007).   In another reaction known as the Fenton 
reaction, ferrous iron(II) is oxidized by hydrogen peroxide, creating ferric iron(III), a 
hydroxyl anion, and a hydroxyl radical (Fe
2+






·).    The 
overall reaction (O2
•-




· + O2), known as the Haber-Weiss reaction, 
therefore creates hydroxyl radicals from superoxide and hydrogen peroxide.  Fortunately, 
in healthy individuals, ferrous iron is not easily oxidized, as it is bound tightly in organic 
complexes, but certain metabolic and disease states can make iron accumulate.  Hydroxyl 
radicals are extremely biologically reactive and are particularly damaging because there 
is no enzymatic reaction that can eliminate OH
-
· (Manda, Nechifor, & Neagu, 2009).    
Therefore, the only defenses against cellular damage from OH
-
· are effective repair 
systems, or preventing their formation to begin with.   
Another radical, nitric oxide (NO
·
), is produced primarily by NO synthase in 
endothelial cells (eNOS), but has recently been shown to be produced in mitochondria 
(Giulivi, Poderoso, & Boveris, 1998).   Although NO
·
 is more commonly known as a 
signaling molecule, it is capable of reacting with O2
•-
 to form peroxynitrite (ONOO
-
), 
another highly reactive oxidant.  Peroxynitrite is more stable than either NO or 





hydroxyl-like and nitrogen dioxide radicals (Kojda & Harrison, 1999).   Beyond the 
damaging effects of peroxynitrite, inactivation of nitric oxide by superoxide is likely a 
contributor of endothelial dysfunction.  In much of the literature, reactive oxygen and 
nitrogen species (RONS) are discussed as a single entity and in this manuscript will be 
referred to, generally, as “ROS” unless otherwise specified.   
Antioxidant Defense 
 Because ROS are continuously formed in healthy individuals, an antioxidant 
defense system is in place to counteract normally produced free radicals.  Antioxidants 
are molecules that inhibit free radical reactions, typically by acting as a reducing agent by 
donating an electron and ceasing the oxidative chain reaction.  Enzymatic antioxidants, 
including superoxide dismutases (SOD), catalases, glutathione peroxidases, thioredoxins, 
and lactoperoxidases, are central to this system (Leffler, 1993).  SOD, found in cytosol, 
mitochondria, and extracellular spaces, catalyzes the dismutation of superoxide into 
hydrogen peroxide and oxygen (2 O2
•-
 + 2 H
+
 →  H2O2 + O2) (Baskin & Salem, 1997).  
While hydrogen peroxide is significantly less destructive than superoxide, it is still a 
harmful toxin, which can be transformed into water by glutathione peroxidase (2 H2O2 + 
2 GSH → GSSG + 2 H2O) or catalase (2 H2O2 → 2 H2O + O2).  If SOD is active, but not 
supported by catalase and glutathione peroxidase, the net result may be enhanced 
oxidative stress, as H2O2 is more reactive than O2
•-
 (Manda et al., 2009).   Non-enzymatic 
antioxidants such as ascorbic acid (vitamin C), α-tocopherol (vitamin E), flavonoids, 
carotenoids, glutathione (GSH) are an important element of the mammalian antioxidant 
system (Halliwell & Gutteridge, 2007).  These antioxidants are typically exogenously 





There is evidence that some degree of exogenously-derived, non-enzymatic antioxidants 
are sequestered, and released during periods of increased ROS production (Mastaloudis, 
Leonard, & Traber, 2001).  Endogenous non-enzymatic antioxidants include proteins like 
albumin and ferritin, and metabolites, including uric acid, bilirubin and pyruvate, can also 
effectively act as free radical buffers, preventing damage to more important molecules, 
namely cellular elements (Manda et al., 2009).    
The antioxidant defense system is capable of modification, primarily in response 
to the production of some degree of oxidative stress.  The concept of hormesis describes a 
beneficial physiological response or adaptation to a mildly damaging stimulus (Ji et al., 
2006).  The adaptive response to exercise is the most well-known example of hormesis, 
and it has been suggested that a similar such effect occurs in response to oxidative stress.  
Indeed, many of the beneficial adaptations that occur with chronic exercise may be 
partially attributed to the presence of ROS during and follow exercise, which may act as 
signaling molecules (Ji, 2008; Powers et al., 2009).  The modulation of antioxidant 
defense in response to exercise training is a paradigmatic example of this hormetic 
response and will be discussed more in depth later.  The human antioxidant defense 
system can respond to acute and chronic exposure to ROS in the absence of exercise as 
well.  Acute (Sasaki, Akamatsu, & Horio, 1997) and chronic (Iizawa, Kato, Tagami, 
Akamatsu, & Niwa, 1994) UVB radiation exposure has been shown to increase SOD 
activity in human keratinocytes.  Similarly, diabetic pancreatic β-cells can increase their 
antioxidant defense (overexpression of numerous antioxidant enzymes) compared to 







Oxidative Stress and Markers 
of Oxidative Stress 
 When the generation of reactive oxygen and nitrogen species exceed cellular 
adaptive and repair capacities, it is known as oxidative stress (Valko 2007).   This occurs 
when acute production of ROS and/or RNS is higher than normal, due to some 
physiological or environmental stress, when the antioxidant enzyme system is 
compromised, or both.  If the antioxidant defense system is in place, ROS produced 
during physiological or pathophysiological processes are never given the chance to cause 
damage, and redox balance is maintained.  Reductive stress is an alternate pathological 
state, in which antioxidant activity, either endogenous or exogenous, far outstrips ROS 
production, resulting in redox imbalance (Rajasekaran et al., 2007).   
 As previously mentioned, proteins, fats and nucleotides are all potential sites of 
oxidative damage.  Due to the extremely transient nature of reactive oxygen species, it is 
difficult to perform a chemical analysis of ROS themselves.  Rather, downstream 
products of oxidative stress in blood and tissues may be analyzed via biochemical 
analysis.  An exception to this is hydrogen peroxide, which is radical-producing, but not a 
radical itself, making it stable enough to measure directly (Bloomer, 2008).  Perhaps the 
most commonly used marker of oxidative stress in malondialdehyde (MDA), a stable end 
product of lipid peroxidation.  Because lipid peroxidation occurs in lipid membranes, all 
cells are potentially targets of lipid peroxidation, making MDA a fairly good marker of 
total body oxidative stress.   MDA accumulation in tissue or plasma can be measured 
directly, or with a thiobarbituric acid reactive substances (TBARS) assay, in which 
thiobarbituric acid reacts with MDA to produce a fluorescent product (Vasankari, Kujala, 





hydroxynonenal (4-HNE) and F2 isoprostanes such as 8-iso-Prostaglandin F2alpha (8-
isoprostane).  MDA itself is capable of further reactivity with nucleic acids, including 
DNA, which may be possibly mutagenic (Marnett, 1999).   A more common pathway to 
DNA damage is by direct modification via superoxide and peroxynitrite.  8-Hydroxy-
2’deoxyguanosine (8-OHdG), a fairly ubiquitous byproduct of oxidative DNA damage, is 
the primary biomarker for DNA oxidation and can be assessed in urine, serum, 
cerebrospinal fluid, cells or tissues.  
Carbonyl derivatives of proline, lysine, arginine and threonine are the most 
common oxidation products of protein, and can be assayed in plasma, serum, cell lysates 
or purified proteins (Paromov, Qui, Yang, Smith, & Stone, 2008).   Similarly, advanced 
oxidation protein products (AOPP) are makers of protein oxidation created during 
oxidative stress through the reaction of plasma proteins with chlorinated oxidants such as 
hypochlorous acid (Marsche et al., 2009; Witko-Sarsat et al., 1996).  Although AOPP are 
most commonly used clinically to screen for chronic diseases such as renal 
complications, diabetes mellitus, and atherosclerosis, they are adequate markers of 
general oxidative stress.  3-Nitrotyrosine, an end product of peroxynitrite reacting with 
tyrosine, while theoretically could be used as a marker of protein oxidation, is in reality 
used as a marker of peroxynitrite, and therefore nitrative damage.    
 A more direct measurement of ROS involves the use of florescent probes or spin 
traps, which directly capture intracellularly produced radicals and convert them into more 
stable molecules (Powers & Jackson, 2008).  While this method allows for determination 
of ROS production in different tissues and cellular compartments, there are disadvantages 





production alone does not indicate a state of oxidative stress, as an increased activity of 
the antioxidant system may maintain redox balance.  Additionally, microprobes and spin 
traps may disturb the intracellular environment, altering ROS production (Halliwell & 
Gutteridge, 2007). 
 Another method of determining redox status in living systems is measurement of 
antioxidant enzyme activity, and non-enzymatic antioxidant concentrations.  Decreased 
enzymatic antioxidant capacity indicates poor ability to handle an increased ROS load, 
but does not actually indicate the level of ROS production.  Commonly measured 
antioxidant enzymes include superoxide dismutase, glutathione peroxidase, and catalase 
(Finaud et al., 2006).  Alternately, a measured reduction in non-enzymatic antioxidants, 
such as glutathione, can indicate a chronic overproduction of ROS.  In particular, ratio of 
reduced glutathione to oxidized glutathione (GSH:GSSG) is a commonly used 
determinant of oxidative stress (Serru et al., 2001).  In normal, healthy individuals, the 
GSH/GSSG ratio is approximately 10:1, but during chronic oxidative stress, GSH is 
depleted by the action of glutathione peroxidase (Ji, Fu, & Mitchell, 1992; Serru et al., 
2001).   Total antioxidant capacity of a tissue or blood sample can be determined, which, 
while lacking specificity, may be a more practical assessment of an individual’s redox 
status.  Several methods of determining total antioxidant capacity, including the Trolox 
equivalent antioxidant capacity (TEAC), oxygen radical absorbance capacity (ORAC), 
and ferric reducing ability of plasma (FRAP) assays, compare the antioxidant power of a 
given sample (e.g., blood, tissue, food items) to a standard antioxidant, Trolox (Wang et 
al., 2004).  This is often a practical method of determining redox status because the 





support mechanisms such as transporters, is complex and complimentary, meaning that 
the expression of any single antioxidant may be misinterpreted.  For example, the 
overexpression of superoxide dismutase without a similar rise in catalase expression has 
been shown to result in increased rather than decreased oxidative stress (McCord, 1993). 
Reactive Oxygen Species as  
Signaling Molecules  
For years, ROS production was thought to be simply an unavoidable, damaging 
by-product of working muscles during exercise.  It had been long assumed that exercise 
acutely induces oxidative stress simply because of the significant (100 to 200-fold) 
increase in oxygen flux through the mitochondria, thereby increasing electron leak and 
superoxide formation (Clanton, Zuo, & Klawitter, 1999).  This was seemingly supported 
by evidence of hyperoxia-induced ROS production, even in the absence of skeletal 
muscle contraction (Flandin, Donati, Barazzone-Argiroffo, & Muzzin, 2005).  This 
notion was countered by the finding that hypoxia can also increase ROS production 
(Bailey, 2001; Waypa et al., 2010).   High altitude exposure similarly induces oxidative 
stress, which may be implicated in acute mountain sickness (Bailey, Davies, Young, 
Hullin, & Seddon, 2001; Bailey et al., 2009; Dosek, Ohno, Acs, Taylor, & Radak, 2007)   
One explanation offered to explain these paradoxical effects was that the reduced 
mitochondrial oxygen saturation (pO2) during exercise may cause ROS production 
(Bailey, 2001).  Mitochondria may act as oxygen sensors by inducing ROS in response to 
low pO2, which in turn mediate transcriptional changes implicated in adaptation to 
hypoxia and aerobic exercise (Brunelle et al., 2005; Chandel et al., 1998; Chandel et al., 





It is now recognized that ROS production by contracting muscle plays an 
important role in the adaptive response to exercise (Jackson, 2005, 2009a; Powers et al., 
2009).  Nitric oxide (first called endothelium-derived relaxing factor) has long been 
recognized for its ability to vasodilate.  When the NO-producing enzyme eNOS 
(endothelial nitric oxide synthase) is downregulated or eliminated, vascular dilation is 
prevented.  (Fleming & Busse, 1999).  Oxidative stress may actually mediate this, as 
superoxide reacts readily with NO, producing peroxynitrite.  Only recently were alternate 
ROS identified as direct cellular signaling molecules.  Low concentrations of ROS are 
important for cellular signaling (Zhang 2007).  For instance, low levels of ROS are 
apparently crucial for normal force production, and a slight increase in ROS generation 
causes an increase in force production (Reid, 2001).   When  higher levels of ROS are 
present, a subsequent reduction in force production occurs, partially explaining the 
development of fatigue in response to submaximal contractions (Reid, Khawli, & Moody, 
1993).  Modification of contractile function may be due to ROS exposure to redox-
sensitive, sulfhydryl groups of myofibrillar proteins, and phosphatases and kinases of  
multiple elements of the contractile system (Jackson, 2009a; Powers & Jackson, 2008), 
including SERCA  (Smith & Reid, 2006), ryanodine receptors (Zima & Blatter, 2006), 
and myosin heavy chains (Powers et al., 1994). 
 Recently, the role of ROS as a mediator in numerous signaling pathways involved 
in growth, differentiation, proliferation and apoptosis has gained attention (Ji, 2008).    
Among these are the mitogen-activated protein kinase (MAP-K), nuclear factor (NF) κB, 
activator protein 1 (AP-1) heat shock proteins, p53, and the p38 cascade.  One primary 





antioxidant enzymes (Allen & Tresini, 2000), so that with chronic ROS exposure, 
antioxidant enzyme activity increases (Hammeren et al., 1992; Powers, Ji, & 
Leeuwenburgh, 1999; Witt, Reznick, Viguie, Starke-Reed, & Packer, 1992).  ROS 
stimulated MAP-K activation can also acutely trigger glucose uptake in skeletal muscle, 
both during muscle contraction (Sandstrom et al., 2006), and independent of active 
contraction, (Chambers, Moylan, Smith, Goodyear, & Reid, 2009)  indicating a metabolic 
signaling role of ROS.  Because these signaling cascades are implicated in numerous 
acute and chronic responses to exercise, including muscular hypertrophy, angiogenesis, 
and vascular adaptation (Ji, 2008), it is possible that these too may be ROS dependent to 
some degree.   
The precise redox balance of a healthy cell, in response to signaling cascades, 
exercise, and exogenous stimuli, has a potent and sometimes counterintuitive effect. For 
instance, a hormetic response to ROS in skeletal muscle adaptation is apparent, as ROS 
signaling likely contributes both to muscle fiber adaptation following contractile activity, 
as well as prolonged muscle disuse (Powers et al., 2009).  This seemingly contradictory 
interaction is likely due to the time course and magnitude of ROS generation.  Exercise is 
a relatively short (minutes to hours) and moderate stimulus for ROS production, 
facilitating cellular adaptation and protection against future insult, while chronic, high 
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 The complex interaction between the so-called “tumor suppressor protein,” p53, 
ROS, and antioxidant enzymes illustrates the intricate interrelationship between cellular 
signaling, oxidative stress, and cancer etiology, pathology, and prevention.  (Y. Chen et 
al., 2007; Hussain et al., 2004; Liu et al., 2008; Tu et al., 2009).  ROS act as both 
upstream mediators of p53 signaling, as well as downstream second messengers of p53- 
regulated apoptosis.  Physiological levels of p53 help maintain cellular redox balance, 
and this may be one of the tumor-suppressing mechanisms of p53.  Alternately, both 
hypo- and hyper-physiological levels of p53 result in ROS generation via antioxidant 
suppression and/or prooxidant activation (Liu et al., 2008).  Although p53 is known to 
induce antioxidant enzymes, overexpression of p53 may increase cellular MnSOD and 
glutathione peroxidase (GPX), but not catalase, potentially resulting in inadequate 
removal of H2O2  (Hussain et al., 2004).  In response to stressors, including oxidative 
stress, a small proportion (~2%) of cellular p53 is translocated to the mitochondria, 
signaling apoptosis (Marchenko, Zaika, & Moll, 2000).  In this way, in response to mild 
oxidative stress, p53 protects the mitochondria genome (Liu et al., 2008).  Similarly, in 
response to chemotherapeutic agents, ROS-activated p53 activity leads to apoptosis 
(Ueno et al., 1999).  When the degree of oxidative stress is more severe, the DNA-
binding activity of p53 is abolished.  Because p53 is pivotal for most DNA-damage-
induced apoptosis, and p53 mutations are found in 70% of human cancers, its 
dysregulation, either via ROS or other means, is implicated in cancer initiation (Brosh & 
Rotter, 2009).   Apoptotic dysregulation can additionally make these cancer cells resistant 





 Like with p53, ROS have been shown to act both upstream and downstream of 
inflammatory cytokines.  Tumor necrosis factor (TNF)-α, interleukin-1β (IL-1β), and 
interferon-γ (IFN-γ),  elicit mitochondrial ROS production (Yang et al., 2007), yet ROS 
have been shown to induce production of macrophage inflammatory protein-2 (MIP-2), 
tumor necrosis factor-α (TNF-α) and interleukin-6, (IL-6) (Naha, Davoren, Lyng, & 
Byrne, 2010).  Further demonstrating their diverse role in cellular signaling and 
maintenance, ROS are known to be the second messengers responsible for regulation of 
angiogenesis and tumor growth through vascular endothelial growth factor VEGF (C. Xia 
et al., 2007), and they act as the initial signal for heat shock protein (HSP) 72 induction, 
which in turn are molecular chaperones capable of cellular protection (Tang et al., 2007). 
ROS Production with Acute  
and Chronic Exercise 
 Contractile activity of skeletal muscle has been known to produce ROS since 
1978, when Dillard et al. demonstrated that lipid peroxidation occurs during exercise 
(Dillard, Litov, Savin, Dumelin, & Tappel, 1978).  Since then, more than 300 articles 
have directly investigated the effect of acute exercise on oxidative stress (Fisher-
Wellman & Bloomer, 2009).  An early study reported that MDA increased in subjects 
subjected to a graded exercise test to exhaustion, but not in those who exercised at 70% 
of VO2 max or less (Lovlin, Cottle, Pyke, Kavanagh, & Belcastro, 1987).  This helped 
illustrate the dose-dependent nature of exercise-induced oxidative stress; a concept 
already hypothesized because of increased flux through the electron transport chain, and 
therefore increased electron leakage.  Similarly, there was a significantly greater 
concentration of plasma protein carbonyls following 120 minutes of steady state exercise 





Davis, Consitt, & Wideman, 2007).  Single bouts of exercise have been shown to alter 
thiobarbituric acid reactive substances (TBARS), a marker of malondialdehyde and 
phospholipid peroxidation (Radak et al., 1999), reactive carbonyl derivatives, a marker of 
amino acid modification (Radak et al., 1998), and 8-hydroxydeoxyguanosine (8-OHdG), 
a marker of DNA mutation (Asami et al., 1998; Niess, Hartmann, Grunert-Fuchs, Poch, 
& Speit, 1996).  Exercise can decrease the ratio of glutathione (GSH) to glutathione 
disulfide (GSSD), indicating antioxidant depletion in response to oxidative stress 
(Vollaard et al., 2005).  As will be discussed later, transient, post-exercise oxidative stress 
is a potent stimulus for increasing antioxidant enzyme activity, and ultimately confers 
resistance to future ROS exposure. 
Chronic exercise is also capable of measurably increasing markers of oxidative 
stress.  With chronic exercise, overtraining seems to induce oxidative stress, whereas 
moderate exercise can reduce resting and post exercise ROS production (Finaud et al., 
2006; Ji, 2002).  Excessive aerobic exercise, such as 30km/day for 8 days (Okamura et 
al., 1997) and 10 hours/day for 30 days (Poulsen, Loft, & Vistisen, 1996) drastically 
increased urinary 8-OHdG levels, even to a greater extent than intense, acute bouts of 
exercise.  Individuals with a compromised antioxidant defenses, such as cancer patients 
during and following treatment, have a much lower threshold for such exercise-induced, 
chronic oxidative stress.           
While electron leak is clearly a primary source of ROS production, more recently, 
alternate mechanisms of exercise-induced ROS have been proposed, supporting the 
notion that ROS production is not simply a byproduct, but rather a tightly regulated 





negligible increase in mitochondrial oxygen flux (Alessio et al., 2000).  More recently, it 
was shown that mechanical loading (stretch) of isolated myotubes induced ROS 
production, despite no change in oxygen flux (Chambers et al., 2009).  The transverse 
tubule NADPH oxidase produces superoxide in response to depolarization, stimulating 
calcium release for muscle contraction (Espinosa et al., 2006; Hidalgo, Sanchez, 
Barrientos, & Aracena-Parks, 2006), indicating superoxide’s vital signaling role in 
muscular function, and an alternate pathway for exercise induced ROS production.  
Similarly, NADPH oxidases of plasma membranes (Javesghani, Magder, Barreiro, 
Quinn, & Hussain, 2002), as well as cardiac (Cherednichenko et al., 2004) and skeletal 
(R. Xia, Webb, Gnall, Cutler, & Abramson, 2003) sarcoplasmic reticula may be 
implicated in exercise-induced ROS production.  Furthermore, following intense exercise 
and muscular damage, phagocytic cells typically invade the area and contribute to the 
total exercise-associated ROS production (Malech & Gallin, 1987).  ROS production in 
this manner can be significant enough to damage tissue that had been undamaged by the 
exercise dose (Zerba, Komorowski, & Faulkner, 1990).  Another consideration when 
exercising outside is exposure to airborne pollutants that may directly or indirectly 
increase oxidative stress (O'Neill et al., 1995).  Alternate mechanisms may exist, but have 
not been elucidated as of yet. For instance, the mitochondria from fast, type II muscle 
fibers of rats have a greater inherent propensity to produce ROS (Anderson & Neufer, 
2006).  Interestingly, oxidative, type I muscle fibers still have higher antioxidant enzyme 







Exercise Increases Antioxidant Capacity 
Numerous studies indicate increased antioxidant enzyme activity (SOD, GPx, 
CAT) in skeletal and cardiac muscle tissues and blood following endurance training in 
animals and healthy humans (Finaud et al., 2006; Ji, 2002).  While an acute bout of 
exercise can transiently activate MnSOD gene transcription, substantial MnSOD 
upregulation may require more chronic stimulation, or in other words, training (Hollander 
et al., 1999).  Aerobic training, in particular, has elicited augmentation of antioxidant 
defense.  Accumulation of 8-OHdG was significantly less in exercise trained (9wks 
swimming) rats than age matched controls (Radak et al., 1999).  Similarly, F2-isoprostane 
levels (a measure of lipid peroxidation) decreased 34% in premenopausal women 
following 15 weeks of aerobic exercise training (Schmitz et al., 2008).  Surprisingly, 
there is also evidence for mobilization of non-enzymatic antioxidants (vitamins C and E) 
from body reserves during an exercise bout (Mastaloudis et al., 2001), but the plasticity 
of this mechanism in response to training has not been characterized.   
 Regardless of the mechanism, acute exercise is clearly a potent mediator of ROS 
formation.  As discussed, these ROS are necessary signaling molecules, orchestrating 
changes in muscle function, glucose uptake, and endothelial function.  While exhaustive 
exercise may result in transient oxidative stress, moderate levels of oxidative stress can 
have a hormetic effect on antioxidant enzymes (Ji et al., 2006), imparting individual 
tissues and the organism as a whole with a greater capacity to tolerate a serious oxidative 







The Role of ROS in Aging and Diseases 
Increased baseline oxidative stress in cancer patients may precipitate cancer-
related anorexia/cachexia (Mantovani et al., 2004).  Specifically, cachexia has been 
associated with elevated levels of muscle malondialdehyde, a marker of lipid 
peroxidation and total body oxidative stress (Laviano et al., 2007).  The mechanism 
behind this may be an increase in protein degradation via the ubiquitin-proteasome 
pathway upregulation in response to cancer or treatment-associated oxidative stress.  
There is evidence indicating increased life span associated with calorie restriction (CR) in 
many organisms, including rodents (Barger, Walford, & Weindruch, 2003; Masoro, 
1988) primates, and humans (Cruzen & Colman, 2009; Ristow & Zarse, 2010), possibly 
due to reduced free radical generation and increased antioxidant enzyme activity.  Ristow 
& Zarse, (2010) suggest an effect of mitochondrial hormesis (mitohormesis) in response 
to both CR and exercise, in which exposure low level stress (ROS and otherwise) within 
the mitochondria increases resistance to stress ameliorates oxidative stress which may 
increase lifespan.  In elderly rats (34 mo), a 50% loss of muscle mass occurred in hind 
limb muscles but this was countered by CR (Weindruch, 1995).  Caloric restriction 
resulted in significantly increased GPX and CAT activity.  Reactive oxygen species may 
also contribute to sarcopenia and muscle aging, likely due to the combined effect of 
premature cellular senescence, dysfunctional sarcoplasmic reticuli, and reduced 
regenerative capacity (Fulle et al., 2004).   Increased serum protein carbonyls were 
associated with decreased grip strength in elderly women (mean age, 77.4 yrs), 
suggesting that oxidative damage to contractile proteins may directly reduce strength and 





Although a low level of ROS production (“redox tone”) may be crucial for 
contractile function at rest, increased ROS production results in oxidative stress and 
decreased contractile function.  Whereas antioxidant exposure at rest results in net 
reduction in force development in response to electric stimulation (Reid et al., 1993), 
during fatiguing stimulations, treatment with the superoxide scavenger, Tiron, augmented 
force generation (Mohanraj, Merola, Wright, & Clanton, 1998).  Oxidative stress can also 
alter skeletal muscle function by modifying ryanodine receptors and the calcium pump in 
SR membranes (Kagan, Ritov, Gorbunov, Menshikova, & Salama, 1998), specifically by 
oxidation of critical channel proteins in the presence of high hydrogen peroxide levels 
(Brotto & Nosek, 1996).  Reactive oxygen species, therefore, may alter Ca
++
 movement 
in and out of the cell, resulting in some degree of excitation-contraction uncoupling with 
aging (Renganathan, Messi, & Delbono, 1997).  Caloric restriction can preserve the 
mechanical properties of hind-limb skeletal muscle in elderly rats, and is associated with 
increased ryanodine receptor and dihydropyridine receptor activity (Mayhew, 
Renganathan, & Delbono, 1998), possibly due to reduced oxidative damage.  
 Beyond its interrelationship with cancer (which will be discussed in full later), 
oxidative stress has been implicated in the development or progression of numerous 
chronic diseases, including diabetes (Houstis, Rosen, & Lander, 2006; Kojda & Harrison, 
1999; Rudich et al., 1998; Wu, Chiou, Chang, & Wu, 2004), hypertension (Kojda & 
Harrison, 1999), vascular disease (Kotur-Stevuljevic et al., 2007), cachexia (Mantovani et 
al., 2004; McClung, Judge, Powers, & Yan, 2010), neurodegeneration (Pope, Land, & 
Heales, 2008), cartilage degradation (Henrotin, Kurz, & Aigner, 2005), Parkinson’s 





2009; Kojda & Harrison, 1999).  Free radical damage is well recognized as a fundamental 
mechanism of ischemia-reperfusion injury (Chan, 2001; Omar et al., 1990; Powers et al., 
1998).  Some infectious diseases, such as influenza, Helicobacter pylori, and HIV, exert 
their cytotoxicity via oxidative stress (Mates & Sanchez-Jimenez, 1999).  Additionally, 
generalized phenomena such as aging (Berlett & Stadtman, 1997; Finkel & Holbrook, 
2000; Harman, 1956; Jackson, 2009b) fatigue, (Fulle et al., 2000; Richards, Roberts, 
McGregor, Dunstan, & Butt, 2000; Richards, Wang, & Jelinek, 2007), muscle weakness 
(Powers & Jackson, 2008; Smith & Reid, 2006) and muscle wasting (Moylan & Reid, 
2007) are commonly attributed, at least in part, to oxidative stress. 
Dietary and Other Exogenous Antioxidants 
Dietary supplementation of antioxidants has been shown to prevent some of the 
health promoting effects of exercise.  Although chronic, continuous ROS exposure is 
associated with insulin resistance (Houstis et al., 2006; Rudich et al., 1998), exercise 
training, is well known to improve insulin sensitivity (Duncan et al., 2003; James, 
Kraegen, & Chisholm, 1984).  Ristow et al. (2009) demonstrated that the exercise-
induced ROS may be essential to mediate these changes.  Both trained and untrained 
groups improved indices of insulin sensitivity following exercise in the absence of 
antioxidant supplementation (vitamin C and vitamin E), whereas antioxidants prevented 
these improvements.  Similarly, increased RNA expression of SOD and GPX was 
inhibited by dietary antioxidant supplementation.  Again, this demonstrates the beneficial 
hormetic effect of repeated, transient ROS production due to exercise, and this may be 





While exogenous SOD administration is an effective method of protection against 
ischemia-reperfusion injury, very high doses of SOD can actually exacerbate the damage 
(Omar et al., 1990).   The apparent bell-shaped curve in the effectiveness of SOD in this 
case may be due to over-scavenging of superoxide, which may actually reduce the 






 → LOOH + 
O2) (McCord, 1993).  This concept is supported by research showing that SOD 
overproduction in transfected cells can mimic oxidative stress, by increased lipid 
peroxidation (Elroy-Stein, Bernstein, & Groner, 1986).  Additionally, endogenous 
antioxidant enzymes are coordinately regulated, so that glutathione peroxidases and 
catalases are upregulated in concert with SOD to match the currently level of ROS 
production (McCord, 2008).  Exogenous administration of any one of these alone will 
likely result in aberrant redox regulation.   
Because many cancer therapies are thought to initiate side effects such as 
cardiotoxicity via oxidative stress, there have been numerous attempts to reduce such side 
effects via antioxidant treatment.  For instance, pretreatment of mice with 
metallothionein, a free radical scavenging protein, attenuated doxorubicin-associated 
cardiotoxicity without reducing its antitumor action (Naganuma, Satoh, & Imura, 1988).  
Unfortunately, in humans, antioxidant therapy has failed to produce similarly positive 
results (Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004).  Moreover, antioxidant 
supplementation has the potential to decrease oxidative damage to healthy tissues during 
or following cancer treatment, it may also protect cancer cells, decreasing the 
effectiveness of treatment.  Lawenda et al., (2008) reviewed several clinical studies, and 





related side effects, should be avoided because of the potential for reduced treatment 
effectiveness.  Most significant among these studies were two authored by Bairati et al., 
in which 540 cancer patients undergoing radiation were either given a placebo or 
antioxidants (α-tocopherol with or without β-carotene).  Although they reported a 38% 
reduction in severe, acute side effect in the antioxidant group (Bairati, Meyer, Gelinas, 
Fortin, Nabid, Brochet, Mercier, Tetu, Harel, Abdous, et al., 2005), this was accompanied 
by a 29% and 56% reduction in the local tumor control rates for α-tocopherol and α-
tocopherol plus β-carotene, respectively. (Bairati, Meyer, Gelinas, Fortin, Nabid, 
Brochet, Mercier, Tetu, Harel, Masse, et al., 2005).  While some studies indicate that 
antioxidant supplementation can reduce risk of mortality and recurrence (Nechuta et al., 
2011) and increase effectiveness of treatment (Chinery et al., 1997), and several authors 
suggest that dietary AOX supplementation during treatment should be avoided because of 
the contentious nature of the subject (Block, 2004; D'Andrea, 2005).   A paper by 
Achuthan et al. (2011) indicated that in chemotherapy resistant cancers, a primary 
mechanism behind the failure of treatment regimens is low level of ROS associated with 
the hypoxic environment in the cell.  This suggests that reduced ROS in tumorous tissues 
may support the survival of cancer cells.  
Venkataraman et al. found that SOD overexpression inhibited the growth of 
androgen-independent prostate cancer cells (Venkataraman et al., 2005), but in the 
presence of a stressor (hyperthermia), SOD promoted cell survival (Venkataraman et al., 
2004).  This illustrates the intricacies of redox balance, whereas cells are protected by 
SOD in the presence of an environmental stressor, but are hindered by SOD in the 





radiation may similarly protect cancer cells from the environment stress of treatment 
(Conklin, 2000). There is recent evidence that a state of reductive stress, characterized by 
excessive levels of reducing equivalents, may be implicated in human disease, namely 
cardiomyopathy caused by mutations in the alpha B-crystallin gene of mice (Rajasekaran 
et al., 2007).   It is possible that on overabundance of dietary antioxidants may similarly 
result in other unfavorable effects, including the development and progression of cancer 
(D. P. Jones & Go, 2010).  
Cancer and Oxidative Stress 
 The interrelationship between cancer and oxidative stress is interesting, in that 
oxidative stress is implicated in both the etiology and pathology of cancer (Laviano et al., 
2007; Loft & Poulsen, 1996; Toyokuni, Okamoto, Yodoi, & Hiai, 1995; C. Xia et al., 
2007).  Reactive oxygen species are implicated in initiation, promotion and progression 
of cancer, as well as inhibition of processes that can normally interrupt the cell cycle and 
repair damage within cancer cells or otherwise initiate apoptosis (Valko et al., 2006).  
The rise in ROS associated with breast cancer is common enough that a reduced 
GSH/GSSG ratio has been identified as an important biochemical parameter for detecting 
breast malignancy (Yeh et al., 2006).  Further complicating things, both ROS and 
antioxidants have been proposed as a treatments for cancer in recent years (Renschler, 
2004; Tandon, Sharma, Mahajan, & Bardi, 2005; Trachootham, Alexandre, & Huang, 
2009; J. Wang & Yi, 2008).  Alternately, oxidative stress is capable of interfering with 
cancer treatment (Shacter, Williams, Hinson, Senturker, & Lee, 2000), yet there is 





2008).  Clearly, the normal physiological redox balance is delicate and complicated, and 
is dependent on cell type, as well as endogenous and environmental stressors. 
Oxidative Stress 
 A cursory comparison of exogenous sources of ROS production with known 
carcinogens reveals striking parallels (e.g., chemotherapeutics, UV light, ionizing 
radiation, environmental toxins).  It is therefore not surprising that soon after the 
discovery of ROS, Harman (1962) hypothesized that oxidative stress was implicated with 
not just aging, but cancer as well.  An abundance of epidemiological evidence supports 
the notion that oxidative stress may promote cancer (Bjelakovic, Nikolova, Simonetti, & 
Gluud, 2008; Dai et al., 2009; Hopkins, Fedirko, Jones, Terry, & Bostick, 2010; Li et al., 
2009; Loft & Poulsen, 1996; Matsui & Rai, 2008; Minelli, Bellezza, Conte, & Culig, 
2009; Singh & Kulawiec, 2009; Valko et al., 2006; Zipprich et al., 2009).   Additionally, 
secondary cancers caused by radiation therapy are likely associated with oxidative stress 
(Bostrom & Soloway, 2007).  Several mechanisms confirming this interaction have been 
identified (Loft & Poulsen, 1996; Valko et al., 2006), and will be discussed in the 
proceeding section.  
Mechanisms of ROS-Mediated  
Carcinogenesis 
ROS may potentiate carcinogenesis at various steps in cancer initiation, 
promotion and progression.  ROS are implicated in initiation by creating genomic 
instability.   For instance, hydroxyl radicals can react with guanosine to form 8-
hydroxydeoxyguanosine (8-OhdG), potentially resulting in G:C to T:A transversion point 
mutations (Loft & Poulsen, 1996; Wu et al., 2004). As discussed previously, DNA 





can potentiate survival of  cancer cells via proliferation, angiogenesis, metastasis and 
resistance to apoptosis (Halliwell, 2007).  
ROS promote cell proliferation primarily through activation of growth factor 
receptors and intracellular signaling pathways (J. Wang & Yi, 2008).  Elevated ROS 
activate NFκB and AP-1, both of which mediate tumor cell proliferation (Laurent et al., 
2005).  Additionally, ROS are capable of inhibiting protein tyrosine phosphatases, control 
elements of numerous growth factor receptors, including platelet-derived growth factor 
receptor (PDGFR), by oxidizing cysteine residues on their active site, ultimately 
abolishing their negative regulatory function (Chiarugi, 2005; Meng, Fukada, & Tonks, 
2002).  In other words, even in the presence of their ligands, these growth factors 
receptors are perpetually inactivated in the presence of sufficient ROS, resulting in 
unconstrained growth.   
ROS can similarly interact with protein tyrosine kinases, which are activated by 
oxidation of their thiol groups, resulting in aberrant growth signaling (Chiarugi, 2005).  
Vascular endothelial growth factor (VEGF) can promote tumor angiogenesis, and 
NADPH oxidase (NOX)-associated H2O2 production has been shown to increase VEGF 
expression (Arbiser et al., 2002).  Supporting the notion that ROS mediate angiogenesis 
via VEGF, Xia et al. (2007) demonstrated that NOX4 knockdown in ovarian cancer cells 
resulted in decreased expression of VEGF and tumor angiogenesis.  The metastatic 
potential of several types of tumors is also associated with ROS level (Lim et al., 2005), 
possibly due to altered expression of integrins, improved metastatic invasion, and 
avoidance of anoikis, a type of programmed cell death associated with detachment from 





shown to be correlated with level of 8-OHdG, and therefore may trigger the transition 
from benign to malignant tumor (Loft & Poulsen, 1996).    
The precise redox status of a cancer cell, depending on cell type and cancer stage, 
can alter the interaction between ROS and cancer treatment.  Figure 3 (Valko et al., 2006) 
shows the continuum of ROS exposure in cancer development.  Lee and Shacter (1999) 
found that H2O2 induced apoptosis in lymphoma within a very limited concentration 
range (~50μm), but induced necrosis instead at higher concentrations (~75-100 μm).  
Although the primary objective of cancer killing is achieved, necrosis invariably leads to 
inflammation and more significant side effects.  Shacter et al. (2000) later found that 
including the antioxidants agents Desferal, Tempol, and dimethylsulfoxide in various 
chemotherapy regimens enhanced chemotherapy-induced apoptosis and phagocytosis of 
cancer cells, while reducing H2O2 associated ATP depletion, and subsequently cellular 
necrosis and/or pyknosis (nucleus degeneration).  Recalling that these effects are in 
contrast to other studies, the disparity may be explained by variations in cancer type, 







Figure 3.  The level of free radicals at various stages of carcinogenic process.   
From  “Free radicals, metals and antioxidants in oxidative stress-induced cancer”  
in Chemico-Biological Interactions by Valko et al., 2006, pg 20. 
 
Antioxidant Enzymes in Cancer Cells 
 Cancer cells have altered antioxidant enzyme expression (Oberley, 2002; Oberley 
& Oberley, 1997; Trachootham et al., 2009).  Depending on the type of tumor and the 
location of the cell, manganese superoxide dismutase (MnSOD, found in mitochondria) 
may be either increased or decreased, but enzyme activity is universally altered (Oberley, 
2002).  Most cancer cells exhibit reduced MnSOD, but metastatic prostate cells have 
been shown to have increased MnSOD imparting particular resistance to treatment.  
Similarly, cells at the invading edge of tumors often exhibited elevated levels of MnSOD. 
Because there are no longitudinal studies on oxidative stress and cancer, it is difficult to 
determine whether altered antioxidant enzyme expression is a cause, side effect, or 
comorbidity of cancer.   As has been mentioned previously, oxidative damage to DNA is 
implicated in cancer development, and impaired antioxidant defenses may contribute to 





Cancer Treatment Side Effects 
Treatments for cancer such as surgery, chemo, radiation, and hormone therapies 
result in detrimental physical and psychological side effects. The most frequently 
reported symptom is cancer-related fatigue, which, according to the National Cancer 
Institute, occurs in 14 to 96% of cancer survivors who have been treated for cancer 
(National Cancer National Cancer Institute, 2013).  Other side effects include 
immunosuppression, cardiomyopathy, neurological dysfunction, and reduced aerobic 
fitness and muscular strength.  Loss of physical function and the ordeal of cancer 
treatment can be a psychological, social, and economic burden, resulting in a further 
reduction in quality of life and an increased level of depression 
Immune System 
 Both radiation and chemotherapy are associated with hematological toxicities and 
cause myelosuppression by damaging the blood cell-producing machinery of the bone 
marrow and directly destroying mature, circulating leukocytes (Schneider et al., 2003).  
Leukopenia is a condition in which the total leukocyte count is reduced.  Neutropenia 
describes an absolute decrease in the number of circulating neutrophils, and greatly 
increases the risk of infection.  Lymphocytopenia results from low white blood cells 
production in the lymph system.  Thrombocytopenia is a condition characterized by low 
levels of circulating platelets.   All of these conditions result in immunosuppression, and 
can result from cancer therapy, or the disease itself.  Extreme immunosuppression can 
become the limiting factor in treatment dosage, and increases the risk of prescribing 
exercise to cancer patients, as intense and even moderate exercise can also suppress the 






 Data from the Rocky Mountain Cancer Rehabilitation Institute (RMCRI) 
illustrates the severely reduced cardiorespiratory fitness of cancer survivors.  Average 
VO2 peak values for the RMCRI cancer population were markedly lower than the general 
US population, with a median VO2 value of 22 mL/kg/min, and a mean of 21.6 ± 6.3 
mL/kg/min (unpublished data). When using norms for the general US population 
(Thomson, Gordon, & Pescatello, 2010), the mean value for all age and gender groups 
were classified as “very poor.”  Similarly, individuals who had been treated with 
chemotherapy in childhood retained significantly reduced cardiorespiratory fitness, as 
evidenced by VO2 max values that are often only 50% - 70% of age- and gender-matched 
controls (Johnson et al., 1997).  Even in very fit cancer patients, radiation and 
chemotherapy can substantially reduce cardiorespiratory fitness.  Schumacher et al. 
(2008) showed that a 37% decrease in total hemoglobin mass in an elite endurance athlete 
following cancer diagnosis and chemotherapy was associated with a 42% reduction in 
aerobic capacity.   Additionally, Wiley (1998) demonstrated an average decrease in 
VO2max from 28.23 ± 5.54 mL/kg/min before surgery and chemotherapy, to 24.52 ± 6.13 
mL/kg/min after both surgery and chemotherapy in ten women with stage II breast 
cancer.  Primary causes of decrements in cardiorespiratory fitness include anemia 
(Barrett-Lee et al., 2006; Glaspy, 2001; Harrison et al., 2001), cardiotoxicity (Ascensao, 
Ferreira, Oliveira, & Magalhaes, 2006; Chaiswing et al., 2004; B. Chen, Peng, 
Pentassuglia, Lim, & Sawyer, 2007; Chicco, Hydock, Schneider, & Hayward, 2006; 
Hayward & Hydock, 2007; Hydock, Lien, Schneider, & Hayward, 2008; Kanter et al., 





Majid & Waters, 2008; Bonetto et al., 2009; Laviano et al., 2007), and mitochondrial and 
metabolic dysfunction  (Kovacic, Pozos, Somanathan, Shangari, & O'Brien, 2005). 
Cardiovascular System  
Reduced cardiorespiratory fitness following cancer therapy is often demonstrated 
by the damage to systems supporting aerobic capacity, particularly in the animal model.   
The majority of cancer patients receiving chemotherapy  (Barrett-Lee et al., 2006; Kitano 
et al., 2007) and radiation (Harrison et al., 2001) develop anemia.   Numerous 
chemotherapy treatments, particularly antitumor anthracyclines such as doxorubicin, are 
characterized by a dose dependent cardiotoxicity (Simunek et al., 2009), resulting in 
altered myosin heavy chain expression, reduced left ventricular mass, relative wall 
thickness, fractional shortening, and mean and maximal flow velocity in rats (Chicco, 
Hydock, et al., 2006; Hayward & Hydock, 2007; Hydock, Lien, & Hayward, 2009).   
Doxorubicin cardiotoxicity-caused morphological damage within the myocardium is 
often apparent when left ventricular ejection fraction (LVEF) falls below 45%, and may 
result in congestive heart failure (Ng et al., 2006).  In animal studies, doxorubicin has 
been shown to inactivate important mitochondrial enzymes, such as myocardial 
cytochrome c oxidase (Chandran et al., 2009).  Further treatment-associated side effects, 
including additional mitochondrial (Miyagawa et al., 2010) and cardiac pathologies 
(Meinardi et al., 1999), cachexia (Samuels et al., 2000; Takahashi, Yasumoto, & Mai, 
2005), and pulmonary and endothelial dysfunction, are well established in the clinical 
oncology and cancer rehabilitation literature (DeVita, 2005; Schneider et al., 2003).  The 
individual or combined effects of any of these pathophysiological defects, in addition to 





majority of cancer survivors experience fatigue following cancer treatment (Kasper & 
Sarna, 2000; Smets, Garssen, Schuster-Uitterhoeve, & de Haes, 1993; Winningham, 
2001), which often results in reduced physical activity and subsequent deconditioning.   
Animal models also indicate reduced physical activity with chemotherapy treatment.  
Hydock et al. found that voluntary wheel running in rats reduced significantly within two 
weeks of doxorubicin treatment, and was reduced to less than 50% of baseline by week 5 
(Hydock, Wonders, Schneider, & Hayward, 2009). 
Doxorubicin, in particular, has been extensively studied because it is a very 
effective antineoplastic agent, but is associated with severe, dose-dependent 
cardiotoxicity (Ascensao et al., 2006; B. Chen et al., 2007; Chicco, Hydock, et al., 2006; 
Hayward & Hydock, 2007; Hydock et al., 2008; Wonders et al., 2008).  Oxidative stress 
is among the mechanisms attributed to the DOX-induced cardiomyopathy (Chaiswing et 
al., 2004; Kanter et al., 1985), in addition to apoptosis (Arola et al., 2000), metabolic 
alterations (Wakasugi et al., 1993), and cardiac myosin heavy chain shifts (Hydock, 
Wonders, et al., 2009).  While the primary antineoplastic mechanisms of DOX are 
inhibition of topoisomerase II and intercalation in DNA, resulting in inhibition of DNA 
replication and RNA transcription, the induction of ROS may contribute to antitumor 
activity (Figure 4).  Some authors even argue that “induction of oxidative stress is 
responsible for most if not all biological activity” of anthracyclines (Taatjes et al., 1998).    
Antioxidant therapy has been investigated as a means to minimize doxorubicin 
cardiotoxicity, with mixed results.  Grape seed proanthocyanidins, a dietary antioxidant 
supplement, have been shown to improve tumor response rates and mitigate DOX-





2005).  In contrast, patients receiving high doses of vitamin E or N-acetylcysteine failed 
to exhibit reduction of cardiomyopathy in clinical trials (Myers et al., 1983; Unverferth et 
al., 1983).  The use of the iron chelator dexrazoxane (DRZ) has also been used as a 
method to reduce cardiotoxicity (Moss, 2007).  While DRZ is able to reduce the 
incidence of contractile dysfunction, the possibility that it may reduce DOX efficacy has 
prevented its universal use.  
 
Figure 4. Doxorubicin-induced generation of ROS/RNS in the heart.  From Collateral 
damage in cancer chemotherapy: oxidative stress in nontargeted tissues in Molecular 
Interventions, 7(3).    By Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., and St 






Fatigue associated with both cancer and cancer treatments has been well 
documented for decades (Piper, Lindsey, & Dodd, 1989; Questad, Malec, Harvey, 
Kienker, & Romsaas, 1982; Rieger, 1988; Smets et al., 1993).   Fatigue is the most 
frequently reported symptom in cancer survivors and is similar in nature to chronic 
fatigue syndrome, as both are more chronic and debilitating than standard fatigue, 
causing individuals to alter their behavior and demeanor, but all patients experience 
cancer-related fatigue differently (de Jong, Courtens, Abu-Saad, & Schouten, 2002).  
Because fatigue is both a physiological and psychological condition, it is difficult to 
pinpoint a specific mechanism, but there are likely many.  Some proposed factors 
contributing to fatigue are muscular wasting related to cachexia,  sleep disturbances, 
psychological depression, (Piper, Lindsey, & Dodd, 1987), anemia (de Jong et al., 2002), 
increased metabolic byproducts (e.g., inflammatory cytokines)  and metabolic imbalance 
due to increased energy requirement (e.g., due to tumor growth), decreased metabolic 
capacity (mitochondrial damage), and decreased substrate availability (due to anorexia, 
nausea, or vomiting) (Glaspy, 2001).   
While there is a lack of evidence explicitly relating oxidative stress to cancer-
related fatigue, most of the proposed mechanisms of fatigue can be driven by ROS and 
oxidative stress.  Indirect evidence comes from Gramignano et al., who demonstrated  
that four weeks of L-carnitine administration successfully reduced both fatigue, and 
resulted in a non-significant decrease in oxidative stress in patients currently undergoing 
cancer treatment (Gramignano et al., 2006).  Chronic fatigue syndrome, a very similar 





Bregeon, & Delliaux, 2005) and glutathione deficiency (Bounous & Molson, 1999).   The 
hypothesized interaction between oxidative stress and fatigue warrants further 
investigation.  
Muscular Strength 
Decreased strength following cancer treatment is a significant factor in decreased 
quality of life in cancer patients (Courneya & Friedenreich, 1999; Extermann et al., 2006; 
Kasper & Sarna, 2000; Schneider et al., 2003).  The primary mechanism of loss of 
muscular strength with cancer and cancer treatment appears to be related to cachexia and 
muscle wasting.  Numerous studies link cancer and treatment-related ROS production 
with cachexia, among other potential mechanisms (Laviano et al., 2007; Mantovani et al., 
2004).   Oxidative protein damage has been shown to be associated with poor grip 
strength in healthy elderly women (Howard et al., 2007).    The loss of muscle mass and 
cardiovascular fitness is compounded by significant decreases in physical activity 
following treatment.  Studies have shown that muscular endurance declines after only 
two weeks of physical inactivity in healthy individuals (Haddad, Roy, Zhong, Edgerton, 
& Baldwin, 2003), and oxidative enzymatic activity decreases following 3 months of 
inactivity (Coyle et al., 1984).  Fortunately, it has been demonstrated that resistance 
exercise can prevent or reverse losses in muscular strength (Schneider et al., 2007a) and 
muscle wasting.  This exercise-induced protection against muscle wasting appears to be 
at least partially due to a reduced oxidative damage in the skeletal muscles of rats treated 
with DOX.  Exercise was shown to diminish skeletal muscle protein oxidation and 





(Smuder, Kavazis, Min, & Powers, 2011a) and proteases such as caspase-3 (Smuder, 
Kavazis, Min, & Powers, 2011b).    
Cancer Treatment-Related Side Effects 
 and Oxidative Stress 
Both cancer and its treatments induce considerable oxidative stress.  Even the 
physiological stress of surgery is capable of producing enough ROS as a side effect to 
facilitate increased growth of metastatic tumors (Hyoudou, Nishikawa, Kobayashi, 
Umeyama, et al., 2006).     Because treatment-associated oxidative stress is implicated in 
cancer-related fatigue (Fulle et al., 2000), cachexia (Laviano et al., 2007), 
cardiomyopathy (Ascensao et al., 2005b), and neuropathy (Kannarkat, Lasher, & Schiff, 
2007), it often governs the tolerance limit of treatment.  Treatment-associated oxidative 
stress also can result in second malignancies, also known as treatment-induce cancer 
(Bostrom & Soloway, 2007).  Additionally, cancer cells have lower levels of MnSOD, 
GPx and CAT, but produce high levels of hydrogen peroxide (Oberley, 2002), resulting 
in greater oxidative stress in cancer patients even prior to cancer therapy.  
Cancer treatments, particularly radiation and chemotherapy, are associated with 
significant, whole-body side effects, many of which are associated with oxidative stress.  
Whereas radiation therapy actually depends on free radical generation as a means of 
destroying cancer cells (Ahn et al., 2006), oxidative stress associated with chemotherapy 
is often a side effect.  Doxorubicin (DOX), for instance, is a very effective anti-cancer 
agent, but is known for its cardiotoxic effects (Chaiswing et al., 2004; Y. Chen et al., 
2007; Gilliam et al., 2009; Hayward & Hydock, 2007; Shacter et al., 2000; Simunek et 
al., 2009).  Although DOX kills cancer cells through DNA inhibition and topoisomerase 








Table 3   
 
Chemotherapy drugs known to induce significant oxidative stress 




bleomycin   Blenoxane 
 
mitomycin  Mitomycin-C, MTC 
(Anthracyclines) Doxorubicin   Adriamycin 
 












Endoxan, Cytoxan, Neosar, 
Procytox, Revimmune 
 





Melphalan  Alkeran 
 
chlorambucil  Leukeran 


































Eposin, Etopophos, Vepesid, 
VP-16 
 




topotecan   Hycamtin 
 





Adrucil, Carac, Efudex and 
Fluoroplex 
 








132 FDA approved anticancer drugs, 56 are known to induce oxidative stress (Chen et 
al., 2007).  Table 3 lists chemotherapy drugs known to induce substantial oxidative stress.  
While late effects of radiation treatment have been associated with chronic oxidative 
stress (Robbins & Zhao, 2004; Zhao & Robbins, 2009), there is little information 
regarding long-term effects of chemotherapy on oxidative stress. 
Currently, there is no good characterization of the time-course of chronic 
oxidative stress status following the end of cancer chemotherapy or radiation treatment in 
the literature.  Many papers evaluate oxidative stress while patients are undergoing 
treatment (Cetin et al., 2004; Conklin, 2000; Honda, Yamada, Tomonaga, Ichinose, & 
Kamihira, 2000; Sabitha & Shyamaladevi, 1999; Weijl et al., 1998) or within hours and 
days after treatment (Sangeetha, Das, Koratkar, & Suryaprabha, 1990), but rarely 
evaluate markers of oxidative stress or antioxidants more than a week after the end of 
treatment.  In mice, extracellular MDA levels remained elevated one week after 
chemotherapy, and oxidized glutathione was significantly higher than controls 6 weeks 
after treatment (Abushamaa, Sporn, & Folz, 2002).  Unfortunately, it is difficult to 
extrapolate these data to humans due to varying lifespans.  Jonas et al. (Jonas et al., 2000) 
found that GSH/GSSG ratio continually decreased over the two weeks following the end 
of treatment, indicating either that treatment directly impairs the antioxidant system, or 
that chronic oxidative stress is capable of depleting the glutathione pool and diminish 
reductive capacity.       
While some studies show increased oxidative stress in response to treatment 
(Abushamaa et al., 2002; Cetin et al., 2004; Faber, Coudray, Hida, Mousseau, & Favier, 





treatment compared to pretreatment, likely due to reduced tumor burden.  For instance, 
Gadjeva et al. (Gadjeva, Dimov, & Georgieva, 2008) found that plasma MDA 
concentration dropped in melanoma patients following surgery.  While chemotherapy 
subsequently increased oxidative stress compared to post-surgery levels, MDA levels 
were still significantly lower than pre-surgery values.   This discrepancy is likely due to 
variations in treatment method and cancer type.  Moreover, Erhola et al. (Erhola et al., 
1997) found that the overall response to chemotherapy (“complete or partial remission”, 
versus “no change or progressive disease”) determined whether urinary 8-OHdG 
concentration increased or decreased.  Therefore it appears that it is justifiable to further 
investigate the level of oxidative stress in patients in the weeks and months following 
cancer treatment.   
Targeted delivery of SOD (Hyoudou et al., 2008) or catalase (Hyoudou, 
Nishikawa, Kobayashi, Umeyama, et al., 2006) to cancer cells have the potential to 
inhibit proliferation and metastasis, largely by decreasing the ROS-mediated growth 
signaling.  At this time, no clinical trials have been conducted to confirm the 
effectiveness of these strategies.  An alternate strategy to reduce ROS in cancer cells is 
inhibition of NADPH oxidase, which in turn reduces VEGF signaling, which may inhibit 
tumor growth.  NADPH oxidase inhibition with minodronate (Kubo et al., 2006; Sato et 
al., 2006) and histamine (Agarwala & Sabbagh, 2001) have been demonstrated to be 
effective cancer treatment methods in clinical trials.  In the case of ROS production 
following oncological surgery, administration of catalase successfully inhibited 





Alternately, the use of targeted ROS production has been used as a cancer 
treatment, both as a single agent, employing ROS to destroy cancer cells, or as an 
adjuvant therapy to facilitate the therapeutic effects of radiation and chemotherapy (Fang 
et al., 2009; Manda et al., 2009; Trachootham et al., 2009; J. Wang & Yi, 2008). Because 
cancer cells often have chronically elevated oxidative stress due to increased ROS 
production, reduced antioxidant capacity, or both, exogenous ROS may be sufficient to 
trigger cellular death.  Indeed, most cancer therapies increase ROS as a primary or 
secondary mechanism of antitumor activity.  Procarbazine, a ROS-producing 
antineoplastic drug, has been used alone and in conjunction with radiation since the 
1960s (Renschler, 2004).  Even then, Berneis and colleagues recognized that ROS 
mediated the anticancer effects of the drug (Berneis, Kofler, Bollag, Kaiser, & 
Langemann, 1963).   Radiation therapy has been used as a treatment for cancer for even 
longer, about 100 years, owing largely to Marie Curie, but the production of ROS by 
radiation was not recognized until 1948 (Stein & Weiss, 1948).  Later, Harman identified 
the implication of free radicals in the ability of radiation to both treat and cause cancer 
(Harman, 1956, 1962).    
 Today, we have alternate methods of ROS induction to treat cancer.  As 
previously mentioned, augmenting ROS induction with hyperbaria during radiation 
treatment can improve its efficacy.  Another approach to this involves administration of 
radiation sensitizers, which include the drug classes tirapazamine, 2-nitroimidazoles, and 
indolequinones (Kovacic, 2007).   A more recently developed anticancer modality is 
called photodynamic therapy (J. Wang & Yi, 2008).  In this treatment, a drug 





tends to stay in cancer cells longer.  Approximately 24 to 72 hours later, the 
photosensitizer is activated by light, producing ROS that can destroy the cells containing 
the drug (Dolmans, Fukumura, & Jain, 2003).  Inhibition of antioxidant enzyme defense 
within tumor cells to induce ROS has also been explored.  Β-phenylethyl isothiocyanate 
is a natural compound that depletes cellular GSH and inhibits the GPx enzyme, resulting 
in severe ROS accumulation in malignant cells (Trachootham et al., 2006).  
Methoxyestradiol, an anticancer agent in clinical trials, inhibits SOD and induces 
apoptosis in leukemia cells (J. Wang & Yi, 2008). 
One particularly valuable use of pro-oxidant therapy may the reduction of drug-
resistance in tumors.  A decreased reductive state, specifically increased glutathione 
redox potential, has been long recognized as a factor in acquired multidrug resistance 
(Kramer et al., 1988).  The introduction of either a NADPH oxidase (NOX1) 
(Wartenberg et al., 2005) or a ROS-producing agent (emodin) (Pelicano, Carney, & 
Huang, 2004) into cancer cells can reduce multi-drug resistance via decreased expression 
of the multi-drug resistance transport and hypoxia-inducible factor 1α.   
Exercise Before, During, and Following  
Cancer Treatment 
The beneficial effects of exercise on cardiopulmonary function, strength, and 
overall health status in healthy individuals has been well-documented for decades.  The 
role of exercise to promote improved physical and mental health and rehabilitation in the 
cancer population during and following cancer treatments has only more recently become 
recognized as important.  In the 1980s, Winninghan et al. conducted some of the first 
studies investigating the effect of exercise on cancer treatment-related side effects 





MacVicar, 1988; Winningham, MacVicar, Bondoc, Anderson, & Minton, 1989).  In the 
more than 20 years since then, a growing body of evidence has supported the use of 
exercise as a means to rehabilitate individuals from cancer and treatment-related side 
effects.   
Exercise during treatment is known to increase tolerance for higher doses of 
chemotherapy (Chicco, Schneider, et al., 2006), and exercise following treatment can 
reduce or reverse the damaging side effect of cancer treatments (Hydock et al., 2007) and 
even reduce the chance for cancer recurrence (Courneya, 2003).  In particular, resistance 
and aerobic exercise have been found to be beneficial as a means to reduce fatigue, while 
improving quality of life (QOL), muscular strength and endurance, and cardiorespiratory 
endurance (Courneya et al., 2007; Schneider et al., 2007a, 2007c).  Exercise following 
surgery has been shown to be beneficial in increasing the natural killer (NK) cell 
cytotoxic activity (NKCA) , suggesting that exercise may play a role in cancer treatment, 
rather than simply rehabilitation (Na et al., 2000).  Like so many physiological and 
pathophysiological processes, NKCA are known be mediated (in this case, inhibited) by 
ROS, (Betten, Dahlgren, Mellqvist, Hermodsson, & Hellstrand, 2004) perhaps explaining 
the increase following exercise and the decrease associated with cancer (Mellqvist et al., 
2000).   
Cardiorespiratory Fitness 
 While it may seem intuitive that an aerobic exercise intervention improves 
cardiorespiratory fitness in cancer survivors, the reasons for the reduced fitness level in 
this population are complex and multifactorial, potentially altering the normal 





prescribed intervention in cancer survivors until 15 years ago, there had previously been 
little evidence to support the exercise as a rehabilitation modality.  There is now a very 
large body of evidence demonstrating the effectiveness of an exercise intervention for the 
improvement of cardiorespiratory fitness (Courneya et al., 2003; Courneya et al., 2007; 
Dimeo et al., 2004; Schneider et al., 2007c; Segal et al., 2009).  Unpublished data from 
the Rocky Mountain Cancer Rehabilitation Institute indicates that improvement in 
cardiopulmonary fitness, and fatigue following a 3-month, multimodal exercise program 
did not differ between cancer types, regardless of baseline values.  A recent study in 
leukemia patients currently receiving high-dose treatment indicated that an in-hospital 
exercise intervention significantly improved performance in a submaximal cycle 
ergometer test time to termination, from 8.9 ± 8.8 minutes at baseline to 17 ± 14.3 
minutes post-intervention (Battaglini et al., 2009).  In a 2011 meta-analysis investigating 
the effect of exercise on VO2 peak, pooled data of all six studies (571 adult cancer 
patients; 344 exercise and 227 usual care control) indicated that exercise training 




), whereas usual care was 




)  (L. W. Jones, Liang, et al., 
2011).   
There has been relatively scarce clinical confirmation of mechanisms of exercise-
induced improvements in (or maintenance of) cardiorespiratory fitness in cancer patients 
during or following cancer treatment.  In a study by Dimeo et al. (1997), cancer survivors 
who participated in an exercise program following high dose chemotherapy had higher 
aerobic capacity as well as increased hemoglobin concentration compared to non-





maintained cardiorespiratory fitness, many of which include cardiac preservation via 
increased myocardial antioxidant status (Kanter et al., 1985; Pushpalatha, Nishanth, & 
Sathyavelu Reddy, 2007; Simunek et al., 2009; Wouters, Kremer, Miller, Herman, & 
Lipshultz, 2005).  Other possible mechanisms include reduced inflammatory cytokines 
(Battaglini et al., 2009), increased or maintained muscle mass (Laviano et al., 2007) and 
mitochondrial hormesis (Ji et al., 2006; Ristow & Zarse, 2010).  
Fatigue  
Because cancer related fatigue is multifactorial, appropriate treatment for this 
condition is difficult to determine.  Treating this fatigue as a psychological pathology 
alone, using pharmacological methods (Bruera, Roca, Cedaro, Carraro, & Chacon, 1985; 
Rozans, Dreisbach, Lertora, & Kahn, 2002) or counseling (Gramignano et al., 2006), has 
been generally ineffective.  Alternately, exercise has been shown to have significant 
therapeutic benefit (Dimeo, 2001), and daytime inactivity may actually worsen fatigue 
symptoms (Berger & Farr, 1999).   Various methods of prescribed exercise, including 
resistance and aerobic exercise, both  supervised and at home, have been shown to 
improve fatigue symptoms in cancer patients following treatment  (Courneya & 
Friedenreich, 1999; Courneya et al., 2007; F. Dimeo et al., 2003; F. Dimeo, Schwartz, 
Wesel, Voigt, & Thiel, 2008; F. C. Dimeo, 2001; Hsieh et al., 2008; Peddle, Au, & 
Courneya, 2008; Saylor & Smith, 2009; Schneider, Hsieh, Sprod, Carter, & Hayward, 
2007b; Schneider et al., 2007c; Schwartz, 2007; Smets et al., 1993).     
Studies have indicated that the effect of exercise on cancer-related fatigue may be 
associated with modulation of  5-HT neurotransmitter regulation,
 
vagal afferent 








circadian rhythms, and/or cytokine regulation (Ryan et al., 2007).  To date, there has been 
no research regarding the interaction between cancer related fatigue and oxidative stress. 
Because individuals with chronic fatigue disorders have an amplified oxidative stress 
response from an acute exercise bout (Jammes et al., 2005) it is reasonable to postulate 
that an exercise intervention capable of increasing antioxidant enzyme capacity may 
reduce postexertional fatigue following an exercise intervention.   
Muscular Strength  
 As has been noted, cancer patients often suffer from muscle wasting disorders, or 
more generalized losses in muscular strength.  A whole-body, 6-month exercise 
intervention was capable of significantly increasing muscular fitness for bench press 
(+47.6%), lat pull-down (+51.1%), leg press (+67.1%), shoulder press (+41.8%), and 
curl-up crunches (+32.5%) in cancer patients following the end of treatment (Schneider et 
al., 2007a).  Remarkably, this exercise intervention also increased muscular fitness for lat 
pull-down (+83.6%) and leg press (49.7%) in cancer patients still undergoing radiation or 
chemotherapy.  Similarly, Courneya et al., (2007) found that an isolated resistance 
exercise training (RET) program increased muscular strength in breast cancer patients 
receiving chemotherapy 25% to 35%.  This finding was accompanied by an increased 
chemotherapy completion rate, from 84.1% in a usual care group, versus 89.8% in the 
RET group, as well as an increase from 65.9% (usual care) to 78.0% (RET) of patients 
who received at least 85% of their planned relative dose intensity.  These findings 
indicate that exercise training can increase treatment tolerance as well as muscular 





Despite the recognition that oxidative damage plays a role in cancer treatment 
side effects, the literature describing these mechanisms often fail to suggest exercise as a 
means of attenuating this damage.  Instead, antioxidant or pharmacological treatment is 
suggested.  A noteworthy exception to this is paper by Peng et al. (2005), which 
acknowledged the biological and therapeutic benefits of exercise as a strategy of 
improving physiological function and quality of life in cancer survivors.  The authors also 
mention the difficulties of attracting research funding for a therapy that is inherently free, 
and therefore is not a wise investment for private funding agencies or pharmaceutical 
companies.  Simultaneously, cancer rehabilitation researchers espouse the use of 
exercise, but rarely investigate the underlying mechanisms for the efficacy of exercise.  
Therefore, further biochemical and genetic studies regarding the mechanisms underlying 
the effectiveness of exercise as a means to minimize side effects in cancer patients during 
and following treatment are warranted. 
Counteracting Cancer Treatment-Associated  
Oxidative Stress With Exercise 
 Although it was in a non-cancer population, Parise et al. (2005) offer some insight 
for the prescription of exercise as an intervention to counteract oxidative stress.  This 
study evaluated antioxidant enzyme activity in the vastus lateralis muscle of both legs of 
older males (71 ± 7 yrs) following unilateral resistance exercise training.  There was a 
significant increase in catalase and CuZnSOD activity, as well as muscular strength in the 
subjects’ training leg, but not in the untrained leg.  This demonstrates the importance of 
total body exercise interventions in cancer survivors, as training effects and changes in 
antioxidant enzyme capacity are local.  Additionally, it may be surmised that because of 





active tissue, but not in cancer cells.  Krause et al. indicated that antioxidant enzymes 
may not be sufficient to protect cardiac cells against damage, as illustrated by a lack of 
effect by antioxidant therapy.  Additional aspects of antioxidant defense, such as 
multidrug resistance-associated proteins (MRP) and MRP1 gene product (a GS-X pump 
ATPase), a physiological GSSG transporter, may play a role in total body antioxidant 
capacity (Krause et al., 2007).  This illustrates that exercise, and multi-system, 
multidimensional, intervention, may be superior to pharmacological interventions as a 
method to reduce treatment-related side effects mediated by ROS.   
Wonders et al., (2008) reported that doxorubicin treatment increased left 
ventricular MDA concentrations in sedentary rats, but rats that had performed an acute 
exercise bout 24 hours before receiving treatment had no increase in MDA .  This 
accompanied an attenuation of doxorubicin cardiotoxicity, indicating a protective role of 
exercise, possibly via resistance to oxidative stress.  Yamashita et al., (1999), found that a 
single bout of exercise resulted in time sensitive changes in infarct size in mice exposed 
to left ventricular artery occlusion.  Exercise was most protective against infarction at 0.5 
and 48 hours prior to LVA occlusion, which was mirrored by significant increases in 
MnSOD activity at those time points only.  Furthermore, mice treated with N-2 
mercaptopropionyl glycine (MPG), a synthetic analog of glutathione, completely 
eliminated the protective effect of exercise against infarction at both 0.5h and 48h as well 
as the increase MnSOD activity.   The antioxidant activity of MPG prevented the 
moderate, transient oxidative stress normally produced by exercise, thereby interrupting 
the redox-sensitive signaling cascade, which would ultimately increase MnSOD via the 





chemotherapy induced damage (in these instances, cardiotoxicity) is at least partly due to 
upregulation of antioxidant enzymes following a transient, low level increase in oxidative 
stress (i.e., exercise).  Unfortunately, there has been no research investigating the role of 
exercise (and subsequently increased antioxidant capacity and reduced chronic oxidative 
stress) following treatment as a mediator of reduced chronic side effects related to cancer 
treatment. 
Perhaps the best evidence for improved antioxidant defense in cancer survivors is 
a 1985 study by Kanter et al. (1985).   This group randomly assigned rats to exercise (n = 
53) and nonexercise (n = 52) groups.  After nine weeks of swim training, nine rats from 
each group were sacrificed and tissue and blood samples were taken.  The remaining rats 
were then subdivided into swim trained, swim trained-DOX treated, sedentary, and 
sedentary-DOX treated.  After an additional twelve weeks, tissue and blood samples were 
taken, and the rats were tested for CAT, SOD, and GPx.  Swim training significantly 
reduced cardiotoxicity of doxorubicin and increased blood values for all three antioxidant 
enzymes (Table 4).  Heart antioxidant levels of DOX treated swimmers were lower 
compared to nontreated swimmers, indicating that DOX not only produces ROS, but also 
decreases antioxidant enzyme capacity.  Therefore it seems wise to prescribe exercise to 
patients for a time before chemotherapy, if possible, to augment antioxidant capacity 
before treatment.  This also indicates that certain cancer treatment regimens may induce 
both acute (ROS production) and chronic (antioxidant defense disturbances) changes in 










   
Enzyme activity following 9 weeks of exercise training    
Group Catalase Glutathione Peroxidase Superoxide Dismutase 
Swim 122.2 ± 21.0* 10.9 ± 0.6* 247.1 ± 21.2* 
Sedentary 74.9 ± 11.8 8.3 ± 0.6 164.2 ± 18.5 
Note: Values are expressed as enzyme units/ml blood.  * Significantly greater than 
sedentary.  Adapted from Kanter et al. 1985. 
 
A more recent article by Ascensao et al., (2005a) expanded on these findings.  
Using a similar swim-training protocol as Kanter, this group found that DOX treatment 
increased GSSG and GSSG% (indicating a strain on the glutathione antioxidant system) 
but this effect was countered by swim training.  Cardiac damage was evaluated by 
cardiac troponin I (cTnI) presence in the plasma.  Exercise trained mice treated with 
DOX had significantly less cTnI than non-exercise trained mice treated with DOX (0.65 
vs. 1.40 ng/ml).  Although swim training did not result in significant differences in total 
antioxidant status or CAT, SOD, GPx, or glutathione reductase activity between exercise 
and non-exercise DOX groups, there were clearly changes in antioxidant defense, as 
reduced glutathione levels increased substantially compared to exercised mice treated 
with a placebo or non-exercise mice treated with DOX.  Additionally, both exercise 
groups (DOX and placebo) had significantly lower cardiac muscle protein carbonyls than 
the non-exercised DOX group. 
Although there have been few human studies investigating the effect of exercise 
on antioxidant capacity in cancer patients, Bloomer et al. (2008) studied the effect of 
resistance training on blood oxidative stress in Parkinson disease, another disease 
implicated with oxidative stress.  Thirteen subjects with Parkinson’s disease completed 





control group.  Eight weeks of low volume resistance training (2d/wk) in Parkinson 
disease patients showed trends toward increased antioxidant capacity (SOD, CAT, GPx, 
Trolox-equivalent antioxidant capacity) and reduced hydrogen peroxide (H2O2) and 
malondialdehyde levels, but were not significant.  Post hoc power analyses indicated that 
a total sample size of 16 and 22 subjects would be needed to observe a statistically 
detected interaction effect for MDA and H2O2, respectively.  It should be noted that there 
was no significant difference in baseline oxidative stress or antioxidant biomarkers 
between Parkinson’s disease patients and a healthy control population.     
Summary 
Reactive oxygen species, once thought to be nothing more than biochemical 
byproducts of aerobic metabolism, are now recognized as crucial signaling molecules at 
low levels, but cytotoxic and potentially carcinogenic at high levels. This duality makes 
the study of ROS complicated, particularly in relation to chronic diseases, including 
cancer.  Cancer patients often have high systemic oxidative stress, which is further 
aggravated by cancer treatments, particularly radiation and chemotherapy.   Most cancer 
cells have marked oxidative stress due to increased ROS production and compromised 
antioxidant defense, but certain cancer cells, such as prostate and metastatic cells, are 
known to have increased antioxidant enzyme capacity.   ROS are thought to play a role in 
cancer risk and etiology, but cancer itself is known to increase ROS production, resulting 
in further cellular mutation and proliferation.  Ironically, ROS are known to induce 
apoptosis and necrosis in cancer cells, and ROS production is a mechanism shared by all 





ROS in cancer patients are likely associated with many of the side effects of 
cancer and its treatments, including fatigue, cachexia and anorexia, muscle weakness, and 
reduced cardiorespiratory function.  Therefore, it is reasonable to employ strategies 
which counteract both the oxidative stress and physiological decrements associated with 
cancer and its treatments.  Both AOX therapy and exercise are potential strategies.  
Because antioxidants have been shown to protect cancer cells in some circumstances, this 
method is not suggested without further research, even following treatment, as 
micrometastases may still be present.  Additionally, because the delicate redox balance is 
dose-responsive and synergistic by nature, exogenous administration of antioxidants may 
be unwise even as a preventative measure without a complete understanding of the 
interactions.  Therefore, exercise is a recommended strategy to reduce ROS and cancer 
treatment side effects without artificially altering the redox status and potentially 























 The primary purpose of this study is to determine the effects of a 10-week aerobic 
and resistance prescribed exercise intervention on plasma markers of oxidative stress and 
antioxidant enzyme capacity in cancer survivors versus a non-exercising control group. 
Markers of oxidative stress that were measured included 8-OHdG and reactive carbonyl 
derivatives.  Trolox-equivalent antioxidant capacity (TEAC) was measured as a universal 
marker of antioxidant capacity in the blood.   Additionally, selected physiological 
variables, including peak VO2, muscular strength, and fatigue were compared between 
groups.  Baseline oxidative stress and antioxidant enzyme capacity in cancer patients 
were compared to healthy individuals.  The relationship between oxidative stress and 
baseline physiological variables was determined.  Similarly, the relationship between the 
change in oxidative stress and changes in physiological variables was determined.  This 
chapter describes the research methodology for the study and includes discussion of the 








 This study consisted of a 10-week prescribed exercise intervention in cancer 
patients following oxidative stress-inducing cancer treatments, including radiation and 
several chemotherapy agents (see Table 3 on page 65).  Subjects had completed radiation 
or chemotherapy treatment within the previous 6 weeks.  Currently there is no good 
characterization of the time-course of chronic oxidative stress status following the end of 
cancer chemotherapy or radiation treatment in the literature.  Many papers evaluate 
oxidative stress while patients are undergoing treatment (Cetin et al., 2004; Conklin, 
2000; Honda et al., 2000; Sabitha & Shyamaladevi, 1999; Weijl et al., 1998) or within 
hours and days after treatment (Sangeetha et al., 1990), but rarely evaluate markers of 
oxidative stress or antioxidants more than a week after the end of treatment.  In mice, 
extracellular MDA levels remained elevated one week after chemotherapy, and oxidized 
glutathione was significantly higher than controls 6 weeks after treatment (Abushamaa et 
al., 2002).  Unfortunately, it is difficult to extrapolate these data to humans due to varying 
lifespans.  Jonas et al. (Jonas et al., 2000) found that GSH/GSSG ratio continually 
decreased over the two weeks following the end of treatment, indicating either that 
treatment directly impairs the antioxidant system, or that chronic oxidative stress is 
capable of depleting the glutathione pool and diminish reductive capacity.       
Cancer patients were assigned to an exercise group or a standard care control 
group.  Pre- and post- intervention fasting blood samples were drawn from cancer 
patients to determine markers of oxidative stress (8-OhdG, protein carbonyls) and 
antioxidant capacity (Trolox equivalent antioxidant status).  An initial screening and 





groups.  These assessments determined fatigue, cardiorespiratory endurance, and 
muscular strength.   Additionally a group of age-matched healthy individuals without 
cancer (NC) completed the Piper Fatigue questionnaire (Appendix A) and had fasting 
blood samples drawn to determine the relative degree of fatigue and oxidative stress in 
cancer patients at baseline.  Reassessments were obtained after a 10-week individually 
prescribed exercise intervention.  The same physiological and psychological parameters 
were assessed using identical protocols during the initial assessment.  See Figure 5 for 
experimental design. 
 
Figure 5.  Experimental design  
 
Subjects 
 Sixteen cancer survivors and eight healthy, age-matched subjects were recruited 
for participation in this study. A similar study on Parkinson’s disease patients (Bloomer 
et al., 2008) determined that a sample size of 16 would be needed for adequate power, 
and this study was only twice per week, and only consisted of three sets of leg press, leg 





referred clients at RMCRI, as well as at McKee Hospital in Loveland, Poudre Valley 
Hospital in Fort Collins, and Northern Colorado Medical Center in Greeley.  
Additionally, a newspaper article in the Greeley tribune was used to promote this study. 
All cancer diagnoses were considered for this study, but subjects were required to 
have undergone radiation treatment, or one of the listed chemotherapy drugs (Table 3).  
Cancer patient inclusion criteria consisted of: (1) completed radiation or approved cancer 
therapy regimen within 6 weeks of initial blood draw, (2) currently sedentary (less than 
two days/week or 20 minutes of aerobic or resistance exercise) (Brooks et al., 2005), (3) 
have not consistently supplemented with dietary antioxidants, including vitamins C and 
E, in the previous month (dietary half-life of ascorbate, for instance, is 8-40 days) (Otten, 
Hellwig, & Meyers, 2006), (4) non-smokers (for at least 6 months), and (5) were able to 
walk comfortably on a treadmill.  Non-cancer, healthy controls were primarily recruited 
from among the faculty and staff at the University of Northern Colorado via campus-
wide email and by word of mouth.  This group was asked to fast for 12 hours, and avoid 
strenuous physical activity for 72 hours prior to their single, baseline blood draw.  
Inclusion criteria for the non-cancer group included:  (1) currently sedentary (less than 
two days/week or 20 minutes of aerobic or resistance exercise), (2) no history of cancer 
or other disease, (3) have not consistently supplemented with dietary antioxidants in the 
previous month, and (4) non-smokers.   The University of Northern Colorado 








Data Collection Procedures 
An initial phone interview with potential clients determined eligibility to 
participate, which and included a complete cancer history discussion, and availability and 
willingness to complete the study.  Subjects were informed that the study includes 
participation in 10 weeks of one-on-one exercise training at the Rocky Mountain Cancer 
Rehabilitation Institute, or standard care.  Additionally, subjects were verbally given 
information regarding the nature of data collection, including the risk involved in a 
standard blood draw, and a maximal, graded treadmill test.  After this brief discussion 
and clearance to exercise for high cardiac risk subjects by the RMCRI Medical Director, 
subjects met with the lead investigator and signed an informed consent. 
Prior to arrival at RMCRI, subjects were mailed questionnaires to complete, 
including the Piper Fatigue Scale (Piper et al., 1998), lifetime physical activity, and 
medical history.  For 72 hours prior to the blood draw, subjects were asked to avoid 
exhaustive exercise and antioxidant supplementation.  The day before the cancer patient’s 
initial exercise assessment, a 12-hour fasting blood sample was taken by the lead 
investigator, the RMCRI medical director, or an otherwise experienced phlebotomist.  On 
the day of the initial assessment, the standard RMCRI assessment protocol (details to 
follow) was utilized.  Height, weight, cardiorespiratory endurance, and muscular strength 
were evaluated, and results were used to develop individualized exercise interventions. 
Piper Fatigue Inventory 
 The Piper Fatigue Inventory (Piper et al., 1998) was used to assess total cancer-
related fatigue, as well as the subscales of behavioral, affective, sensory, and 





used to assess the impact of fatigue on school and/or work, interacting with friends, and 
overall interference with activities that are enjoyable. The affective fatigue subscale 
includes five questions and assessed the emotional meaning attributed to fatigue. The 
sensory fatigue subscale includes five questions and assessed the mental, physical, and 
emotional symptoms of fatigue. The cognitive and/or mood fatigue subscale includes six 
questions and assessed the impact of fatigue on concentration, memory, and the ability to 
think clearly. The average score on the 22 total questions from the subscales provides the 
total fatigue score.  The range of possible scores on the subscales as well as total fatigue 
ranges from “0” to “10”. A score of a “0” indicates that the cancer survivor has no 
fatigue; scores ranging from “1” to “3” are indicative of mild fatigue; scores “4” to “6” 
suggest moderate fatigue; and scores of “7” or greater indicate severe fatigue.  
Maximal Treadmill Testing 
 The RMCRI treadmill protocol (Table 5) was developed at the Rocky Mountain 
Cancer Rehabilitation Institute as a cancer-specific protocol, more suitable for the cancer 
population.  Unlike the Bruce treadmill protocol, there are no abrupt increases in speed 
and grade.  Smaller changes in effort and patient stride provide a more manageable 
progression through stages and results in reduced premature peripheral fatigue and more 
valid maximal treadmill tests (Bruce, Kusumi, & Hosmer, 1973).  The RMCRI treadmill 
protocol begins at 1.0 mph and 0% grade during the first stage.  For the next three stages, 
the speed increases 0.5 mph, but grade is maintained at 0%.  Stage 5 increases the grade 
to 2% but maintains speed at 2.5 mph, and stage 6increases to 3.0 mph and 2% grade.  





grade.  The subjects continue until volitional fatigue, at which point grade is reduced to 
0% and speed is reduced to 1.5 mph for a three minute recovery period.   
 
Table 5   
 
RMCRI Treadmill Protocol 
Stage Speed (mph) Grade (%) Time 
1 1.0 0 1 min 
2 1.5 0 1 min 
3 2.0 0 1 min 
4 2.5 0 1 min 
5 2.5 2 1 min 
6 3.0 2 1 min 
7 3.3 3 1 min 
8 3.4 4 1 min 
9 3.5 5 1 min 
10 3.6 6 1 min 
11 3.7 7 1 min 
12 3.8 8 1 min 
13 3.9 9 1 min 
14 4.0 10 1 min 
15 4.1 11 1 min 
16 4.2 12 1 min 
17 4.3 13 1 min 
18 4.4 14 1 min 
19 4.5 15 1 min 
20 4.6 16 1 min 
21 4.7 17 1 min 
Cool-Down 1.5 0 3 min 
 
 Prior to each incremental treadmill test, subjects were fitted with a heart rate 





speed and grade during each one-minute stage were given and the participant was 
encouraged to walk or run until exhaustion or volitional fatigue (to VO2peak).   Blood 
pressure was assessed at rest, every three minutes during exercise, at immediate post 
exercise, and after three minutes of recovery (slow walking).  Rating of perceived 
exertion was assessed every three minutes of exercise, according to Borg’s 1-10 scale 
(Table 6).  Heart rate and oxygen saturation was assessed at the end of every one-minute 
stage.  Subjects were asked to only use handrails throughout the test if they required it for 
balance support.  If they felt they would need handrails, they were asked to use them 
throughout the test.  
Table 6 
 
Borg Scale: Rating of Perceived Exertion 
          Maximum Exertion 
10 Very, very hard 
 9  
      8 
 7 Very hard 
6 
 5 Hard 
 4  Somewhat hard 
 3 Moderate 
 2 Light 
 1 Very light 
 0 No exertion 
           
Adapted from Category-Ratio Perceived Exertion Scale: Relationship to Blood and 
Muscle Lactates and Heart Rate. Med Sci Sports Exerc, 15:523-528, 1983.   
 
For individuals who were walking during the final stage, the ACSM metabolic 
equation (VO2 (ml/kg/min) = (0.1 × S) + (1.8 × S × G) + 3.5 ml/kg/min) was used, 
whereas the equation (VO2 (ml/kg/min) = (0.2 × S) + (0.9 × S × G) + 3.5 ml/kg/min) was 





treadmill speed, expressed as meters/minute, and “G” represents treadmill grade, 
expressed as a decimal, such that 0.08 would represent a grade of 8%, for example.  
 
Muscular Strength Assessment 
 A true 1-repetition max (1-RM) assessment of strength can be the most accurate 
and reliable method of muscular strength assessment, but may be subject to variability 
due to unfamiliarity with weight lifting, lack of adequate facilities, and risk of injury, 
even in healthy individuals.  In the cancer population, the variability and risk for injury 
are even greater.  Therefore, the Brzycki equation, 
1-RM = weight lifted (lb) / (1.0278 – (repetitions to failure × 0.0278)) 
can be used to estimate 1-RM using the number of repetitions of a given submaximal 
load to fatigue, provided that the repetitions do not exceed 10 (Brzycki, 1993).  Muscular 
strength was assessed using the lat pull-down, shoulder press, chest press, seated row, leg 
press, leg extension, and leg curl exercises, using Cybex® gym equipment (Cybex 
International, Medford MA).  The goal was to choose a weight that will elicit muscle 
failure in 4-6 repetitions.  Suggested values for the initial amount of weight lifted for the 
exercises were based upon previous muscular strength data from RMCRI (Table 7)  
(Schneider et al., 2003).  Repetitions were performed without resting until muscle failure, 
or until the subject’s form deteriorates.  If the client exceeded 10 repetitions for any 
exercise, they were stopped, and proceeded with the other muscular strength exercises.  
Following all exercises, those exercises which had been stopped were completed after 








Table 7   
 
Suggested initial resistance (% of Body Weight)  
Exercise Men Women 
Lat Pull-down    0.900   0.500 
Shoulder Press    0.350   0.150 
Chest Press    0.750   0.250 
Seated Row    0.750   0.300 
Leg Press    1.500   0.750 
Leg Extension    0.750   0.400 
Leg Curl    0.750   0.400 
 
Lat Pull-Down 
The participant sat on the bench seat with thighs positioned comfortably 
underneath the roller pads, which were adjusted if needed. The participant's hands were 
positioned on the bar slightly outside shoulder width, with palms facing inward 
(supinated) and torso remaining upright throughout the lift, without leaning forward or 
backward.  A full repetition included a down motion, in which the training arm was 
pulled down until it is approximately even with the middle of the chest, and an up motion 
in which the training arm was allowed to rise until arms were extended but not locked.  
Shoulder Press 
The back of the seat was adjusted so that it was in the upright position, ensuring 
that the seat was locked. The participant sat on the seat with back and buttocks against 
the backrest. The participant's hands were placed on the lower handles at a comfortable 
width, depending on body size.  Feet were placed flat on the floor approximately shoulder 





until arms were extended but not locked, and a down motion in which the training arm 
was lowered until the weight touched the top of the weight stack.  
Chest Press 
The participant sat on the seat with back and buttocks against the backrest and 
feet placed flat on the floor approximately shoulder-width apart.  The seat was adjusted 
so the handles were at mid-chest height.   A full repetition included an up motion in 
which the subject pressed outward until arms were at near full extension, and a down 




Seat height was adjusted to align the top of the participant’s shoulders with the 
top of the handles.  The chest pad was adjusted to allow both hands to reach the handles 
with arm fully extended.  The participant sat upright, grasped the handles, and brought 
their elbows back, attempting to pinch shoulder blades together.  The handles were 
returned to the starting position in a controlled manner, without slamming the weights 
back onto the stack. 
Leg Press 
The participant sat on the leg press seat with back flat against the backrest and 
buttocks tucked as far back as possible. The backrest was adjusted forward or backward 
until the upper leg was approximately perpendicular to the floor and there was a 90
o
 bend 
in the participant's knees. The participant placed feet on the platform approximately 
shoulder width apart and in a position in which the quadriceps and hamstrings were 
exercised as evenly as possible.   Prior to increasing the weight to the value indicated in 





determine this position. A full repetition included an up motion in which the platform 
was pushed out until legs were fully extended, but knees not locked, and a down motion 
in which the platform was allowed to move back toward the participant until the weight 
touched the top of the weight stack. 
Leg Extension 
The back pad was adjusted to ensure that the participant’s knees were aligned 
with axis of rotation.  The participant’s thighs were positioned parallel to each other and 
the shin pad was lifted to the appropriate position on the lower shin to ensure comfortable 
positioning.  The participant’s was instructed to relax ankles, grip handles firmly, and 
maintain proper posture by pressing back against the back pad.  A full repetition 
including an up motion, in which the knees were straightened as far as possible without 
“kicking,” and a controlled down motion in which the lower leg slowly returned to the 
starting position without slamming the weights back onto the stack. 
Leg Curl 
The back pad was adjusted to ensure that the participant’s knees were aligned 
with axis of rotation.  The leg starting position (0-12) was set so that knees were fully 
extended.  The leg pad was adjusted for comfortable positioning slightly above ankles.  
The subject sat with lower legs resting upon pad, thighs parallel to each other and ankles 
relaxed.  The thigh pad was lowered to fit securely across participant’s thighs, while they 
held the grip handles on the thigh pad.  A full repetition included a down motion in which 
the participant flexed their knees until they reached at least 90
o
 without moving the pelvis 
or spine, and a controlled up motion in which the participant returned their legs to the 






 The lead investigator and Certified Cancer Exercise Specialists developed 
individualized exercise prescriptions and exercise interventions tailored to each subject in 
the exercise group based upon cancer history, health status, and results of the initial 
physical assessments.  Subjects attended one-on-one supervised exercise sessions three 
days per week for the 10 week intervention.  Prior to each training session, the lead 
investigator or Certified Cancer Exercise Specialists asked each participant a series of 
questions that elucidated whether it was necessary to alter that day’s exercise intervention 
(Appendix E).  Questions focused on how the participant felt after the last exercise 
session, if the participant had any soreness or specific problems that would affect 
training, and if changes in medication or treatment had been implemented since the last 
exercise session.  The exercise sessions lasted one hour each, and consisted of 25 minutes 
of aerobic exercise, 25 minutes of resistance training, and 10-minutes of flexibility and/or 
balance training.  Because the exercise intervention was personalized, there were some 
variations, but subjects spent a majority of the exercise session performing cardiovascular 
fitness, muscular strength and muscular endurance exercises.   
The mode of aerobic exercise selected for each participant was based on the mode 
offering the greatest anticipated benefit.  Options included treadmill walking, stationary 
cycling, and recumbent stepping.  Initially, exercise intensity was based on the results 
from the treadmill assessment.  Intensity was monitored via heart rate and RPE.  The 
Karvonen, or percent heart rate reserve (HRR), method was used to determine exercise 
heart rate intensity utilizing the formula:  





See Table 8 for recommended exercise intensity based on health and fitness status upon 
inclusion into the study.  High intensity exercise was avoided, as it can result in excessive 
ROS production which may magnify, rather than reduce, chronic oxidative stress in 
cancer survivors due to inadequate antioxidant defenses associated with the disease and 
its treatments (Finaud et al., 2006; Fisher-Wellman & Bloomer, 2009; Poulsen et al., 
1996).    
Table 8 
Recommended Exercise Intensity 
Health and fitness status   Recommended intensity 
Sedentary, poor health, low fitness  Start at 30-45% HRR; RPE of 1-3 
Moderate health, average fitness  Start at 50-60% HRR; RPE of 4-5       
Adapted from Exercise and Cancer Recovery, Schneider 2003, p. 87.  Copyright 2003 
Human Kinetics Publishers, Inc.  
  
 Resistance training followed the aerobic portion of the exercise session.  Subjects 
progressively increased the resistance load over the 10-week intervention, and progressed 
through various modalities, including resistance tubing, Cybex® weight machines and 
free weights.  Stability balls, balance pads, and Bosu ™ balls were integrated into the 
resistance training exercises to increase proprioception and balance.  Larger muscles were 
targeted first (chest, back, and thighs), followed by the smaller muscle groups (biceps and 
triceps).  Patients performed 2-3 sets of each exercise, with 8-12 repetitions per set.  
Resistance was based upon the initial assessment, and was monitored by heart rate 
response to the exercise and RPE.       
Cancer patients in the standard care control group were asked to maintain their 





“standardized” between hospitals and patients, it did not involve routine, systematic 
exercises (van Waart, Stuiver, van Harten, Sonke, & Aaronson, 2010).  Following the 10-
week study period, control subjects had the opportunity to exercise at RMCRI for three 
months at no cost.   A stretching intervention was not utilized for the control group, as it 
may acutely increase oxidative stress, and chronically augment the antioxidant defense 
system.  Although a control, stretching group was used by Campbell et al. (2010) without 
any change in F2-isoprostane levels in obese and overweight women, there was no 
significant difference between those engaged in aerobic exercise or stretching regimens.  
Moreover, passive stretch of isolated muscle fibers has been shown to increase cytosolic 
oxidant activity, (Chambers et al., 2009) and presumably could result in a hormetic 
response in antioxidant status over 12 weeks.   Along the same lines, yoga is not a viable 
control intervention, as 40 days of yoga asanas (postures) reduced serum MDA from 5.9 
± 3.6 to 2.9 ± 2.3 mmol/ml in patients with non-insulin dependent diabetes mellitus (S. 
Singh et al., 2001).  
Evaluation of Oxidative Stress 
 Blood was drawn from cancer patients on the day prior to both the initial 
assessment and the reassessment 10 weeks later.  A minimum of 4mL of blood was 
withdrawn into sterile tubes containing potassium-EDTA and immediately put on ice.  
Samples were centrifuged at 3,000 rpm for 10 minutes, and the plasma was separated and 
stored in multiple aliquots at -80°C until analysis.  All assays were performed in 
duplicate or triplicate on the first thaw.  Protein carbonyls and 8-OHdG were measured in 
plasma using an enzyme-linked immunosorbent assay (ELISA) according to the 





Antioxidant capacity was measured in serum using the Trolox-equivalent antioxidant 
capacity (TEAC) assay using procedures outlined by the reagent provider (Sigma 
Chemical, St. Louis, MO).    
Biochemical Assays 
 Reactive carbonyl derivatives were measured as a marker of oxidative protein 
damage.  A pilot study at RMCRI indicated that an exercise intervention reduced plasma 
protein carbonyl concentration by 76% in an individual undergoing high dose 
chemotherapy (unpublished data).  Oxidative DNA damage was determined by plasma 8-
OHdG.  This value is associated with the risk of cancer development and recurrence 
(Yamamoto et al., 1996).  To assess plasma antioxidant capacity and concentrations of 8-
OHdG and protein carbonyls, the following biochemical methodologies were used.    
Protein Carbonyls 
 The OxiSelect ™ Protein Carbonyl ELISA kit (Cell Biolabs, Inc., San Diego, CA) 
was used to assess byproducts of protein oxidation present in blood plasma.  In this 
enzyme immunoassay, 100 µl of 10 µl/mL diluted protein samples or standards with  
known concentrations of oxidized bovine serum albumin (BSA) were adsorbed to each 
well in the provided 96-well Protein Binding Plate and incubated overnight at 4ºC.  
Protein carbonyls present in the plasma sample or standard were derivatized to 
dinitrophenylhydrazine (DNPH), and probed with an anti-DNP antibody and a 
horseradish peroxidase (HRP) conjugated secondary antibody.  After adding a stop 








 The OxiSelect ™ Oxidative DNA Damage ELISA kit (8-OHdG Quantitation) 
(Cell Biolabs, Inc., San Diego, CA) was also utilized for analysis of DNA oxidation.  50 
µl of plasma or 8-OHdG standard was added to each well of a 96-well 8-OHdG 
Conjugate coated plate provided by the manufacturer.  Following  a 10 minute 
incubation, 50 µl of anti-8-OHdG antibody was added to each well and incubated for an 
hour.   Wells were washed and 100 µl of HRP secondary antibody was added and 
incubated for another hour.  After washing well, 100 µl of room temperature substrate 
solution was added to each wells and incubated for approximately 30 minutes.  100 µl of 
stop solution was added to each well and the results were read immediately at 450 nm 
using a plate reader.  
Trolox Equivalent Antioxidant Capacity 
 A commercially available assay kit (Sigma-Aldrich, Saint Louis, MO) was use to 
evaluate plasma antioxidant capacity, with 6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid (Trolox) serving as a control antioxidant.  The principle of this assay is 
the formation of a ferryl myoglobin radical from metmyoglobin (derived from horse 
heart) and hydrogen peroxide.  This oxidizes with 2,2’azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid) (ABTS) to produce ABTS
•+
, a soluble chromogen radical that can be 
determined spectrophotometrically at 405nm.  Antioxidants present in blood plasma 
samples or Trolox standards suppress the production of this radical in a concentration 
dependent manner, with a proportional decrease in color intensity.  10 µl or Trolox 
standard or test sample and 20 µl or Myoglobin Working Solution was added to each well 





minutes, at which time a stop solution was added and the plate was read within an hour at 
405 nm using a plate reader  
Other studies have examined exercise-associated changes in antioxidant enzyme 
capacity in healthy (Bloomer, 2008; Ji, 2002; Powers et al., 1999), diseased (Bloomer et 
al., 2008; Fisher-Wellman, Bell, & Bloomer, 2009) and elderly (Carvalho et al., 2010; 
Hammeren et al., 1992) populations.  Because the antioxidant defense system is complex 
and not fully elucidated, measurement of individual enzymes may not appropriately 
represent the dynamics of antioxidant status, as other mechanisms (non-enzymatic 
antioxidant status, transport mechanisms) may be involved in the adaptive response to 
exercise.  For instance, despite an attenuation of doxorubicin- associated lipid 
peroxidation (as measured by MDA) and cardiotoxicity, exercise pre-training in rats 
failed to increase SOD activity (Chicco, Schneider, & Hayward, 2005).    It should be 
noted that null findings in some studies were likely due to an insufficient variety of 
analyzed biomarkers (Fisher-Wellman et al., 2009).  Therefore, TEAC may be a suitable 
marker for examination of changes in antioxidant status, as it is non-specific, and 
determines total antioxidant activity in a sample.     
Statistical Analysis 
 Data were presented as means  SD.  Subjects’ baseline characteristics in the two 
cancer groups (exercise training versus control) and the non cancer group were compared 
using independent t-tests.  A repeated measures 2 (group) × 2 (pre- and post-intervention)  
analysis of variance (ANOVA) with Bonferroni post hoc was used to determine 
differences within (across time) and between the two groups related to markers of 





a normal probability plot and the Kolmogorov-Smirnov test, the residuals from the 
model(s) show no evidence of a lack of normality. Therefore the standard repeated-
measures ANOVA model appears appropriate for the data.  Spearman correlation 
coefficients were calculated to determine associations between baseline markers of 
oxidative stress and baseline VO2peak, muscular strength, and fatigue.  Additionally, 
Spearman correlation coefficients were calculated to determine associations between 
post-intervention changes in markers of oxidative stress and post-intervention changes in 
VO2peak, muscular strength, and fatigue.  Although repeated measures ANOVA was 
used for analysis of change within the cancer population, the nonlinear Spearman's rank 
correlation was used due to the expectation of a nonlinear trend, as antioxidant and 
oxidative stress values may plateau at optimal levels in both healthy and cancer subjects, 
even as fitness and fatigue parameters continue to improve.   A significance level of α = 





















CANCER RELATED FATIGUE AND MARKERS OF OXIDATIVE 
STRESS IN CANCER PATIENTS FOLLOWING 
AN EXERCISE INTERVENTION 
 
Abstract 
PURPOSE.  The last two decades have produced an abundance of research indicating 
that exercise interventions in cancer patients are capable of reducing cancer-treatment 
related side effects, including fatigue.  Cancer-related fatigue is a somewhat nebulous 
concept, as both physiological and psychological factors contribute to this phenomenon.  
Although the underlying mechanisms of cancer-related fatigue are not fully 
characterized, treatment-associated oxidative stress is thought to play a role.   The 
purpose of this study was to determine the effect of an exercise intervention on blood 
markers of oxidative stress, antioxidant status, and cancer-related fatigue compared to a 
cancer control group.  METHODOLOGY.  An initial fasting blood draw and fatigue 
questionnaire were administered to fifteen cancer patients within six weeks of completing 
radiation or chemotherapy treatment, as well as seven age-matched individuals with no 
history of cancer (NC) to compare baseline values.   Eight of the cancer patients 
participated in a 10-week exercise intervention (EX), while seven continued standard care 





were administered.  Changes in plasma 8-OHdG and antioxidant status were compared 
between the EX and cancer CON groups.  Baseline markers of oxidative stress were 
compared between NC subjects and cancer patients.  A correlation analysis of fatigue and 
oxidative stress in all subjects was conducted.   RESULTS.  Mean total fatigue scores 
decreased significantly from 5.0 ± 2.2 to 2.6 ± 1.5 (p < 0.05) in EX, whereas changes in 
CON (4.7 ± 2.5 to 3.2 ± 2.4) were not significant.  All fatigue subscales significantly 
decreased in EX, while only cognitive fatigue increased significantly in CON (p < 0.05).  
No group by time interaction effect between groups was found for fatigue scores.  Total 
antioxidant capacity increased significantly over time in EX (p < 0.01), but not in CON.  
No significant changes over time were found in 8-OHdG, but a group by time interaction 
effect was detected (p < 0.05).  Baseline antioxidant capacity significantly correlated (p < 
0.05) with total (r = -0.41) affective (r = -0.39), sensory (r = -0.40), and cognitive fatigue 
(r = -0.57).  Increases in antioxidant capacity were correlated with reductions in affective 
(r = -0.49), sensory (r = -0.47), and cognitive fatigue (r = -0.58). Although 8-OHdG was 
not correlated with any fatigue parameter at baseline, changes in total (r = 0.46) and 
affective (r = 0.47) fatigue exhibited significant correlations with changes in 8-OHdG 
over time.  CONCLUSION.  An exercise intervention reduced fatigue in cancer patients 
following cessation of treatment, whereas standard care resulted in non-significant 
reductions in fatigue.  Oxidative stress may be implicated in cancer-related fatigue, while 
improved antioxidant capacity following an exercise intervention may play a role in 
mitigating fatigue. 
Introduction 
The National Cancer Institute estimates that 13.7 million Americans with a 





to be diagnosed in 2014 (American Cancer Society, 2014).   Although survival rates 
continue to improve, these patients can expect to experience adverse side effects of 
surgery, radiation, chemotherapy, and other treatment modalities that may last for years.  
Typical side effects include muscle weakness (Christensen et al., 2014; Schneider et al., 
2007a), reduced cardiorespiratory fitness (Burnett, Kluding, Porter, Fabian, & Klemp, 
2013), and general fatigue (Campos, Hassan, Riechelmann, & Del Giglio, 2011; Puetz & 
Herring, 2012), resulting in an overall decrease in quality of life.   
Acute and chronic cancer-related fatigue associated with radiation therapy, 
chemotherapeutic agents, and the tumor burden itself, have been well documented for 
decades (Piper et al., 1989; Questad et al., 1982; Rieger, 1988; Smets et al., 1993).   Up to 
90% of cancer patients report experiencing fatigue following cancer treatment, and it is 
commonly reported as the most problematic side effect for cancer survivors (Hofman, 
Ryan, Figueroa-Moseley, Jean-Pierre, & Morrow, 2007).  Cancer-related fatigue is 
similar in nature to chronic fatigue syndrome in terms of symptoms and etiology 
(Rovigatti, 2012).  Both conditions are more chronic and debilitating than standard 
fatigue, causing individuals to alter their behavior and demeanor, but all patients 
experience cancer-related fatigue differently (de Jong et al., 2002).   
 Because fatigue is both a physiological and psychological condition, it is difficult 
to identify a specific mechanism, but there are likely many.  Some proposed factors 
contributing to fatigue are muscular wasting related to cachexia (Christensen et al., 2014; 
Gilliam & St Clair, 2011); sleep disturbances  (Roscoe et al., 2007); psychological 
depression; (Piper et al., 1987); anemia (de Jong et al., 2002); and metabolic imbalance 





capacity (mitochondrial damage), or decreased substrate availability associated with 
anorexia, nausea, or vomiting (Glaspy, 2001).   Additionally, many of the mechanisms 
responsible for exercise-associated fatigue have been postulated to contribute to cancer-
related fatigue, including serotonin dysregulation, hypothalamic-pituitary-adrenal (HPA) 
axis dysfunction, vagal afferent nerve activation, and cytokine dysregulation (Ryan et al., 
2007). 
 Although cancer-related fatigue is undoubtedly a product of a combination of 
these physiological and psychological factors, and may vary between individuals, 
oxidative stress is thought to play a pivotal role in many pathological processes 
associated with cancer and its treatments (Fang et al., 2009; Robbins & Zhao, 2004; Zhao 
& Robbins, 2009).  Oxidative stress is a state in which reactive oxygen species (ROS) are 
produced at a rate that exceeds cellular adaptive and repair capacities, resulting in 
damage to local tissues, including lipid membranes, protein structures, and nucleic acids, 
(Halliwell & Gutteridge, 2007).  Cancer cells often are characterized by elevated levels of 
oxidative stress.  ROS production associated with breast cancer is common enough that a 
decreased GSH/GSSG ratio (reduced to oxidized glutathione ratio) has been identified as 
an important biochemical parameter for detecting breast malignancy (Yeh et al., 2006).  
Additionally, radiation and many chemotherapy regimens depend on ROS as an 
antineoplastic mechanism (Kovacic, 2007; Tandon et al., 2005).  Although ROS exert a 
greater cytotoxic effect on cancer cells, cancer treatments are associated with collateral 
oxidative damage to healthy tissues (Chen, Jungsuwadee, Butterfield, & St Clair, 2007).  





status, potentially resulting in acute and chronic side effects, including cancer-related 
fatigue.   
While cancer-related fatigue has been theoretically tied to oxidative stress 
(Gilliam & St Clair, 2011), and many of the proposed mechanisms previously mentioned 
can be driven by ROS and oxidative stress, there is a general lack of evidence explicitly 
relating oxidative stress to cancer-related fatigue.  Gramignano et al. (2006), 
demonstrated that four weeks of L-carnitine administration simultaneously reduced 
fatigue and resulted in a non-significant decrease in oxidative stress in patients currently 
undergoing cancer treatment.   Additionally, chronic fatigue syndrome has been 
associated with oxidative stress (Fulle et al., 2000; Jammes et al., 2005; Richards et al., 
2000; Richards et al., 2007) and deficiency of the antioxidant glutathione (Bounous & 
Molson, 1999).   Maes et al. (2009) found that 8-hydroxy-deoxyguanosine (8-OHdG), a 
marker of oxidative damage to DNA, was elevated in individuals suffering from both 
depression and chronic fatigue syndrome.  DNA oxidation is linked to oncogenesis, as 
well as atherosclerosis and neurodegeneration, factors that are associated with 
psychological and cognitive dysfunction.  Accordingly, oxidative stress may represent a 
potential mechanistic link between cancer and psychological dysregulation, including 
cancer-related fatigue.   
 Until recently, oncologists and primary care physicians treating cancer patients 
prescribed rest as a strategy to counteract cancer-related fatigue.  Although it is somewhat 
counterintuitive, research has shown that physical activity is a more effective method of 
reducing acute and chronic fatigue in cancer survivors.  Whereas exercise has been 





Schneider & Hayward, 2013), daytime inactivity may actually worsen fatigue symptoms 
(Berger & Farr, 1999).   In particular, resistance and aerobic exercise have been found to 
be beneficial as a means to reduce fatigue, while improving quality of life (Ferrer, 
Huedo-Medina, Johnson, Ryan, & Pescatello, 2011), muscular strength and endurance 
(Focht et al., 2013; Schneider et al., 2007a), cardiorespiratory endurance (Courneya et al., 
2007; L. W. Jones, Liang, et al., 2011; Lakoski, Eves, Douglas, & Jones, 2012; Schneider 
et al., 2007c), and even survival rates (Holmes, Chen, Feskanich, Kroenke, & Colditz, 
2005; Irwin et al., 2011).   Various methods of prescribed exercise, including resistance 
and aerobic exercise, both  supervised and at home, have been shown to improve fatigue 
symptoms in cancer patients following treatment (Brown et al., 2011) .   
Although exercise interventions are known to improve antioxidant capacity in 
healthy individuals (Ji, 2008; Powers, Sollanek, Wiggs, Demirel, & Smuder, 2014; 
Radak, Chung, Koltai, Taylor, & Goto, 2008), minimal research on exercise-associated 
oxidative stress modifications in cancer patients is available.   Allgayer et al (2008) 
demonstrated reductions in urinary 8-OHdG excretion, from 8.47 to 5.81 ng/mg 
creatinine (p = 0.02), after two weeks of moderate intensity exercise, while two weeks of 
high intensity exercise training resulted in a non-significant increase in 8-OHdG 
excretion.  More recently, Jones et al (2011) demonstrated a nonsignificant gain (+ 32%, 
p = 0.08) in F2-isoprostanes following a high intensity 3-month exercise program.  These 
disparate results indicate that, among other factors, exercise intensity likely plays a role 
in the redox balance response to exercise interventions.  In animal models, exercise has 
been shown to attenuate oxidative damage and reduce treatment-associated side effects 





Interestingly, individual antioxidant enzymes, such as superoxide dismutase, have been 
shown to increase with exercise training in rodents in some studies (Kanter et al., 1985) 
but not others (Chicco et al., 2005).  This may be explained by the plastic and time-
sensitive nature of redox signaling.   For instance, although exercise training in rats 
resulted in increased activity of the antioxidant enzyme catalase in left ventricular tissue, 
upon cessation of exercise, catalase activity returned to pre-exercise values by day 9 
(Lennon et al., 2004).   
 It is possible that the exercise-mediated reductions in oxidative stress are in part 
responsible for exercise-associated decreases in cancer-related fatigue, but to date, this 
relationship is largely uncharacterized.   Therefore, the purpose of this study was to 
investigate changes in total antioxidant capacity, DNA oxidation, and fatigue parameters 
in cancer patients following a whole body exercise intervention versus a cancer control 
group.  Furthermore, correlations between baseline fatigue and oxidative stress, as well as 
changes in oxidative stress and fatigue parameters were evaluated.  
Methodology 
 This study consisted of a 10-week prescribed exercise intervention in cancer 
patients following oxidative stress-inducing cancer treatments, including radiation or 
chemotherapy.  Subjects had completed radiation or chemotherapy treatment within the 
previous 6 weeks, with an average time out of treatment of 4 weeks.  Fifteen cancer 
patients and seven individuals with no history of cancer or other chronic diseases (NC) 
participated in this study. Cancer patients were admitted to either an exercise intervention 
group (EX) or a standard care group (CON) based upon date of initial contact (pseudo-
randomization), while NC subjects were only evaluated at baseline.  Cancer patients were 





Rehabilitation Institute (RMCRI) at the University of Northern Colorado (UNC) in 
Greeley, Colorado.  Additionally, oncology patient navigators and clinical oncology 
research specialists at Northern Colorado Medical Center in Greeley, Poudre Valley 
Hospital in Fort Collins, and McKee Hospital in Loveland, Colorado identified qualifying 
individuals as they completed radiation or chemotherapy treatments.  Newspaper articles 
in the Greeley Tribune and UNC today, posters at the local American Cancer Society 
office and outpatient oncology waiting areas, and a recruitment page on the RMCRI 
webpage were used to promote this study. 
Twenty six cancer patients made contact with the primary investigator, but 
exclusion criteria or attrition resulted in the loss of 11 potential subjects.  Refer to Figure 
6 for flow of the subjects through this study.  All cancer diagnoses were considered for 
this study, but subjects were required to have undergone radiation or a chemotherapy 
treatment explicitly known to elicit oxidative stress, either as a side effect or as an 
antineoplastic mechanism.  Chemotherapy agents included anti-neoplastic antibiotics, 
alkylating agents, platinum coordinating complexes, epipodophyllotoxins, fluorouracil 
and tamoxifen (Y. Chen et al., 2007; Conklin, 2004; Look & Musch, 1994).  Cancer 
patient inclusion criteria consisted of: (1) completed radiation or approved cancer therapy 
regimen within six weeks of initial blood draw, (2) currently sedentary (less than two 
days/week or 20 minutes of aerobic or resistance exercise) (Brooks et al., 2005), (3) have 
not consistently supplemented with dietary antioxidants, including vitamins C and E, in 
the previous month, (4) non-smokers (for at least 2 months), and (5) were able to walk 







26 non-smoking, sedentary cancer patients who had completed chemotherapy or radiation within 
the previous 6 weeks contacted the PI directly or were identified by RMCRI, a nurse navigator, or 
another member of the local oncology community. 
  
Exclusion criteria: 
1 patient too physically active 
  
Attrition: 
2 patients failed to return phone calls after initial contact 
2 patients missed the scheduled initial blood draw or assessment, and never agreed to reschedule 
1 patient “too busy to participate” 
2 patients were unwilling to make commitment to more cancer-related appointments 
1 cancelled initial assessment appointment because the drive for training was too far 
1 patient diagnosed with brain metastasis after initial blood draw but prior to initial assessment 
1 patient returned to chemotherapy after 4 weeks of exercise training 
  
8 subjects participated in a 10-week exercise intervention 
7 subjects were cancer control subjects, and received standard care for 10 weeks 
  
Total sample size: 
15 subjects completed the 10-week intervention, blood draw and reassessment of fitness 
Figure 6.  Flow of cancer patients through the study. 
 
Non-cancer, healthy controls were primarily recruited from among the faculty and 
staff at the University of Northern Colorado via campus-wide email and by word of 
mouth.  Inclusion criteria for the non-cancer group included:  (1) currently sedentary (less 
than two days/week or 20 minutes of aerobic or resistance exercise), (2) no history of 
cancer or other major chronic disease, (3) have not consistently supplemented with 
dietary antioxidants in the previous month, and (4) non-smokers.   The University of 
Northern Colorado Institutional Review Board (IRB) approved all procedures.   
Prior to arrival at RMCRI, all cancer and non-cancer subjects were provided with 
the Piper Fatigue Scale (Piper et al., 1998) to complete within 24 hours of the initial 





exhaustive exercise and antioxidant supplementation.  The day before the cancer patient’s 
initial exercise assessment, a 12-hour fasting blood sample was taken by the lead 
investigator or an otherwise experienced phlebotomist.   
Piper Fatigue Inventory 
 The Piper Fatigue Inventory (Piper et al., 1998) was used to assess total cancer-
related fatigue, as well as the subscales of behavioral, affective, sensory, and 
cognitive/mood fatigue. The behavioral fatigue subscale includes six questions and was 
used to assess the impact of fatigue on school and/or work, interacting with friends, and 
overall interference with activities that are enjoyable. The affective fatigue subscale 
includes five questions and assessed the emotional meaning attributed to fatigue. The 
sensory fatigue subscale includes five questions and assessed the mental, physical, and 
emotional symptoms of fatigue. The cognitive and/or mood fatigue subscale includes six 
questions and assessed the impact of fatigue on concentration, memory, and the ability to 
think clearly. The average score on the 22 total questions from the subscales provides the 
total fatigue score.  The range of possible scores on the subscales as well as total fatigue 
ranges from “0” to “10”. A score of a “0” indicates that the cancer survivor has no 
fatigue; scores ranging from “1” to “3” are indicative of mild fatigue; scores “4” to “6” 
suggest moderate fatigue; and scores of “7” or greater indicate severe fatigue.  
Fitness Assessment 
 In order to appropriately prescribe an individualized exercise intervention, an 
initial assessment of cardiorespiratory endurance, muscular strength, flexibility, and 
balance was performed.  An incremental treadmill test to volitional fatigue was used to 





measurements (predicted one-repetition maximum [1-RM]) was utilized to allow for 
appropriate prescription of resistance exercise, and included lat pull-down, shoulder 
press, chest press, seated row, leg press, leg extension, and leg curl exercises, using 
Cybex® gym equipment (Cybex International, Medford MA). Flexibility was assessed 
with a modified sit and reach test and the back scratch test, while the Bertec Balance 
Check™ Screener and Trainer Package (Bertec Corporation, Columbus OH) was used to 
assess postural stability and limits of stability.  The RMCRI treadmill protocol, an 
internally validated graded exercise test to volitional fatigue, determined maximal aerobic 
capacity.   
Exercise Intervention 
 Each exercise participant completed a 10-week exercise intervention that was 
individually supervised by a cancer exercise specialist 3 days per week.  Each 1-hour 
session was in accordance with the subject’s prescribed training modes, intensity, and 
volume, based upon their goals and assessment results.  Exercise sessions varied 
depending on the subject’s health and fitness status, but typically included a 5-minute 
warm-up, 20 minutes of aerobic exercise, 25 minutes of resistance training, and 10 
minutes of flexibility and balance training.  Blood pressure and HR were measured at the 
beginning and end of the exercise session, and HR, RPE, and SaO2 were monitored 
throughout.  Aerobic exercise intensity was based on the survivors’ initial VO2peak, and 
was generally low to moderate intensity, generally ranging from 30% to 60% of heart rate 
reserve (HRR). The Karvonen or percent heart rate reserve method was used to determine 
exercise heart rate intensity using the formula  





Subjects with poor overall health status health or low fitness were initially prescribed an 
intensity level of 30%-45% HRR or a RPE of 1-3, whereas subjects with a moderate 
health status or average fitness began their aerobic exercises at 50%-60% of HRR or an 
RPE of 4-5.  The mode of aerobic exercise selected for each subject was based on the 
mode offering the greatest anticipated benefit.  Options included outdoor or treadmill 
walking, stationary cycling, or recumbent stepping.  Although rate of progression varied 
significantly by subject, cancer exercise specialists aimed to increase increases speed or 
resistance weekly, while keeping RPE values below 5 and HR values below 75% HRR.   
At the beginning of the intervention, initial percent of 1-RM corresponded with 
the percent of HRR values for aerobic exercise, based upon initial health and fitness 
status (30%-45% 1-RM for low fitness, 50%-60% for average fitness).  Cybex Eagle 
Selectorized Strength Machines
©
 (Cybex International Inc, Medway, MA, USA), free 
weights, resistance bands and body weight exercises were all used for the exercise 
intervention, depending upon fitness, mobility, and comfort of the cancer patient.  
Muscular endurance was emphasized over hypertrophic training, as subjects performed 8-
15 repetitions per set and typically ended each set at muscular fatigue rather than muscle 
failure.  Resistance was increased when 8-15 repetitions no longer resulted in muscular 
fatigue.  
All cancer patients were asked to avoid any substantial changes in their diet, 
assuming a physician or nutritionist did not prescribe a change in eating habits.  Subjects 
in the standard care control group were asked to maintain their exercise habits during the 
10-week study period.  Although standard care cannot be “standardized” between 





2010).  Neither yoga nor stretching programs were utilized for the control group because 
both interventions have the potential to alter markers of oxidative stress and antioxidant 
capacity (Chambers et al., 2009; S. Singh et al., 2001).  Control subjects were asked to 
complete an exit survey inquiring about any changes in physical activity, dietary habits, 
medications, and medical procedures.  Following the 10-week study period, control 
subjects had the opportunity to exercise at RMCRI for three months at no cost.    
Blood Handling and Analysis 
 A minimum of 4mL of blood was withdrawn into sterile tubes containing 
potassium-EDTA and immediately put on ice.  Samples were centrifuged at 3,000 rpm 
for 10 minutes, and the plasma was separated and stored in multiple aliquots at -80°C 
until analysis.  All assays were performed in duplicate or triplicate on the first thaw.  
Oxidative DNA damage was determined by plasma 8-OHdG ,which was measured using 
an enzyme-linked immunosorbent assay (ELISA) according to the procedures 
recommended by the manufacturer (Cell Biolabs, Inc., San Diego, CA).  This value is 
associated with the risk of cancer development and recurrence (Yamamoto et al., 1996).  
Antioxidant capacity was measured in plasma using the Trolox-equivalent antioxidant 
capacity (TEAC) assay using procedures outlined by the reagent provider (Sigma 
Chemical, St. Louis, MO).    
Statistical Analyses 
 Data are presented as means  SD.    Subjects’ baseline characteristics in the two 
cancer groups (EX versus CON) and the NC group were compared using independent t-
tests.  A repeated measures 2 (group) × 2 (pre- and post-intervention)  analysis of 





(across time) and between the two groups related to markers of DNA oxidation, 
antioxidant capacity, and fatigue.  A Kolmogorov-Smirnov was used to ensure that the 
normality assumption was met for this data set.  Spearman correlation coefficients were 
calculated to determine associations between baseline markers of oxidative stress and 
baseline fatigue.  Additionally, Spearman correlation coefficients were calculated to 
determine associations between post-intervention changes in markers of oxidative stress 
and post-intervention changes in fatigue.   A significance level of α = 0.05 was used for 
all statistical analyses.   
Results 
 Baseline subject characteristics for the EX, CON, and NC groups are summarized 
in Table 9.  The two cancer groups had statistically similar height, weight, body mass 
index, and time out of treatment, and no significant differences in age were found 
between the three groups.  Although exit surveys in control subjects indicated no notable 
changes in dietary habits, qualitative physical activity in this group increased from 
baseline as, even in the absence of an exercise intervention, time out of treatment resulted 
in greater vigor for activities of daily living and leisure time activity.  Increases in 
housework, light yard work, and walking were most commonly reported, but no control 














Exercise Control Non-Cancer 
      N 8 7 7 
      Age (years) 64.0 ± 10.8 62.4 ± 9.7 55.1 ± 9.7 
      Females 7 4 5 
      Males 1 3 2 
      Height (in) 65.4 ± 2.5 66.8 ± 4.7 - 
      Weight (lbs) 174.0 ± 32.3 179.5 ± 40.8 - 
      BMI 28.4 ± 4.3 28.1 ± 3.8 - 
Primary treatment (# of subjects) 
        Radiation  4 4 - 
      Chemo 3 4 - 
Days out of Treatment 29.9 ± 18.6 31.4 ± 21.7 - 
Exercise adherence rate (%) 83.9 ± 12.8 - - 
 
 Baseline fatigue parameters, including total fatigue as well as all four 
subcategories of the Piper Fatigue Scale, were significantly elevated in the cancer 
population compared to the age-matched, non-cancer population (Table 10).  Mean total 
fatigue values were greater than 4 out of 10 in both cancer groups, resulting in a 
“moderate fatigue” classification.  In the EX group, 3 subjects reported mild fatigue, 4 
subjects reported moderate fatigue, and 1 subject was severely fatigued.  The CON group 
displayed similar baseline fatigue distribution, as 2 subjects were mildly fatigued, 4 
subjects moderately fatigued, and 1 subject severely fatigued.  The NC group had a total 
fatigue score of 1.0, which corresponds with the cutoff for “no fatigue” and “mild 









Table 10  
 
Baseline Fatigue Scores 
  Total Behavioral Affective Sensory Cognitive 
Cancer (N = 15)   4.8 ± 2.3 
a 
  4.4 ± 3.1
 a
   5.5 ± 2.4
 a
   5.5 ± 2.3
 a
   4.8 ± 2.1
 a
 
NC (N=7) 1.0 ± 1.0 0.9 ± 1.3 0.7 ± 0.8 1.4 ± 1.3 1.2 ± 1.2 
a
 Significantly greater than NC  
 Following the 10 week study period, total fatigue and all four fatigue 
subcategories were significantly reduced in EX, while only cognitive fatigue significantly 
diminished in CON.   Fatigue parameter means at all time points are displayed in Figures 
7-11, and changes over time are tabulated in Table 11.  No group by time interaction 
effects were found between EX and CON for any fatigue parameter.  Mean total fatigue 
in the EX group fell from 5.0 ± 2.3 to 2.6 ± 1.9 (p < 0.01), indicating a change in group 
mean classification from “moderate fatigue” to “mild fatigue.”  The only subject in this 
group failing to downgrade classification status was the individual with mild fatigue at 
baseline, and therefore little room for improvement.  Mean total fatigue in the CON 
group dropped from 4.6 ± 2.4 at baseline to 3.2 ± 2.4 at follow-up, but this represented 
neither a statistically significant change, nor a change in group mean classification.  
Additional post-hoc analysis revealed that behavioral and affective fatigue in the exercise 
group no longer statistically differed from the NC group (p > 0.05) following the 10-
week exercise intervention. 
Table 11 
  
Changes in Fatigue Scores 
  Total Behavioral Affective Sensory Cognitive 
EX (N=8)   -2.4 ± 0.9 
a
   -2.6 ± 2.4 
b
   -3.4 ± 1.9 
a
   -2.5 ± 1.2 
a
 -1.8 ± 1.1 
a
 




 Significant change over time (p <  0.01) 
b































Figure 7.  Total fatigue scores for all groups and time points. 
*= significantly different than EX Pre (p < 0.01).  # = Significantly different than EX Pre, 
CON Pre (p < 0.01), EX Post and CON Post (p < 0.05).   
 





























Figure 8.  Behavioral fatigue scores for all groups and time points. 
*= significantly different than EX Pre (p < 0.05).  # = Significantly different than EX Pre, 



































Figure 9.  Affective fatigue scores for all groups and time points. 
*= significantly different than EX Pre (p < 0.01).  # = Significantly different than EX Pre, 
CON Pre, and CON Post (p < 0.01).  
 




























Figure 10.  Sensory fatigue scores for all groups and time points. 
*= significantly different than EX Pre (p < 0.01).  # = Significantly different than EX Pre, 




































Figure 11.  Cognitive fatigue scores for all groups and time points. 
* = significantly different than EX Pre (p < 0.01).  † = significantly different than CON 
Pre (p < 0.01).  # = significantly different than EX Pre, CON Pre (p < 0.01), EX Post and 
CON Post (p < 0.05).   
 
 Baseline markers of oxidative stress in cancer and NC patients are found in Table 
12.  Plasma antioxidant status, as determined by TEAC, did not differ between EX and 
CON, but was significantly greater in NC than in the cancer patients (p < 0.01).  Plasma 
8-OHdG, a marker of DNA oxidation, did not differ between any of the groups at 
baseline. (p > 0.05).   
Table 12 
Baseline Oxidative Stress Parameters 
  TEAC (mM Trolox) 8-OHdG (ng/mL) 
Cancer (N = 15)    0.27 ± 0.06
 a
 0.42 ± 0.26 
NC (N=7)    0.37 ± 0.07 0.33 ± 0.18 
a
 Significantly lower than NC (p <  0.01) 
 
 Changes in antioxidant capacity and DNA oxidation for EX and CON are 





0.39 ± 0.05 mM Trolox equivalence (p < 0.01), while in CON, TEAC increased from 
0.26 ± 0.05 to 0.32 ± 0.08 mM, but this did not represent a significant improvement (p > 
0.05).  Following the 10-week study period, antioxidant capacity in NC no longer 
differed significantly from either cancer group (p > 0.05).  DNA oxidation did not change 
significantly over time in either group, but there was a significant interaction effect 
between EX and CON (p < 0.05).   EX decreased plasma 8-OHdG concentration from   
0.47 ± 0.33 to 0.29 ± 0.18 ng/mL, whereas CON increased from 0.35 ± 0.14 to 0.49 ± 
0.22 ng/mL. 
Table 13  
 
Changes in Oxidative Stress Parameters 
  TEAC (mM Trolox) 8-OHdG (ng/mL) 
EX (N=8) + 0.11 ± 0.09
 a
 - 0.18 ± 0.26
 b
 
CON (N=7) + 0.06 ± 0.09 + 0.13 ± 0.19 
a
 Significant increase from baseline (p <  0.01) 
b
Significant group by time interaction effect, compared to CON (p <  0.05) 
 











































Figure 12.  Trolox Equivalent Antioxidant Capacity for all groups and time points. 
*= significantly different than EX Pre (p < 0.01).  # = significantly different than EX Pre 





































Figure 13.  8-OHdG plasma concentration for all groups and time points. 
† = significant group by time interaction effect, compared to CON (p < 0.05).   
 
 Spearman correlation analysis revealed negative correlations between baseline 
antioxidant capacity and total (r = -0.41, p < 0.05), affective (r = -0.39, p < 0.05), sensory 
(r = -0.40, p < 0.05), and cognitive fatigue (r = -0.57, p < 0.01).  No correlations between 
baseline 8-OHdG and fatigue were detected.  Significant negative relationships (p < 0.05) 
between changes in TEAC and changes in affective (r = -0.49), sensory (r = -0.47), and 
cognitive fatigue (r = -0.58) were revealed.  Similarly, changes in 8-OHdG and changes 
in total (r = 0.46) and affective fatigue (r = 0.47) exhibited significant correlations (p < 













Table 14  
 
Correlations Between Oxidative Stress and Fatigue Parameters at Baseline 
    Total Fatigue Behavioral Affective Sensory Cognitive 
TEAC 











Correlation 0.28 0.30 0.27 0.26 0.19 
Significance 0.105 0.088 0.109 0.118 0.199 
a
 Significant correlation between blood parameter and fatigue score (p <  0.05) 
 
 
Table 15  
 
Correlations Between Changes in Oxidative Stress and Fatigue Parameters  
    Total Fatigue Behavioral Affective Sensory Cognitive 
TEAC 
Correlation -0.37 -0.097 -0.49 -0.47 -0.58 













 0.106 0.174 0.485 
a
 Significant correlation between blood parameter and fatigue score (p <  0.05) 
 
Adverse Events and Exercise Adherence   
 Several of the EX patients exhibited chronic musculoskeletal limitations at 
baseline, including osteoarthritis, rheumatoid arthritis, and complications associated with 
previous surgery (including knee surgery, hip replacement, double mastectomy, wrist 
surgery, lumbar fusion, and Whipple procedure for pancreatic cancer).  Because of the 
individualized nature of the exercise intervention, modification of the exercise program 
was sufficient to allow for continued exercise participation and completion of the 
intervention in all EX subjects.  Overall, exercise adherence was good, with subjects 
attending 84% ± 13% of scheduled sessions.  One patient missed three sessions during 
the intervention due to hip pain associated with a previously failed hip replacement, and 





following double mastectomy.  Otherwise, scheduling conflicts and acute respiratory 
infections accounted for most missed training sessions.   
Conclusions 
 Results from this study indicate that exercise training is an effective method of 
reducing fatigue in cancer patients who have completed treatment within the prior 6 
weeks.  It appears that time out of treatment is an important variable in that it clearly has 
a restorative effect on its own, as cognitive fatigue was significantly reduced in the CON 
group and there were no significant interaction effects between EX and CON for any 
fatigue variable.  The attenuation of only cognitive fatigue in CON may indicate that 
physiological components of cancer-related fatigue are more persistent than the cognitive 
impairments in patients who are not actively counteracting the cancer treatment-induced 
physiological damage with physical activity.  It should be noted though, that reported 
increases in physical activity and activities of daily living in several CON subjects 
represent control group contamination.  This may partially explain the universal trend of 
reduced fatigue in control subjects, and subsequently no significant group by time 
interaction effects for fatigue parameters.  Nonetheless, significant correlations between 
antioxidant capacity and both baseline and changes in fatigue indicate that improved 
antioxidant capacity may play a role in reduced fatigue, regardless of physical activity 
level. 
Despite a lack of significant change in 8-OHdG over time, there was a significant 
group by time interaction effect between EX and CON.  Matsumoto et al (2003)  found 
that hepatic cancer patients with higher 8-OHdG levels in noncancerous liver regions 





(p < 0.01).   Therefore, it is possible that variable 8-OHdG response over time between 
the groups may be implicated in a reduced risk for cancer recurrence following the 
cessation of treatment in exercise subjects compared to standard care.  Indeed, it has been 
reported that higher levels of physical activity are associated with an improved disease-
free survival rate (Ibrahim & Al-Homaidh, 2011), and exercise following treatment may 
reduce the chance for cancer recurrence (Courneya, 2003; Loprinzi, Cardinal, Winters-
Stone, Smit, & Loprinzi, 2012). 
While antioxidant capacity was greater in NC than cancer patients at baseline, 8-
OHdG did not differ between cancer and NC groups at baseline.  This may be explained 
by the fact that all subjects were out of treatment, and presumably free of cancer burden.  
Gadjeva et al. (2008) found that plasma malondialdehyde (MDA) concentration dropped 
in melanoma patients following surgery due to the reduced cancer-induced oxidative 
stress.  While chemotherapy subsequently increased oxidative stress compared to post-
surgery levels, MDA levels were still significantly lower than pre-surgery values.   
Without pre-treatment data in our study, it is difficult to draw conclusions about this 
potential interaction.    
 There appeared to be a responder / non-responder effect in regards to 8-OHdG.  
Three EX subjects reduced 8-OHdG by more than 0.3 ng/mL, while the remainder 
changed less than 0.03 ng/mL.  In contrast, while three CON subjects increased 0.2 
ng/mL or more, the remainder changed approximately 0.1 ng/mL, with half exhibiting 
decreases.  Kennedy et al (2005) found that in patients with chronic fatigue syndrome, 
oxidative stress, as measured by 8-iso-prostaglandin-F2α-isoprostanes, were correlated 





hypertensive individuals.   This indicates that oxidative stress may significantly affect 
fatigue in cancer survivors, but due to the multi-causal nature of fatigue, this relationship 
may be uncoupled in certain clinical subsets of the cancer population where other 
physiological factors exist, including body composition, cardiac health, and medication 
status.   
It is not entirely clear why there was a rise in 8-OHdG in the control group during 
the study period.  Although the cancer treatments investigated in this study all are known 
to acutely introduce oxidative stress, the time frame of the persistence of markers of 
oxidative stress is still not wholly characterized, and may be affected by an undetected 
cancer burden.   For instance, Erhola et al. (Erhola et al., 1997) found that the overall 
response to radiation and chemotherapy (“complete or partial remission”, versus “no 
change or progressive disease”) determined whether urinary 8-OHdG concentration 
increased or decreased with treatment.  Furthermore, Jonas et al. (Jonas et al., 2000) 
found that GSH/GSSG ratio continually decreased over the two weeks following the end 
of chemotherapy, indicating that treatment either directly impairs the antioxidant system, 
or that chronic oxidative stress is capable of depleting the glutathione pool and diminish 
reductive capacity.  Regardless, these data indicate that in certain cancer populations, 
oxidative stress may worsen for a period of time after the cessation of treatment, but the 
effects of variable prognostic criteria and differing cancer stages, types, and treatment 
regimens on the timeframe of chronic oxidative stress are unknown at this time. 
 As expected, baseline fatigue was greater, and antioxidant capacity lower, in 
cancer patients compared to non cancer patients.  Previously, sparse data existed 





The current study indicates that additional time out of treatment (in this case, from one 
month to more than three months) helps restore antioxidant capacity, albeit 
nonsignificantly.  Exercise, on the other hand resulted in a more robust, and statistically 
significant, increase in antioxidant capacity.  Moreover, significant correlations between 
increased antioxidant capacity and reduced fatigue indicate that systemic oxidative stress 
may be a potential mechanism for cancer-related fatigue, much as it has been 
hypothesized in chronic fatigue syndrome (Kennedy et al., 2005).  Results from our data 
presented here support the current physical activity guidelines for cancer survivors, which 
suggest moderate physical activity as a means to reduce treatment-associated side effects 
(Rock et al., 2012), an effect that may be in part due to changes in antioxidant capacity 
and oxidative stress.  
Limitations 
 Pseudo-randomization resulted in different gender characteristics between the EX 
and CON groups, but as this was a repeated measures experiment and because changes in 
fatigue parameters over time were not expected to be gender-dependent, this is unlikely 
to represent sampling bias.  NC fatigue values were unexpectedly classified as borderline 
“mild fatigue,” but this may have been influenced by the timing of the fatigue 
questionnaires, which were administered immediately prior to the early morning, fasted 
blood draws.  Due to the self-selected nature of participation in this study, it is possible 
that psychological factors beyond the scope of this study may have independently 
affected fatigue values at baseline or fatigue changes over time.  Although no substantial 
dietary alterations were explicitly reported by either the EX or CON group at follow-up, 





consumption of antioxidant-containing foods.  It is possible that whole foods containing 
variable antioxidant compositions affected plasma antioxidant capacity or oxidative stress 
at either baseline or follow-up.  Finally, although exercise interventions were similar, 
individualization of exercise regimens for each cancer patient based upon specific needs 
may have affected the biochemical and fatigue responses to exercise and could 




























OXIDATIVE STRESS, MUSCULAR STRENGTH AND 
CARDIOPULMONARY ALTERATIONS 





PURPOSE:  Exercise interventions in cancer patients have been shown to reduce cancer-
treatment related side effects, including muscle wasting and diminished cardiorespiratory 
fitness (CRF).  Despite this, the underlying mechanisms associated with the protective 
aspects of exercise are generally uncharacterized, but treatment-associated oxidative 
stress is thought to play a role.   The purpose of this study was to determine the effect of 
an exercise intervention (EX) on muscular strength, CRF and blood markers of protein 
oxidation compared to a non-exercising, cancer control group (CON).  
METHODOLOGY:  Assessments of muscular strength and CRF and an initial fasting 
blood draw and were administered to fifteen cancer patients within six weeks of 
completing radiation or chemotherapy treatment.   Eight of the cancer patients 
participated in a 10-week exercise intervention while seven continued standard care.  
Following the intervention, subjects completed a reassessment of strength and CRF and 





were compared between the EX and CON groups using repeated measures ANOVA.  
Baseline markers of oxidative stress were compared between cancer patients and age-
matched individuals with no cancer history (NC).  A correlation analysis of changes in 
fitness parameters and oxidative stress in cancer patients was conducted.  RESULTS:  
Baseline total antioxidant capacity was significantly lower, and plasma protein carbonyls 
significantly higher in cancer patients compared to NC (p < 0.05).   An exercise 
intervention significantly increased antioxidant capacity and decreased protein carbonyls, 
while standard care did not (p < 0.01).   Improvements in composite arm (41%) and leg 
strength (34%), isometric handgrip strength (11%), and VO2peak (16%) all significantly 
improved in the EX group (p < 0.05), while none of these parameters significantly 
changed in CON.  No significant correlations between changes antioxidant capacity or 
protein oxidation and improvements in fitness parameters were revealed. 
CONCLUSIONS:   A whole-body exercise intervention is an effective method of 
increasing muscular strength, CRF and antioxidant capacity, while reducing markers of 
protein oxidation.  Despite concurrent changes in oxidative stress, strength and CRF, 
Spearman correlations did not suggest a direct relationship between improvements in 
fitness parameters and reduction in oxidative stress. 
Introduction 
Between 1990 and 2010, cancer related mortality dropped from 215 to 172 deaths 
per 100,000 persons, demonstrating improved efficacy of cancer treatment methods 
(Howlader, 2012).  Although this is an encouraging trend, the adverse side effects of 
surgery, radiation, chemotherapy, and other treatment modalities are associated with 
severe physiological side effects that may last for years.  Typical side effects include 





While these decrements are multi-causal and multi-factorial, oxidative stress is thought to 
play a pivotal role in many pathological processes associated with cancer and its 
treatments (Fang et al., 2009; Robbins & Zhao, 2004; Zhao & Robbins, 2009).   
 Oxidative stress is a state in which reactive oxygen species (ROS) are produced at 
a rate that exceeds cellular adaptive and repair capacities (Halliwell & Gutteridge, 2007).  
The interrelationship between oxidative stress and cancer is complex. The development 
and progression of cancer are associated with high levels of oxidative stress-induced 
DNA modification (Valko et al., 2006), but cancer cells themselves can produce 
increased levels of ROS, perpetuating dysfunction and cancer growth (Hileman, Liu, 
Albitar, Keating, & Huang, 2004).  In certain cancers, this allows for therapeutic 
selectivity, and many modes of cancer treatment depend on extremely high doses of ROS 
as a mechanism of cancer killing, including radiation and many chemotherapy regimens 
(Kovacic, 2007).  Unfortunately, treatment-associated oxidative stress typically affects 
healthy tissue in addition to malignant tissue, resulting in both acute and chronic side 
effects (Ascensao et al., 2005b; Laviano et al., 2007).  Doxorubicin (DOX), for instance, 
is a highly effective antineoplastic agent used for various cancers, yet causes a dose-
dependent cardiotoxicity associated with oxidative stress (Chaiswing et al., 2004; 
Hayward et al., 2013; Kanter et al., 1985).  More recently, DOX has been shown to elicit 
a similar degree of dysfunction in skeletal, smooth, and cardiac muscle tissues (Hayward 
et al., 2013).   While the primary antineoplastic mechanisms of DOX are inhibition of 
topoisomerase II and intercalation in DNA (Chen, Jungsuwadee, Butterfield, & St Clair, 
2007), resulting in inhibition of DNA replication and RNA transcription, the induction of 





chemotherapy drugs, including tamoxifen, etoposide, 5-fluorouracil, alkylating agents 
and platinum coordinating complexes are known to induce significant oxidative stress, 
either as an antineoplastic mechanism or as a side effect (Y. Chen et al., 2007; Conklin, 
2000). Radiation, by nature, is characterized by ROS production and exerts its 
physiological effects, both beneficial and harmful, via this mechanism (Ahn et al., 2006; 
Azzam, Jay-Gerin, & Pain, 2012).    
 Muscular dysfunction in cancer patients is likely caused by numerous factors, 
including physical inactivity, malnutrition, inflammatory cytokines, oxidative stress and 
advanced age (Christensen et al., 2014).  Numerous studies link cancer and treatment-
related ROS production with cachexia, among other potential mechanisms (Laviano et 
al., 2007; Mantovani et al., 2004).   In healthy elderly women, oxidative protein damage 
has been shown to be associated with poor grip strength (Howard et al., 2007).  The loss 
of muscle mass and cardiovascular fitness is compounded by significant decreases in 
physical activity following treatment.  Studies have shown that muscular endurance 
declines after only two weeks of physical inactivity in healthy individuals (Haddad et al., 
2003), while mitochondrial enzyme activity decreases following 3 months of inactivity 
(Coyle et al., 1984). 
The selective reduction of oxidative stress in healthy tissues is a strategy which 
holds promise to reduce treatment-associated side effects while maintaining treatment 
efficacy.  Although antioxidant supplementation may seem like a more direct method of 
increasing antioxidant capacity in cancer survivors as a strategy to reduce treatment 
associated side effects, this approach has been discouraged by several authors because of 





although some groups disagree (Pathak et al., 2005).  Post treatment, this concern is less 
pronounced, but the endogenous antioxidant system is complex and coordinately 
regulated, such that a supplementation of one antioxidant may result in the 
downregulation of others (McCord, 2008).  Exogenous administration of any one of these 
alone could result in aberrant redox regulation (Kong & Lillehei, 1998),  with the 
possibility of promoting oncogenesis and cancer recurrence (Acharya, Das, Chandhok, & 
Saha, 2010), particularly in the presence of undetected metastases.  Furthermore, dietary 
antioxidant interventions have not proven particularly effective in the treatment 
treatment-associated side effects (Lawenda et al., 2008; Myers et al., 1983; Unverferth et 
al., 1983).   
An increasingly popular rehabilitation method in cancer patients is prescriptive, 
whole-body exercise.  Exercise has been shown to minimize many side effects of cancer 
treatment, including reduced CRF (Courneya et al., 2003; Courneya et al., 2007; Dimeo 
et al., 2004; Schneider et al., 2007c; Segal et al., 2009) and muscular strength (Lakoski et 
al., 2012; Schmidt et al., 2013; Schneider et al., 2007a).   In a 2011 meta-analysis 
investigating the effect of exercise on VO2peak, pooled data of six studies (571 adult 
cancer patients; 344 exercise and 227 usual care control) indicated that exercise training 




), whereas usual care was associated 




)  (L. W. Jones, Liang, et al., 2011).  
Similarly, a recent review of the impact of resistance exercise programs on muscular 
strength in over 1,000 cancer patients during or following treatment revealed large effect-
size improvements (Cohen’s d = 0.86) in muscular strength (Focht et al., 2013).  A multi-





gain, as an isolated resistance exercise training program increased muscular strength 25% 
to 35% in breast cancer patients receiving chemotherapy (Courneya et al., 2007).   
Exercise may, in part, exert its rehabilitative effects by preferentially increasing 
antioxidant capacity in the tissues that are stressed by exercise.  For instance, in healthy 
individuals, unilateral leg exercise resulted in increased antioxidant enzyme activity in 
the trained leg but not the untrained leg (Parise et al., 2005).   It may be surmised that 
because of this localized change in antioxidant capacity, antioxidant capacity should 
increase in active tissue, but not in cancer cells.  This also demonstrates the importance of 
total body exercise interventions in cancer survivors, as training effects and changes in 
antioxidant enzyme capacity may be local.  
 Minimal research regarding exercise-associated changes in oxidative stress in 
cancer patients has been published.  The existing studies investigating this relationship in 
human cancer populations are not in agreement, as both increases and decreases in 
oxidative stress have been reported (Allgayer et al., 2008; L. W. Jones, Eves, et al., 
2011).  In non-cancer populations, exercise training can elicit acute and chronic 
augmentation of antioxidant defense and reductions in oxidative stress.  Superoxide 
dismutase concentrations in skeletal muscle samples were significantly elevated for 
several days following a single non-damaging cycling bout, with a peak at 2 days, but 
values returned to baseline levels by day 6 (Khassaf et al., 2001).  In obese individuals 
with no history of cancer, an exercise intervention resulted in significant increases in 
VO2peak and decreases in F2-isoprostane levels (a measure of lipid peroxidation), and 





Similarly, F2-isoprostane levels decreased 34% in premenopausal women following 15 
weeks of aerobic exercise training (Schmitz et al., 2008).   
Animal models provide us with more compelling evidence that exercise-induced 
alterations in oxidative stress can influence CRF and muscular strength improvements 
following cancer treatments.  Kanter (1985) found that a swim-training protocol in rats 
improved antioxidant capacity and counteracted doxorubicin-mediated cardiotoxicity.  
Ascensao et al. (2005a) mirrored these results, and also found that cardiac damage, 
evaluated by cardiac troponin I (cTnI) presence in the plasma, and cardiac muscle protein 
carbonyls were significantly lower in exercise trained mice treated with DOX than non-
exercise trained mice treated with DOX.  Treadmill training in rats has been shown to 
reduce cardiotoxicity concurrently with increased glutathione peroxidase expression 
(Chicco, Hydock, et al., 2006) while an acute exercise bout had a cardioprotective effect 
accompanied by a reduction in myocardial lipid peroxidation (Wonders et al., 2008). 
More recently, Smuder et al. (2011) found that exercise training protects against 
doxorubicin-associated increases in both protein carbonyls and proteolysis in skeletal 
muscle tissue.   
 To address the lack of human research on the potential role that oxidative stress 
has in the restorative effects of exercise following cancer treatment, the purpose of this 
study was to investigate the effects of a 10-week exercise intervention on CRF, muscular 
strength, and plasma markers of antioxidant capacity and protein oxidation. 
Methodology 
 Fifteen cancer patients and seven healthy age-matched individuals with no history 





10-week prescribed exercise intervention in an exercise group (EX), while a control 
group (CON) had standard care for the study period.  Subjects were admitted to study 
groups based upon date of initial contact (pseudo-randomization). Cancer patients had 
completed oxidative stress-inducing cancer treatments, namely radiation or chemotherapy 
treatment, within the previous 6 weeks, with an average time out of treatment of four 
weeks.    Cancer patients were recruited from walk-in and oncologist-referred patients at 
the Rocky Mountain Cancer Rehabilitation Institute (RMCRI) at the University of 
Northern Colorado (UNC) in Greeley, Colorado.  Additionally, oncology patient 
navigators and clinical oncology research specialists at Northern Colorado Medical 
Center in Greeley, Poudre Valley Hospital in Fort Collins, and McKee Hospital in 
Loveland, Colorado identified qualifying individuals as they completed radiation or 
chemotherapy treatments.  Newspaper articles in the Greeley Tribune and UNC today, 
posters at the local American Cancer Society office and outpatient oncology waiting 
areas, and a recruitment page on the RMCRI webpage were used to promote this study. 
Twenty six cancer patients made contact with the primary investigator, but 
exclusion criteria or attrition resulted in the loss of 11 potential subjects.  Refer to Figure 
14 for flow of the subjects through this study.  All cancer diagnoses were considered for 
this study, but subjects were required to have undergone radiation or a chemotherapy 
treatment explicitly known to elicit oxidative stress, either as a side effect or as an 
antineoplastic mechanism.  Chemotherapy agents included anti-neoplastic antibiotics, 
alkylating agents, platinum coordinating complexes, epipodophyllotoxins, fluorouracil 
and tamoxifen (Y. Chen et al., 2007; Conklin, 2004; Look & Musch, 1994).  Cancer 





regimen within six weeks of initial blood draw, (2) currently sedentary (less than two 
days/week or 20 minutes of aerobic or resistance exercise) (Brooks et al., 2005), (3) have 
not consistently supplemented with dietary antioxidants, including vitamins C and E, in 
the previous month, (4) non-smokers (for at least 2 months), and (5) were able to walk 
comfortably on a treadmill.   
Initial Pool:   
26 non-smoking, sedentary cancer patients who had completed chemotherapy or radiation within 
the previous 6 weeks contacted the PI directly or were identified by RMCRI, a nurse navigator, or 
another member of the local oncology community. 
  
Exclusion criteria: 
1 patient too physically active 
  
Attrition:  
2 patients failed to return phone calls after initial contact 
2 patients missed the scheduled initial blood draw or assessment, and never agreed to reschedule 
1 patient “too busy to participate” 
2 patients were unwilling to make commitment to more cancer-related appointments 
1 cancelled initial assessment appointment because the drive for training was too far 
1 patient diagnosed with brain metastasis after initial blood draw but prior to initial assessment 
1 patient returned to chemotherapy after 4 weeks of exercise training 
  
8 subjects participated in a 10-week exercise intervention 
7 subjects were cancer control subjects, and received standard care for 10 weeks 
  
Total sample size:  
14 subjects completed the 10-week intervention, blood draw and reassessment of fitness 
1 control subject completed the final blood draw, but not reassessment of fitness 
Figure 14.  Flow of cancer patients through the study. 
 
Non-cancer, healthy controls were primarily recruited from among the faculty and 
staff at the University of Northern Colorado via campus-wide email and by word of 
mouth.  Inclusion criteria for the non-cancer group included:  (1) currently sedentary (less 
than two days/week or 20 minutes of aerobic or resistance exercise), (2) no history of 





dietary antioxidants in the previous month, and (4) non-smokers.   The University of 
Northern Colorado Institutional Review Board (IRB) approved all procedures.   
For 72 hours prior to the blood draw, subjects were asked to avoid exhaustive 
exercise and antioxidant supplementation.  The day before the cancer patient’s initial 
exercise assessment, a 12-hour fasting blood sample was taken by the lead investigator or 
an otherwise experienced phlebotomist.   
Maximal Treadmill Testing 
 The RMCRI treadmill protocol (Table 16) was developed at the Rocky Mountain 
Cancer Rehabilitation Institute as a cancer-specific protocol, more suitable for the cancer 
population.  Unlike the Bruce treadmill protocol, there are no abrupt increases in speed 
and grade (Bruce et al., 1973).  Smaller changes in effort and patient stride provide a 
more manageable progression through stages and results in reduced premature peripheral 
fatigue and more valid maximal treadmill tests.   
 Prior to each incremental treadmill test, subjects were fitted with a heart rate 
monitor (Polar Inc., Lake Success, NY).   Instructions regarding the specific changes in 
speed and grade during each one-minute stage were given and the participant was 
encouraged to walk or run until exhaustion or volitional fatigue (to VO2peak).  Blood 
pressure was assessed at rest, every three minutes during exercise, immediately post 
exercise, and after three minutes of recovery (slow walking).  Rating of perceived 
exertion was assessed every three minutes of exercise, according to Borg’s 1-10 scale.  
Heart rate and oxygen saturation were assessed at the end of every 1-minute stage.  
Subjects were asked to use handrails only if it was required for balance support.  If 





ACSM metabolic equations were utilized to quantify VO2peak at time of volitional 
fatigue (Pescatello, Arena, Riebe, & Thompson, 2014).  
Table 16   
 
RMCRI Treadmill Protocol 
Stage Speed (mph) Grade (%) Time 
1 1.0 0 1 min 
2 1.5 0 1 min 
3 2.0 0 1 min 
4 2.5 0 1 min 
5 2.5 2 1 min 
6 3.0 2 1 min 
7 3.3 3 1 min 
8 3.4 4 1 min 
9 3.5 5 1 min 
10 3.6 6 1 min 
11 3.7 7 1 min 
12 3.8 8 1 min 
13 3.9 9 1 min 
14 4.0 10 1 min 
15 4.1 11 1 min 
16 4.2 12 1 min 
17 4.3 13 1 min 
Cool-Down 1.5 0 3 min 
 
Muscular Strength Assessment 
 A true 1-repetition max (1-RM) assessment of strength can be the most accurate 
and reliable method of muscular strength assessment, but may be subject to variability 
due to unfamiliarity with weight lifting, lack of adequate facilities, and risk of injury, 
even in healthy individuals.  In the cancer population, the variability and risk for injury 
are even greater.  Therefore, the Brzycki equation, 
1-RM = weight lifted (lb) / (1.0278 – (repetitions to failure × 0.0278)) 
was used to estimate 1-RM using the number of repetitions of a given submaximal load 





strength was assessed using the lat pull-down, shoulder press, chest press, seated row, leg 
press, leg extension, and leg curl exercises, using Cybex® gym equipment (Cybex 
International, Medford MA).  The goal was to choose a weight that elicited muscle failure 
in 4-6 repetitions.  Suggested values for the initial amount of weight lifted for each 
exercise were based upon previous muscular strength data from RMCRI (Schneider et al., 
2003) but varied greatly between individual (Table 17).  Repetitions were performed 
without resting until muscle failure, or until the subject’s form deteriorated.  If the subject 
exceeded 10 repetitions for any exercise, he or she was stopped, and moved on the other 
muscular strength exercises.  Following all exercises, those exercises which had been 
stopped were completed after increasing the weight to elicit muscle failure in less than 10 
repetitions.  For the purposes of data analysis, a composite score (sum of weight lifted) 
was used for upper body strength (lat pull-down, shoulder press, chest press, seated row) 
and lower body strength (leg press, leg extension, and leg curl. 
Table 17   
 
Suggested initial resistance (% of Body Weight)  
Exercise Men Women 
Lat Pull-down    0.900   0.500 
Shoulder Press    0.350   0.150 
Chest Press    0.750   0.250 
Seated Row    0.750   0.300 
Leg Press    1.500   0.750 
Leg Extension    0.750   0.400 
Leg Curl    0.750   0.400 
 
 Following 1-RM testing, a Takei TKK 5101 handgrip dynamometer (Takei 
Scientific Instruments, Tokyo, Japan) was utilized to evaluate maximal isometric 
handgrip strength in both hands.  Subjects held the dynamometer parallel to their side 





performed on each side.  The average of the best trial for each hand was used for 
analysis.  In order to appropriately prescribe an individualized exercise intervention, an 
evaluation of flexibility and balance was performed at the time of intake.  Flexibility was 
assessed with a modified sit and reach test and the back scratch test, while the Bertec 
Balance Check™ Screener and Trainer Package (Bertec Corporation, Columbus, OH) 
was used to assess postural stability and limits of stability.   
Exercise Intervention 
 Each exercise participant completed a 10-week exercise intervention that was 
individually supervised by a cancer exercise specialist 3 days per week.  Each 1-hour 
session was in accordance with the subject’s prescribed training modes, intensity, and 
volume, based upon their goals and assessment results.  Exercise sessions varied 
depending on the subject’s health and fitness status, but typically included a 5-minute 
warm-up, 20 minutes of aerobic exercise, 25 minutes of resistance training, and 10 
minutes of flexibility and balance training.  Blood pressure and HR were measured at the 
beginning and end of the exercise session, and HR, RPE, and SaO2 were monitored 
throughout.  Aerobic exercise intensity was based on the subjects’ initial VO2peak, and 
was generally low to moderate intensity, ranging from 30% to 60% of heart rate reserve 
(HRR). The Karvonen (percent heart rate reserve) method was used to determine target 
exercise heart rate intensity using the formula  
  (220-age) − resting HR] × percent of exercise intensity + resting HR.   
Subjects with poor overall health status health or low fitness were initially prescribed an 
intensity level of 30%-45% HRR or a RPE of 1-3, whereas subjects with a moderate 





RPE of 4-5.  The mode of aerobic exercise selected for each subject was based on the 
mode offering the greatest anticipated benefit.  Options included outdoor or treadmill 
walking, stationary cycling, or recumbent stepping.  Although rate of progression varied 
significantly by subject, cancer exercise specialists aimed to increase increases speed or 
resistance weekly, while keeping RPE values below 5 and HR values below 75% HRR.   
At the beginning of the intervention, initial percent of 1-RM corresponded with 
the percent of HRR values for aerobic exercise, based upon initial health and fitness 
status (30%-45% 1-RM for low fitness, 50%-60% for average fitness). Cybex Eagle 
Selectorized Strength Machines
©
 (Cybex International Inc, Medway, MA, USA), free 
weights, resistance bands and body weight exercises were all used for the exercise 
intervention, depending upon fitness, mobility, and comfort of the cancer patient.  
Muscular endurance was emphasized over hypertrophic training, as subjects performed 8-
15 repetitions per set and typically ended each set at muscular fatigue rather than muscle 
failure.  Resistance was increased when 8-15 repetitions no longer resulted in muscular 
fatigue.  
All cancer patients were asked to avoid any substantial changes in their diet, 
assuming a physician or nutritionist did not prescribe a change in eating habits.  Subjects 
in the standard care control group were asked to maintain their exercise habits during the 
10-week study period.  Although standard care cannot be “standardized” between 
hospitals and patients, it did not involve routine, systematic exercises (van Waart et al., 
2010).  Neither yoga nor stretching programs were utilized for the control group because 
both interventions have the potential to alter markers of oxidative stress and antioxidant 





complete an exit survey inquiring about any changes in physical activity, dietary habits, 
medications, and medical procedures.  Following the 10-week study period, control 
subjects had the opportunity to exercise at RMCRI for three months at no cost.    
Blood Handling and Analysis 
 A minimum of 4mL of blood was withdrawn into sterile tubes containing 
potassium-EDTA and immediately put on ice.  Samples were centrifuged at 3,000 rpm 
for 10 minutes, and the plasma was separated and stored in multiple aliquots at -80°C 
until analysis.  All assays were performed in duplicate on the first thaw.  Reactive 
carbonyl derivatives were measured as a marker of oxidative protein damage.  Protein 
carbonyls were measured in plasma using an enzyme-linked immunosorbent assay 
(ELISA) according to the procedures recommended by the manufacturer (Cell Biolabs, 
Inc., San Diego, CA).  Antioxidant capacity was measured in plasma using the Trolox-
equivalent antioxidant capacity (TEAC) assay using procedures outlined by the reagent 
provider (Sigma Chemical, St. Louis, MO).    
Statistical Analyses 
 Data are presented as means  SD.    Subjects’ baseline characteristics in the two 
cancer groups (EX versus CON) and the NC group were compared using independent t-
tests.  A repeated measures 2 (group) × 2 (pre- and post-intervention)  analysis of 
variance (ANOVA) with Bonferroni post hoc was used to determine differences within 
(across time) and between the two groups related to markers of protein oxidation, 
antioxidant capacity, VO2peak, and muscular strength.  A Kolmogorov-Smirnov was 
used to ensure that the normality assumption was met for this data set.  Spearman 





markers of oxidative stress and baseline CRF and muscular strength.  Additionally, 
Spearman correlation coefficients were calculated to determine associations between 
post-intervention changes in markers of oxidative stress and post-intervention changes 
CRF and muscular strength.   A significance level of α = 0.05 was used for all statistical 
analyses.   
Results 
 Baseline subject characteristics for the EX, CON, and NC groups are summarized 
in Table 18.  The two cancer groups had statistically similar height, weight, body mass 
index, and time out of treatment, and no significant differences in age were found 
between the three groups.  Although exit surveys in control subjects indicated no notable 
changes in dietary habits, qualitative physical activity in this group increased from 
baseline as, even in the absence of an exercise intervention, time out of treatment resulted 
in greater vigor for activities of daily living and leisure time activity.  Increases in 
housework, light yard work, and walking were most commonly reported, but no control 
subjects reported participation in a structured exercise program.  One male control 
























Exercise Control Non-Cancer 
      N 8 7 7 
      Age (years) 64.0 ± 10.8 62.4 ± 9.7 55.1 ± 9.7 
      Females 7 4 5 
      Males 1 2 2 
      Height (in) 65.4 ± 2.5 66.8 ± 4.7 - 
      Weight (lbs) 174.0 ± 32.3 179.5 ± 40.8 - 
      BMI 28.4 ± 4.3 28.1 ± 3.8 - 
Primary treatment 
         Radiation 4 4 - 
      Chemo 3 4 - 
Days out of Treatment 29.9 ± 18.6 31.4 ± 21.7 - 
Adherence rate (%) 83.9 ± 12.8 NA - 
 
 Baseline oxidative stress parameters are found in Table 19.  Plasma antioxidant 
status, as determined by Trolox equivalent antioxidant status (TEAC), did not differ 
between EX and CON, but was significantly reduced in cancer patients compared to NC 
(p < 0.01).  Similarly, plasma protein carbonyls did not differ between cancer groups, but 
was significantly greater in cancer patients than NC (p < 0.05).   Blood markers of 
oxidative protein oxidation and antioxidant capacity at all time points are illustrated in 
Figures 15 and 16, respectively. 
Table 19 
 
Baseline Oxidative Stress Parameters in Cancer and Non-Cancer Groups 
  TEAC (mM Trolox) Protein Carbonyls (nmol/mg) 
Cancer (N = 15)    0.27 ± 0.06
 a
 1.24 ± 0.27
 b
 
NC (N=7)  0.37 ± 0.07 0.89 ± 0.25 
a
 Significantly lower than NC (p <  0.01) 
b



































Figure 15.  Plasma protein carbonyl concentration for all groups and time points. 
*= significantly different than EX Pre (p < 0.01).  # = significantly different than EX Pre, 
CON Pre, and CON Post (p < 0.05). 
 











































Figure 16.  Trolox Equivalent Antioxidant Capacity for all groups and time points. 
*= significantly different than EX Pre (p < 0.01).  # = significantly different than EX Pre 






 Changes in antioxidant capacity and protein oxidation for EX and CON are 
presented in Table 20.  Protein oxidation was significantly diminished at follow-up, from 
1.30  ±  0.44 to 0.84  ± 0.33 nmol/mg  in EX  (p < 0.05), whereas no such response was 
apparent in CON (1.18  ±  0.42 to 1.12  ± 0.22 nmol/mg)  Although no interaction effect 
was present, this trend approached significance (p = 0.068).  Increases in antioxidant 
capacity were significant in EX (0.28 ± 0.07 mM to 0.39 ± 0.05 mM, p < 0.01), but not in 
CON (0.26 ± 0.05 to 0.32 ± 0.08 mM p > 0.05).  Following the 10-week study period, EX 
no longer differed significantly from NC for protein oxidation, and neither cancer group 
differed in antioxidant capacity from NC (p > 0.05, Figures 15 and 16).   
Table 20 
  
Changes in Oxidative Stress Parameters in Exercise and Control groups 
  TEAC (mM Trolox) Protein Carbonyls (nmol/mg) 
EX (N=8) + 0.11 ± 0.09
 a
 - 0.46 ± 0.30
 b
 
CON (N=7) + 0.06 ± 0.09 - 0.06 ± 0.47 
a
 Significant increase from baseline (p <  0.01) 
b
 Significant decrease from baseline (p <  0.05) 
 
 Composite values for arm and leg strength were used for statistical analysis, and 
these results are found in Table 21, in addition to isometric handgrip strength and 
VO2peak.  Both arm and leg strength improved significantly (p < 0.01) in EX, with 41% 
and 34% increases, respectively.  There were essentially no changes in arm (+ 2.5%) or 
leg strength (-0.3%) strength in the control group.  Accordingly, a significant time by 
group interaction effect was present for both arm and leg strength (p < 0.01).  Handgrip 
strength gains in EX (+11.2%) were less compelling, but this change was significant 
nonetheless (p < 0.05).  Although CON exhibited a 5.5% mean increase in handgrip 
strength, this result was not statistically significant.  An analysis of indivudal strength 





EX group, but no significant changes in the CON group.  Furthermore, a significant 
interaction effect between CON and EX was apparent in all exercises other than leg curl 
and seated row.  Detailed absolute and relative strength means and standard deviations 
for individual exercises are found in Table 22, while handgrip and composite arm and leg 
strength measurements at all time points are illustrated in Figures 17-19.   
 VO2peak, as determined by a graded exercise test to volitional fatigue, increased 
16% following the exercise intervention in EX, representing a significant increase over 
time (p < 0.05), whereas this parameter remained constant (+3.9%) in CON (p > 0.05).  
There was no significant time by group interaction between these two groups.  Similarly, 
treadmill time improved significantly in the EX group (+2:05) but not in the CON group 
(+0:20).  VO2peak values and time to exhaustion on the treadmill at all time points are 
found in Figures 20 and 21, respectively. 
Table 21  
 
Muscular Strength and Cardiorespiratory Fitness Changes 
 Pre Post 
EX (N=8)   
      Arm Strength (lbs) 230.4 ± 91.4     324.4 ± 125.2
 a,c
 
      Leg Strength (lbs)   332.3 ± 130.9     445.5 ± 157.2
 a,c
 
      Handgrip Strength (lbs) 25.8 ± 4.8 28.6  ± 6.0
 b
 




) 20.1 ± 9.7     23.4 ±  10.9 
b
 
      Treadmill Time (min)  8:44  ±  3:18 10:49  ±  3:15
 a
 
CON (N=6)   
      Arm Strength (lbs)   273.3 ± 148.1   280.1 ± 165.7 
      Leg Strength (lbs)    348.1 ± 166.3   346.9 ± 164.4 
      Handgrip Strength (lbs) 25.6  ± 9.7  26.8  ± 10.0 




)   18.1 ±  4.4 18.8  ±  6.1 
      Treadmill Time (min)   8:59  ±  2:42   9:19  ±  3:31 
a
 Significantly lower than baseline (p < 0.01) 
b
 Significantly lower than baseline (p < 0.05) 
c





Table 22  
 
Changes in Individual Muscular Strength Parameters 
 EX (N=8) CON (N=6) 
 Pre Post Pre Post 
Absolute Strength (lbs)    
      Lat Pulldown 75.1 ± 13.4 102.6 ± 15.5
 a,c
 90.4 ± 39.4 89.9 ± 40.3 
      Shoulder Press 34.0 ± 14.7  53.7 ± 18.6
 a,c
 46.6 ± 29.2 48.3 ± 33.4 
      Chest Press 51.3 ± 24.6  77.8 ± 31.4
 a,c
 62.5 ± 46.8 68.6 ± 50.6 
      Seated Row 69.9 ± 8.5 90.2 ± 8.3 
b
 73.2 ± 36.5 73.6 ± 44.4 
      Leg Curl 74.1 ± 16.7 89.2 ± 10.1 82.3 ± 36.8 82.8 ± 40.4 
      Leg Extension 81.3 ± 26.5  113.8 ± 22.0
 b,c
 88.9 ± 48.1 73.3 ± 61.6 
      Leg Press 176.9 ± 39.2  242.6 ± 33.5
 a,c
 177.0 ± 84.9 172.5 ± 69.9 
Relative strength (lbs / body weight)    
      Lat Pulldown 0.44 ± 0.09   0.61 ± 0.12
 a,c
 0.50 ± 0.18 0.51 ± 0.21 
      Shoulder Press 0.21 ± 0.10   0.32 ± 0.13
 a,c
 0.26 ± 0.15 0.26 ± 0.16 
      Chest Press 0.30 ± 0.14   0.47 ± 0.21
 a,c
 0.34 ± 0.23 0.37 ± 0.25 
      Seated Row 0.41 ± 0.08  0.53 ± 0.11
 b
 0.41 ± 0.18 0.41 ± 0.23 
      Leg Curl 0.43 ± 0.08 0.53 ± 0.12 0.45 ± 0.15 0.46 ± 0.20 
      Leg Extension 0.48 ± 0.16   0.68 ± 0.18
 b,c
 0.49 ± 0.22 0.43 ± 0.34 
      Leg Press 1.04 ± 0.27   1.45 ± 0.43
 a,c
 0.98 ± 0.40 0.95 ± 0.28 
a
 Significantly lower than baseline (p < 0.01) 
b
 Significantly lower than baseline (p < 0.05) 
c
 Significant time by group interaction with control group (p < 0.01) 
 




























Figure 17.  Handgrip strength (average, both hands) for all groups and time points. 



































Figure 18.  Composite arm strength for all groups and time points. 
*= significantly different than EX Pre (p < 0.01).  † = significant group by time 
interaction effect, compared to EX (p < 0.01).   






























Figure 19.  Composite leg strength for all groups and time points. 
*= significantly different than EX Pre (p < 0.01).  † = significant group by time 





































Figure 20.  VO2peak values for all groups and time points. 
*= significantly different than EX Pre (p < 0.05).   
 





























Figure 21.  Time to exhaustion during treadmill test for all groups and time points. 






 Initial VO2peak exhibited a significant negative correlation (r = -0.71) with 
baseline antioxidant capacity (p < 0.01), but not with baseline protein carbonyls.  
Strength parameters did not significantly correlate with either protein oxidation or 
antioxidant capacity at baseline.  Spearman correlation analysis showed no significant 
correlations between changes in VO2peak or muscular strength and changes in protein 
carbonyls or antioxidant capacity.  Correlations matrices are found in Tables 23 and 24. 
Table 23  
 
Correlations Between Oxidative Stress and Fitness Parameters at Baseline 
    VO2 peak  Arm Strength Leg Strength Handgrip 
TEAC 
Correlation -0.71 -0.23 0.1 -0.005 
Significance 0.001
a 
0.206 0.361 0.492 
Carbonyls 
Correlation -0.06 0.046 -0.06 -0.15 
Significance 0.422 0.435 0.415 0.301 
a
 Significant correlation between blood parameter and VO2peak value (p <  0.05) 
 
 
Table 24  
 
Correlations Between Changes in Oxidative Stress and Fitness Parameters  
    VO2 peak Arm Strength Leg Strength HG 
TEAC 
Correlation 0.42 0.26 0.073 0.44 
Significance 0.070 0.189 0.403 0.059 
Carbonyls 
Correlation -0.45 -0.4 -0.35 -0.21 
Significance 0.053 0.078 0.114 0.236 
 
Adverse Events and Exercise Adherence   
 Several of the EX patients exhibited chronic musculoskeletal limitations at 
baseline, including osteoarthritis, rheumatoid arthritis, and complications associated with 
previous surgery (including knee surgery, hip replacement, double mastectomy, wrist 
surgery, lumbar fusion, and Whipple procedure for pancreatic cancer).  Because of the 





was sufficient to allow for continued exercise participation and completion of the 
intervention in all EX subjects.  Overall, exercise adherence was high, with subjects 
attending 84 ± 13% of scheduled sessions.  One patient missed three sessions during the 
intervention due to hip pain associated with a previously failed hip replacement, and 
another missed two sessions due to complications with a breast expander placed 
following double mastectomy.  Otherwise, scheduling conflicts and acute respiratory 
infections accounted for most missed training sessions.   
Conclusions 
 The present study demonstrated that an exercise intervention in cancer patients 
following treatment simultaneously increased muscular strength, CRF and antioxidant 
capacity, and reduced protein oxidation, whereas time out of treatment alone did not 
significantly alter these variables.  Few prior studies have investigated oxidative stress 
changes in response to exercise in cancer patients, and results have varied.  Our results 
are most consistent with Allgayer et al., (2008) who found that 2 weeks of moderate 
intensity exercise was capable of reducing oxidative stress, although a high intensity 
exercise protocol resulted in non-significant increases in oxidative stress.   More recently, 
a 14-week exercise intervention resulted in increased urinary markers of oxidative stress 
in lung cancer patients, but this also was a high-intensity exercise intervention, which 
included 25-minute sessions at ventilatory threshold and 60-second interval bouts at peak 
workload  (L. W. Jones, Eves, et al., 2011).  The positive outcomes in our current study 
helps support the notion that an individualized, low to moderate intensity exercise 






 Despite concurrent changes in protein oxidation, antioxidant capacity, muscular 
strength, and CRF, correlations between fitness and oxidative stress parameters were 
largely absent.  Although baseline CRF unexpectedly exhibited a negative correlation 
with antioxidant capacity (r = -0.71), this relationship trended towards positive at follow-
up (r = 0.35).  Because muscular strength and CRF are strongly influenced by age, 
gender, body composition and lifetime physical activity, it is difficult to quantify cancer 
treatment-associated muscle damage and fitness decrements associated with cancer based 
solely on post-treatment fitness assessment.  Therefore it was not surprising that 
oxidative stress was not correlated with baseline strength values within a population of 
cancer survivors of this size.  Because the pre-treatment muscular strength was not 
known, we cannot exclude the possibility that protein carbonyls contributed to muscle 
wasting, as has been suggested in the literature (Barreiro et al., 2005; Mantovani et al., 
2004; Moylan & Reid, 2007).  Future studies may investigate decrements in muscular 
strength and CRF prior to and following cancer treatment and compare these changes to 
degree of oxidative damage.   
 Although it was anticipated that changes in oxidative stress and antioxidant 
capacity would correlate with changes in fitness parameters, no significant Spearman 
correlations were detected, but changes in VO2peak exhibited a strong trend towards 
correlation with changes in antioxidant capacity (r = 0.42, p = 0.07) and protein carbonyls 
(r = 0.45, p = 0.053).  Due to musculoskeletal limitations in many of the patients, 
including arthritis and history or surgery, muscular strength may have been strongly 
limited by pain or limited range of motion, ultimately uncoupling a potential linear 





Currently there is no good characterization of the time-course of chronic oxidative 
stress status following the end of cancer chemotherapy or radiation.  In mice, 
extracellular malondialdehyde levels remained elevated one week after chemotherapy, 
and oxidized glutathione was significantly higher than controls 6 weeks after treatment 
(Abushamaa et al., 2002).  Unfortunately, it is difficult to extrapolate these data to 
humans due to varying lifespans. Our data presented here suggest that cancer patients 
approximately one month out of treatment have persistent elevations in protein oxidation, 
and furthermore, CON continued to exhibit elevated plasma protein carbonyls 10 weeks 
later.  It should be noted that, although the change in antioxidant capacity over was not 
significant in CON, this variable no longer significantly differed from NC at follow-up, 





 improvement in VO2peak in the exercise group compared 




 increase identified in a meta-analysis of 6 
randomized controlled trials encompassing 344 cancer patients following various 
exercise interventions (L. W. Jones, Liang, et al., 2011).  Despite significant 
improvements, CRF was poor in EX following the exercise intervention.  Regardless, this 




) mean improvement is clinically relevant.  
Gulati et al. (2003) found that in apparently healthy individuals, for every 1-MET 
increase in aerobic capacity, there was an associated reduction in mortality rate of 12% in 
men and 17% in women. While such a relationship has yet to be elucidated in cancer 




 has been proposed for full 
independent living of cancer patients
 
(L. W. Jones et al., 2012).  In the same study, 
patients with an absolute VO2peak greater than1.09 L·min
-1





for death of 0.32 compared to patients with aerobic capacity values below 1.09 L·min
-1
.  
Two EX subjects in the current study were below this threshold at baseline, but both 
surpassed it during the course of the intervention, representing a meaningful clinical 
outcome.    
One control subject demonstrated an impressive 30% increase in VO2peak, 
representing an outlier in this group.  When excluding this subject, VO2peak in the 
control group actually decreased by 2.3%.   Despite increased time out of treatment and 
improved familiarity with the treadmill protocol, CRF in 3 control subjects was 
diminished at follow-up, which may have be associated with prolonged sedentary activity 
or persistent oxidative stress, resulting in continued skeletal and cardiac muscle tissue 
degradation (Powers, Smuder, & Criswell, 2011; Smuder et al., 2011b).  Nishayama et al. 
(1998) demonstrated that oxidative stress may be associated with exercise intolerance in 
clinical populations, as a significant negative correlation between exercise-induced 
malondialdehyde production and VO2peak was present in cardiac patients, whereas no 
such relationship existed in healthy individuals.  Our current investigation evaluated 
chronic redox status rather than acute, exercise-associated oxidative stress, but future 
studies investigating oxidative stress markers immediately following an exercise bout 
may further elucidate the complex dynamic between exercise and oxidative stress in 
cancer patients. 
Summary  
 Cancer patients exhibited decrements in antioxidant capacity and increased 
protein oxidation compared to healthy, age-matched individuals. Fortunately, a 





muscular strength, CRF, and antioxidant capacity, while reducing markers of protein 
oxidation.  It therefore may be surmised that oxidative stress contributes to strength and 
cardiorespiratory decrements in cancer patients following cancer treatment.  Similarly, 
improved antioxidant capacity may play a role in exercise-mediated cancer rehabilitation.  
Limitations 
 Pseudo-randomization resulted in different gender characteristics between the EX 
and CON groups.  Although baseline strength variables were substantially greater in 
males than  females for this study, because this was a repeated measures experiment, 
changes in muscular strength over time were not expected to be gender-dependent, and 
this is unlikely to represent sampling bias.  Because there were a variety of cancer types 
and treatments among the subjects in this study, it is possible that undetected prolonged 
physiological effects of treatment and cancer type may play a role in patient response to 
exercise or time out of treatment.  Although no substantial dietary alterations were 
explicitly reported by either the EX or CON group at follow-up, diets were not controlled 
and food logs were not utilized to evaluate subjects’ consumption of antioxidant-
containing foods.  It is possible that whole foods containing variable antioxidant 
compositions affected plasma antioxidant capacity or oxidative stress at either baseline or 
follow-up.  Finally, although exercise interventions were similar, individualization of 
exercise regimens for each cancer patient based upon specific needs may have affected 
the biochemical and fitness responses to exercise and could potentially limit the 
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PIPER FATIGUE SCALE 
 
Directions: Many individuals can experience a sense of unusual or excessive tiredness whenever 
they become ill, receive treatment, or recover from their illness/treatment. This unusual sense of 
tiredness is not usually relieved by either a good night’s sleep or by rest. Some call this symptom 
“fatigue” to distinguish it from the usual sense of tiredness. 
 
For each of the following questions, please fill in the space provided for that response that best 
describes the fatigue you are experiencing now or for today. Please make every effort to answer 
each question to the best of your ability. If you are not experiencing fatigue now or for today, fill 
in the circle indicating “0” for your response. Thank you very much! 
 
1. How long have you been feeling fatigue? (Check one response only). 
_ 1. not feeling fatigue 
_ 2. minutes 
_ 3. hours 
_ 4. days 
_ 5. weeks 
_ 6. months 
_ 7. other (Please describe) _______________________________________________ 
 
2. To what degree is the fatigue you are feeling now causing you distress? 
No Distress         A Great Deal 
1 2 3 4 5 6 7 8 9 10 
 
3. To what degree is the fatigue you are feeling now interfering with your ability to complete your 
work or school activities? 
None          A Great Deal 
1 2 3 4 5 6 7 8 9 10 
 
4. To what degree is the fatigue you are feeling now interfering with your ability to socialize with 
your friends? 
None          A Great Deal 
1 2 3 4 5 6 7 8 9 10 
 
5. To what degree is the fatigue you are feeling now interfering with your ability to engage in 
sexual activity? 
None          A Great Deal 
1 2 3 4 5 6 7 8 9 10 
 
6. Overall, how much is the fatigue which you are now experiencing interfering with your ability 
to engage in the kind of activities you enjoy doing? 
None          A Great Deal 








7. How would you describe the degree of intensity or severity of the fatigue which you are 
experiencing now? 
Mild          Severe 
1 2 3 4 5 6 7 8 9 10 
 
8. To what degree would you describe the fatigue which you are experiencing now as being? 
Pleasant         Unpleasant 
1 2 3 4 5 6 7 8 9 10 
 
9. To what degree would you describe the fatigue which you are experiencing now as being? 
Agreeable         Disagreeable 
1 2 3 4 5 6 7 8 9 10 
 
10. To what degree would you describe the fatigue which you are experiencing now as being? 
Protective         Destructive 
1 2 3 4 5 6 7 8 9 10 
 
11. To what degree would you describe the fatigue which you are experiencing now as being? 
Positive         Negative 
1 2 3 4 5 6 7 8 9 10 
 
12. To what degree would you describe the fatigue which you are experiencing now as being: 
Normal         Abnormal 
1 2 3 4 5 6 7 8 9 10 
 
13. To what degree are you now feeling: 
Strong          Weak 
1 2 3 4 5 6 7 8 9 10 
 
14. To what degree are you now feeling: 
Awake         Sleepy 
1 2 3 4 5 6 7 8 9 10 
 
15. To what degree are you now feeling: 
Lively          Listless 
1 2 3 4 5 6 7 8 9 10 
16. To what degree are you now feeling: 
Refreshed         Tired 
1 2 3 4 5 6 7 8 9 10 
 
17. To what degree are you now feeling: 
Energetic         Unenergetic 
1 2 3 4 5 6 7 8 9 10 
 
18. To what degree are you now feeling: 
Patient         Impatient 
1 2 3 4 5 6 7 8 9 10 
 
19. To what degree are you now feeling: 
Relaxed         A Great Deal 






20. To what degree are you now feeling: 
Exhilarated         Depressed 
1 2 3 4 5 6 7 8 9 10 
 
21. To what degree are you now feeling: 
Able to Concentrate        Unable to Concentrate 
1 2 3 4 5 6 7 8 9 10 
 
22. To what degree are you now feeling: 
Able to Remember        Unable to Remember 
1 2 3 4 5 6 7 8 9 10 
 
23. To what degree are you now feeling: 
Able to Think Clearly       Unable to Think Clearly 
1 2 3 4 5 6 7 8 9 10 
 









































































Informed Consent for Participation in Research 
Project Title:  
Oxidative Stress Alterations Following and Exercise  
Intervention in Cancer Survivors 
 
Rocky Mountain Cancer Rehabilitation Institute 
Chris Repka, M.S., Research Associate 
Phone Number:  (908) 419-2767 
crepka@skidmore.edu 
Carole M. Schneider, Ph.D., Clinical Director 
Phone Number: (970) 351-2676 
 
 
      You are being asked to participate in a research study collecting information to 
assess the effect of an exercise program on oxidative stress following radiation and 
chemotherapy. The Rocky Mountain Cancer Rehabilitation Institute (RMCRI) supports 
the practice of protection of human subjects participating in research.  The following 
information is provided for you to decide whether you choose to participate in the present 
study.  You should be aware that even if you agree to participate, you are free to 
withdraw at any time without affecting your opportunities in other projects offered by the 
Institute. 
      This project involves the assessment of markers of oxidative stress, or free radical 
damage, which may have been induced by cancer chemotherapy and radiation therapy.  
Oxidative stress is known to play a role in the onset of numerous cancer treatment side 
effects, including fatigue, neurological and psychological detriments, and damage to 
cardiac and skeletal muscle.   Blood samples will be obtained 2 times throughout the 
study at RMCRI and will be analyzed for these markers of oxidative stress.  The blood 
samples will be obtained prior to initial assessment, and prior to reassessment, after 10 
weeks of prescribed exercise.   
In addition to blood draws, all subjects will be given the typical RMCRI fitness 
assessment. Measurement of cardiorespiratory capacity will be conducted on a motor-
driven treadmill and will require you to run/walk at progressively increasing speed and 
grade until exhaustion.  A pulmonary function test requires maximum exhalation into a 
sterile mouthpiece.  Flexibility will be evaluated with a sit and reach test.  A muscular 
strength assessment includes 2-10 repetitions of leg press, leg extension, leg curl, seated 
row, bench press, lat pulldown, and shoulder press.  Heart rate, blood pressure, height, 
weight, and circumference measurements are also recorded.  Forms to be completed 
include cancer history, medical history, cardiovascular risk profile, lifestyle/activity 
questionnaire, and fatigue and depression scales.  Assessments will take place at the 
RMCRI and take approximately 2 hours to complete.  Following the assessment of your 
cardiovascular endurance and pulmonary function, the results will be analyzed, and an 
exercise prescription written, by a cancer exercise specialist.  During the course of the 10-
week exercise intervention, a cancer exercise specialist will be your trainer and will write 
your daily, individualized exercise plan, which consists of 3, one-hour workouts per week 





There is a possibility that you may be randomly selected for a control group.  If 
this is the case, following the 10 week period of the intervention, you will have the 
opportunity to participate in the standard exercise intervention for the following 3 months 
at no cost.   
This study will run under the supervision of the RMCRI director and lead 
investigator, but other persons will be associated with or assist in the data collection.  The 
obtained data may be used in reports or publications but your identity will not be 
associated with such reports.  A number will be used as your identification and your 
medical and exercise information kept in a locked file cabinet available only to the lead 
investigator.  Confidentiality will only be broken if our assessment reveals that you are 
severely depressed or if you indicate you are a threat to yourself or to others, at which 
time you will be referred through our ancillary services for psychological counseling. 
A great benefit for participating in this study is exercise training with trained 
cancer exercise specialists. Additionally, each participant will be provided a summary of 
his or her exercise data at the beginning and the end of the project period with a clear and 
concise exercise intensity recommendation based upon the exercise assessment results.  
There is no compensation for participating in this study.   
      Risks to you are minimal and may include the possibility of shortness of breath, 
mild muscular fatigue and soreness, and moderately uncomfortable test situations (such 
as during the pulmonary function test and the sit & reach test).  Additionally, the 
VO2peak fitness test used to assess your cardiorespiratory capacity can be uncomfortable.  
The duration of the discomfort is short.  Before all testing, an explanation of the 
procedure will be given.  Overall, the risks inherent in this study are no greater than 
during a regular physical exercise session a participant may conduct on his or her own 
time.  All subjects will be cleared through the RMCRI Medical Director before the 
physiological testing commences.  When collecting blood samples for research, there is 
no more risk than that which is encountered when one has blood drawn at a hospital or 
clinic.  Proper containment and disposal of blood will be implemented.  If you are injured 
as a result of this study, you will treated in the usual manner and charges billed to your 
insurance/self.  The study will not pay for health care costs. 
      Participation is voluntary. You may decide not to participate in this study and if 
you begin participation you may still decide to stop and withdraw at any time. Your 
decision will be respected and will not result in loss of benefits to which you are 
otherwise entitled, including continued exercise training at RMCRI. Having read the 
above and having had an opportunity to ask any questions, please sign below if you 
would like to participate in this research. A copy of this form will be given to you to 
retain for future reference.  If you have any concerns about your selection or treatment as 
a research participant, please contact the Office of Sponsored Programs, Kepner Hall, 
University of Northern Colorado Greeley, CO  80639; 970-351-2161.  
 
________________________________ ___________________________________ 
Participant Name     DATE Signature of Researcher  DATE 
 
________________________________ __________________________________________ 
Signature of Subject Agreeing to Participate. Signature of Medical Director DATE                            
By signing this consent you certify you are at  



















































Thursday, February 18, 2010 12:23 PM 
 
Chris: 
Thanks for your revised consent document and answers to my questions regarding your IRB 
application. You now have UNC IRB approval. At the end of your consent document, please 
make one minor change: the phone number for Sponsored Programs is 351-2161. I do not need 
to see that change. 




Gary D. Heise, Ph.D.  
School of Sport and Exercise Science  
University of Northern Colorado  
2760 Gunter Hall  
Greeley, CO 80639  




Thursday, January 14, 2010 9:40 AM 
 
Chris; 
I completed my review of your IRB application and have some comments that I would like you to 
address. Comments on the informed consent document may be better addressed during a short 
meeting. I will be at RMCRI later today (Thursday), but could also meet tomorrow (Friday). 
Essentially, the consent document needs some details added (e.g., VO2peak procedures - as it is 
written, the reader does not know that he/she will be wearing a mouthpiece, nose-clip and 
walking until he/she can no longer continue). The discussion of risks and benefits need to be re-
worded - your narrative reads more clearly. I have a few other comments, but again can be 
quickly addressed with a meeting. 
The control group assignment worries me. People will be coming to RMCRI because they want to 
exercise, so telling them that they are in a control group and cannot exercise is an issue that must 
be addressed (delicately). In contrast to your comment to Dr. Weiler, I have heard some granting 
agencies that do not allow non-exercising control groups for certain studies because it would be 
unethical to withhold a treatment that is known to do good (can this be said for cancer patients?). 
One other comment - "already approved by UNC IRB" should read "previously approved by UNC 
IRB" IRB approval are for specific protocols. Dr. Schneider and I talked about a more "blanket" 
IRB approval for RMCRI, but such approval is not currently in place. 




























































Subject Update Questions 
 
1. Did you have any problems as a result of your last training session? 
(soreness, pain, etc.) 
Yes     No       If yes, identify the specific problem on the Client Update  
            Response Sheet 
 
2. Are you having any specific problems today that would affect training? 
(feeling ill, headache, pain, nausea, dizziness, extreme fatigue, etc.) 
Yes     No      If yes, identify the specific problem on the Client Update 
          Response Sheet  
 
3. Are you taking any new medications?  Has a medication been discontinued or the 
prescribed amount changed?  Has your health status changed?  
Yes     No      If yes, identify the change on the Client Update Response 
                                  Sheet and notify the Clinical Coordinator. 
 
4. Since your last exercise session, have you been diagnosed with cancer recurrence? 
Yes     No If yes, write an explanation and notify the Clinical Coordinator. 
 
5. Since your last exercise session, have you begun chemotherapy treatment? 
Yes     No If yes, immediately report the date and specific chemotherapy 
drugs to the Clinical Coordinator. 
 
6. Since your last exercise session, have you completed your chemotherapy 
treatment? 
Yes     No If yes, immediately report the date completed to the Clinical 
Coordinator. 
 
7. Since your last exercise session, have you begun your radiation treatment? 
Yes     No If yes, immediately report the date of initiation and type of 
radiation to the Clinical Coordinator. 
 
8. Since your last exercise session, have you completed your radiation treatment? 
Yes     No If yes, immediately report the date completed to the Clinical 
Coordinator. 
 
9. Since your last exercise session, did you perform any additional exercise?   
Yes     No If yes, describe the type, duration, and intensity.  If lengthy, 






















































Exit Survey for control subjects, Chris Repka’s Oxidative Stress Study 
Name: _____________________   Date:________________________ 




2. Have you changed your dietary habits 
 
 
3. Have you made any other lifestyle changes since we last met? (yoga, meditation, 











































































































y = 0.0385x + 0.0797 



















Protein Carbonyl (nmol/mg) 
Protein Carbonyl Standard Curve 
y = -0.7499x + 0.5679 


















TEAC Standard Curve 
